Transcription factor GATA6 and ISC gene SMOC2 in the regulation of BMP pathway in intestinal adenoma by Montagni, Elisa, 1984-
Transcription factor GATA6 and ISC gene 
SMOC2 in the regulation of BMP pathway 
in intestinal adenoma 
Elisa Montagni 
TESI DOCTORAL UPF - 2015 
Director 
Eduard Batlle Gómez, PhD 
Tutor 
Antonio García de Herreros Madueño, PhD 
Institute for Research in Biomedicine, Barcelona 
Colorectal Cancer Laboratory 
Experimental and Life Science Department 
  
   
Acknowledgements 
 
The last 5 years have been so intense and significant that I have 
the duty to mention some of the people that mainly contributed to 
this experience. 
 
First of all, I would like to thank IRB Barcelona and my supervisor 
Eduard for selecting me and providing me a great place to work. 
Thank you Eduard for receiving me in your lab, for your guidance 
and giving me the opportunity to conduct top quality research with 
amazing tools. 
 
Many thanks to all the members of ex- and current Batlle lab 
(Elena, Daniele, Enza, Alex, Diana, Marta, Clara, Xavi, Carme, 
Mark, Sergio, Francisco, Carles, Peter, Gemma, Jordi, Gavin, 
Anna, Isabella, Guiomar, Elisa “grande”). I learned something from 
all of you. Thanks for support and patience from my first silent year 
to my fifth noisy year! 
 
In particular, special thanks go to: 
Francisco, for adopting me as “lab older brother” since the first day, 
for daily scientific speculations, for psychological support and 
infinite availability. 
My right-hand person, Xavi, for fun, support and great team work… 
thanks for your competence and for taking so much care of my 
work. 
The histology team, Marta, Begoña and Alicia, for your 
competence, your care and for sharing ups and downs. 
Enza, for lightening the working days and for self-confidence 
injections… (and I’m infinitely grateful for your help when my flat 
was falling apart right during the thesis writing!). 
Peter, for support and patience. 
Gavin, for selecting me as collaborator and for training me with 
high throughput experiences! 
Finally, during the writing of the thesis, I could count on the 
precious help of Eduard, Elena, Francisco, Mark and Xavi for text 
corrections. 
 
   
Un grazie speciale va a chi ha rappresentato il “punto di partenza”, 
a chi mi ha iniziato a questo lavoro con passione, onestà e 
pazienza: la mia Sis Michi e Silvanetta. 
 
Thanks to my “PhD studies background”: this amazing city, 
Barcelona, so vibrant and surprising. It made me feel home and 
meet lovely people. 
 
In particular, two people shared with me each step of this intense 
experience: Gius and Const, thank you for your genuine friendship. 
 
Grazie agli AMICI di sempre (Lalli, Simo, Marco, Ale, Giò, Giù e 
Marghe) per esserci quando serve, per sdrammatizzare, per creare 
un nido protettivo. 
 
Grazie infinite al mio angelo custode: Dá, non ci sono parole per 
spiegare quanto siamo forti insieme. Infinito affetto, supporto, aiuto, 
empatia e divertimento. Ricambio dicendo che questa tesi è anche 
un po’ tua. 
 
Infine grazie di cuore alla mia famiglia, a chi c’è e a chi non c’è più. 
Grazie per l’educazione che mi avete trasmesso e le possibilità che 
mi avete offerto. Grazie per la fiducia incondizionata e per dare 
immenso valore alle mie scelte. Grazie per spingermi sempre a 
guardare avanti senza recriminare il passato. Grazie per essere 
così forti e uniti. 
 
  I 
Abstract 
 
The first chapter identifies the transcription factor GATA6 as 
negative regulator of a transcriptional circuit dedicated to prevent 
the expansion of Adenoma Stem Cells (AdSCs) during the onset of 
colorectal cancer (CRC). In particular, we show that GATA6 directly 
activates the expression of the WNT pathway component LGR5 
and represses BMP levels in adenoma by competing with the β-
catenin/TCF4 complex for the binding to BMP4 enhancer regions. 
As a result of this mechanism, two compartments are established 
within an adenoma: a BMP positive differentiated cell zone and a 
BMP negative undifferentiated cell zone, where AdSCs reside. 
Genetic deletion of Gata6 increases BMP levels in the AdSC 
compartment, inhibiting self-renewal and intestinal tumorigenesis. 
These findings represent a key contribution to understand the 
mechanisms that regulate tumor hierarchy and reveal for the first 
time the existence of a niche that protects AdSCs from BMP 
signals. 
 
The second chapter focuses on the functional characterization of 
Smoc2, a novel Intestinal Stem Cell (ISC) gene. We generated 
genetic mouse models in order to overexpress or ablate Smoc2 in 
the intestine. We found that SMOC2 acts as a BMP inhibitor in the 
intestine and that it is not only restricted to epithelial Stem Cells 
(SCs) but it is also expressed by the stroma. Although it is 
dispensable for normal ISC maintenance and intestinal 
homeostasis, high levels of SMOC2 are required for tumorigenesis. 
Indeed, Smoc2 overexpression leads to spontaneous development 
of hamartomas and enhances adenoma formation in mice with an 
Apc mutant background; inversely, Smoc2 deficiency decreases 
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tumorigenesis and prolongs survival of Apc mutant mice. In 
particular, we observed that SMOC2-mediated BMP inhibition 
positively affects Insulin-like Growth Factor (Igf1) expression in 
adenoma endothelial cells (ECs). Our data suggest that SMOC2 
could enhance tumor-associated inflammation through BMP-
mediated Igf1 regulation in the stroma. 
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Resumen 
 
El primer capítulo describe la identificación del factor de 
transcripción GATA6 como regulador negativo de un circuito 
transcripcional fisiológico dedicado a reprimir la expansión de las 
células madre de los adenomas (Adenoma Stem Cells o AdSCs) 
en el inicio de la tumorogénesis colorrectal. De manera específica, 
mostramos como el factor GATA6 activa directamente la expresión 
del componente de la ruta de WNT, LGR5, y también directamente 
reprime niveles de hormona BMP (Bone Morphogenetic Protein) a 
través de la competición directa con el complejo beta-catenina-
TCF4 por la unión a regiones enhancer del gen BMP4. Como 
resultado de este circuito transcripcional que hemos descubierto, 
en los adenomas se generan dos compartimentos, una zona 
positiva para la señalización mediada por BMP que contiene las 
células diferenciadas de los adenomas, y un área negativa para 
BMP, donde residen y se expanden las AdSCs. La ablación 
genética de Gata6 incrementa los niveles de BMPs en el 
compartimento de las AdSCs, inhibiendo la autorenovación de las 
mismas y por ende la tumorogénesis. Este descubrimiento 
representa una aportación clave para entender los mecanismos 
que regulan la jerarquía tumoral y revelan por primera vez la 
existencia de un nicho que protege las AdSCs de las señales de 
BMP. 
 
El segundo capítulo describe la caracterización funcional de 
Smoc2, uno de los genes identificados en el laboratorio dentro del 
programa genético específico de las células madre del intestino 
(Intestinal Stem Cells o ISCs).  Durante el transcurso de la tesis 
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doctoral, hemos generado modelos animales de ratón que 
permiten manipular la expresión de Smoc2 (sobreexpresión y 
depleción). A través de la caracterización de estos modelos 
animales demostramos que SMOC2 actúa como un inhibidor de la 
señalización mediada por BMP el intestino, y que se expresa no 
solamente en las ISCs, sino también en el estroma.  Si bien Smoc2 
es dispensable para la homeostasis intestinal y el mantenimiento 
del pool de células madre, se requieren elevados niveles de 
SMOC2 durante la tumorogénesis intestinal. La sobreexpresión de 
Smoc2 en el epitelio intestinal da lugar al desarrollo espontáneo de 
hamartomas. Asimismo, aumenta la formación de adenomas en un 
fondo genético que presenta mutaciones en el gen supresor de la 
tumorogénesis intestinal Apc. De manera inversa, la ablación 
genética de Smoc2 disminuye la formación de tumores y prolonga 
la supervivencia de ratones con el gen Apc mutado. 
Concretamente, hemos observado que la inhibición de la ruta de 
BMP mediada por SMOC2 afecta la expresión de Igf1 (Insulin-like 
Growth Factor 1) en células endoteliales de adenomas. Nuestros 
datos sugieren que SMOC2 promueve la inflamación asociada al 
tumor a través de la regulación de la ruta de BMP que a su vez 
controla la expresión de Igf1 en el estroma tumoral. 
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Preface 
 
The body of this thesis is composed of two result chapters, 
preceded by an introduction and followed by discussion and 
conclusion sections. The experimental work was carried out in the 
Colorectal Cancer laboratory at the Institute for Research in 
Biomedicine (IRB) located at the Parc Científic de Barcelona 
(PCB). 
The first chapter is based on a scientific article that, at the time of 
this thesis submission, was published in the journal Nature Cell 
Biology. First author of this work is Gavin Whissell who presented it 
in his doctoral thesis at the moment of the first submission for 
publication. Since then, we have been going through a long 
experimental revision that lasted 8 months, which I took care of. 
This included the planning, execution and analysis of a large 
proportion of the experimental work. In particular, I was involved in 
experiments using cell lines and primary cell cultures. This first 
chapter describes the identification of transcription factor GATA6 
as a mediator of a transcriptional circuit that targets BMP and 
regulates the expansion of AdSCs. This circuit contributes to the 
establishment of hierarchies in adenoma, with high BMP 
expression defining differentiated tumor cell zones, and low BMP 
zones defining the SC compartment. Through repression of BMP 
signaling, GATA6 maintains the AdSC compartment and ensures 
tumor progression. 
The second chapter describes my main thesis project that started 
five years ago. At that time, the first ISC signatures had been 
generated and Lgr5 was the only gene known to specifically mark 
ISCs. Our laboratory had a great interest in dissecting the functions 
  VI
encoded by specific SC genes. In particular, we decided to focus 
on SMOC2, a secreted extracellular matrix protein implicated in the 
regulation of BMP pathway during invertebrate development. The 
accumulating evidence supporting the crucial role of BMP signaling 
for intestinal homeostasis, led us to hypothesize that SMOC2 could 
be a BMP inhibitor directly secreted by the SCs to regulate BMP 
levels in the surrounding niche and maintain homeostasis. We 
demonstrated the involvement of SMOC2 in the negative regulation 
of BMP signaling, however its biological function emerged to be 
more complex than hypothesized. In fact, we observed that 
SMOC2 exerts pro-inflammatory and pro-tumorigenic roles in the 
intestine by targeting the stromal compartment. The lack of 
functional antibodies against SMOC2 denied us the possibility to 
detect the protein and its spatial range of action. To explore its 
function we undertook several experimental approaches, which 
mainly focused on the generation of different genetic mouse 
models and ex vivo primary stem cell cultures. The specific 
mechanism of action of SMOC2 is still currently unclear, however 
we hope that through the use of the tools generated during this 
thesis, we will soon be able to uncover the function of this gene in 
the intestine.  
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Introduction 
 
1. Adult stem cells (SCs) and tissue homeostasis 
 
Evolution from single cell-organisms to multicellularity entailed the 
appearance of differently specialized types of cells and the 
consequent need for a hierarchical organization in order to 
maintain the tissue homeostasis. The concept behind tissue 
hierarchy involves the separation between tissue maintenance and 
tissue function. Hierarchy is achieved through the existence of 
tissue-specific pools of long-lived undifferentiated cells that 
maintain the tissue. These cells have the potential to generate 
short-lived specialized cells, which in turn exert the appropriate 
functions of a given tissue. 
The cells responsible for tissue maintenance are termed adult SCs 
and they act as a repair system for the body by replenishing adult 
tissue. The classical definition of adult SC requires it to possess 
two properties: self-renewal and multipotency. Self-renewal 
identifies the ability to go through numerous cycles of cell division 
while maintaining the undifferentiated state. Multipotency refers to 
the ability to give rise to different types of specialized cell types. 
Differentiated cells represent the major component of the tissue 
and exert all the required physiological functions. Yet, these cells 
are short-lived and need to be replenished by the SC activity in 
order to maintain the tissue homeostasis. 
The rate of division of SCs and differentiated cells determines the 
turnover of the tissue. Tissues exposed to constant environmental 
insult, such as the intestine, skin and the hematopoietic system, 
have rapid cycling SC pools, whereas tissues such as liver, 
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muscle, pancreas and brain activate their SC population only upon 
severe stress. 
As the SCs are generally less abundant than their progeny, they 
often give rise to an intermediate pool of highly proliferative cells 
termed transit-amplifying (TA) cells. TA cells are committed 
progenitors with low self-renewal capability that undergo several 
cycles of expansion before undergoing differentiation (Figure 1). 
 
 
 
 
Figure 1: Schematic representation of a hierarchically organized 
tissue. SCs reside at the top of the hierarchy. They have the ability to 
self-renew and differentiate in to multiple lineages. Before differentiating 
into mature functional cells, the direct descendants of the SCs (progenitor 
cells or TA cells) undergo several rounds of division in order to expand the 
compartment. Adapted from (Jordan et al., 2006). 
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1.1 Adult SC self-renewal 
 
1.1.1 Asymmetric and symmetric SC division 
 
In order to accomplish self-renewal and potency, SCs can undergo 
asymmetric or symmetric cell division. 
Upon asymmetric cell division, a SC generates one daughter cell 
with a SC fate and one daughter cell that undergoes differentiation 
(Figure 2 A, left panel). Asymmetric cell division implies that SCs 
would be unable to expand in number, an essential process during 
development or after injury. 
Thus, there is an alternative mechanism, the symmetric cell 
division, that leads to the generation of daughter cells that acquire 
the same fate (either stem or differentiated) (Figure 2 A, right 
panel). 
Both mechanisms ensure the maintenance of the stem and 
differentiated cell populations (Figure 2 B) and can be used 
depending on the needs of the tissue (Morrison and Kimble, 2006). 
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Figure 2: Asymmetric and symmetric SC division. A. In asymmetrical 
cell divisions, cell fate specification is coupled to mitosis and involves 
unequal partitioning of cellular components to the resulting daughter cells 
(left panel). In symmetrical cell divisions, cellular components are equally 
distributed to the two daughter cells that result to be identical (right panel). 
From (Fuchs and Chen, 2013). B. (a) SCs (orange) must accomplish the 
dual task of self-renewal and generation of differentiated cells (green). (b-
d) Possible SC strategies to maintain a balance between SCs and 
differentiated progeny. From (Morrison and Kimble, 2006). 
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1.1.2 The SC niche 
 
Most SCs can divide by either asymmetric or symmetric division 
and the balance between these two models is controlled by 
developmental and environmental cues that ensure tissue 
homeostasis. 
In particular, the SC niche represents a defined anatomical 
compartment that provides signals to the SCs in the form of 
secreted and cell surface molecules that control the rate of SC 
proliferation, determine the fate of SC daughters, and protect SCs 
from exhaustion or death (Jones and Wagers, 2008; Schofield, 
1978). First of all, the signals coming from the niche regulate SC 
self-renewal, survival and maintenance. Second, the particular 
spatial relationship between SCs and support cells can polarize 
SCs within the niche to promote asymmetric SC divisions. 
Moreover, adhesion between SCs, supporting stromal cells and the 
extracellular matrix (ECM) anchors SCs within the niche in close 
proximity to self-renewal and survival signals. Thus, the SC niche 
provides structural support, trophic support, topographical 
information and the appropriate physiological signals to regulate 
SC function in both invertebrate and vertebrate organisms (Jones 
and Wagers, 2008). 
In general, the SC niche is composed by stromal support cells; 
ECM proteins that provide structure, organization and mechanical 
signals to the niche; blood vessels that carry systemic signals and 
provide a conduit for recruitment of inflammatory and other 
circulating cells into the niche; and neural inputs that might similarly 
communicate distant physiological signals to the stem cell 
microenvironment (Figure 3). 
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Finally, increasing evidence implicates deregulation of the SC 
niche as a cause of many pathologies associated with tissue 
degeneration (Visnjic et al., 2004), ageing (Boyle et al., 2007; 
Conboy et al., 2005) and tumorigenesis (Corre et al., 2007; Zhu et 
al., 2002). 
 
 
 
Figure 3: Components of the SC niche. The SC niche is a complex and 
dynamic structure that transmits and receives signals through cellular and 
non-cellular mediators. The niche includes different cellular components 
(stromal cells, immune cells and the vascular network), soluble factors, 
extracellular matrix, neural inputs, physical parameters and metabolic 
control. From (Lane et al., 2014). 
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1.2 Experimental strategies to determine SC populations 
 
1.2.1 Transplantation assay 
 
The term “stem cell” is based on the strict criterion of extensive 
clonal self-renewal capability. This definition derives from the 
hematopoietic field where in vivo transplantation assays are 
available to assess replicative potential. The concept behind this 
approach in based on the purification of a determined bone marrow 
cell population and its consequent transplantation into a host 
mouse that has been previously depleted of the Hematopoietic 
Stem Cells (HSCs) by irradiation treatment. The expected result is 
that only HSCs will be able to fully regenerate the bone marrow 
functionality for extended periods of time. This approach has been 
particularly useful to identify the difference between long term 
HSCs and short term HSCs (Ficara et al., 2008). However, similar 
in vivo reconstitution assays do not yet exist for many adult tissues 
and thus it is not possible to clearly prove self-renewal in those 
organs by this classic approach. 
 
1.2.2 Label retention and quiescence 
 
Label retention was once considered a hallmark of tissue SCs 
(Duvillié et al., 2003; Mackenzie and Bickenbach, 1985; Morris and 
Potten, 1994; Terskikh et al., 2012). 
In order to identify label-retaining cells (LRCs), replicating DNA was 
labeled by administration of radioactive thymidine or 
Bromodeoxyuridine (BrdU). Tissues were then stained and cells 
that still retained their labels months or years after labeling were 
considered to be SCs (Potten and Hendry, 1975). This paradigm 
was based on the notion that SCs should persist in tissues and 
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divide only rarely to protect their genome. Nevertheless, recent 
works performed in skin and intestine have shown that LRCs are 
not the only SCs (Barker et al., 2007; Claudinot et al., 2005; Li and 
Clevers, 2010) demonstrating that quiescence and label retention 
are not innate properties of all tissue SCs. 
 
1.2.3 Lineage tracing 
 
In some rapidly regenerating tissues (most notably the intestine), 
clonal marking techniques can prove life-long self-renewal in the 
absence of transplantation and firmly establish the identity of SCs. 
Lineage tracing is a technique that consists of genetically labeling a 
cell population and following the label in its progeny. The most 
utilized system for lineage tracing is based on the Cre recombinase 
fused to the ligand binding domain of the estrogen receptor: the 
Cre-ERT2 fusion protein. The expression of this protein is driven by 
a gene specific for a certain cell population (stem, progenitor or 
differentiated cells). Animals engineered with this allele are then 
treated with the ERT2 agonist 4-OH Tamoxifen that specifically 
activates the nuclear translocation of the Cre recombinase in the 
cells expressing the gene of interest. The reporter allele usually 
consists of an ubiquitous promoter followed by a transcriptional 
stop signal which prevents the transcription of the reporter gene. 
Commonly, the stop signal is a tandem of three polyadenylation 
sequences flanked by loxP sites. Upon 4-OH Tamoxifen treatment, 
the Cre is induced and the stop signal is removed allowing the 
expression of the reporter (Figure 4 A). In this experimental 
setting, only the population that expresses the gene driving the 
recombinase will be initially labeled. In the long term, all the 
progeny derived from the initially labeled population will also bear 
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the reporter expression. In particular, if the Cre is driven by a 
differentiation gene, no population will be labeled in the long term 
as the labeling will be lost as the cells die. Like the SCs, progenitor 
cells are often multipotent and may give rise to several different 
mature lineages. However, they can be distinguished from true 
stem cells by the fact that their clonal labeling will be transient and 
will not last for the life of the animal. In contrast, SCs will produce 
labeled offspring permanently (Figure 4 B). Therefore, when the 
labeling permanently persists in all the cells composing the tissue, 
it can be concluded that the gene of interest marks adult SCs. 
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Figure 4: Schematic representation of a lineage tracing experiment. 
A. Components of the lineage tracing experiment based on Tamoxifen-
driven Cre recombinase activation. B. (a) When the gene of interest marks 
SCs, all cells in the hierarchy will be permanently marked in the long term. 
(b) If the gene marks differentiated cells, the label will disappear as the 
mature cells die. (c) If the gene marks progenitor cells, the descendent 
lineages will be marked after a short follow up, but not after longer times. 
From (Grompe, 2012). 
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Notably in the intestine, the cells located in the crypt at the +4 
position were long thought to be the true and only SCs (Potten, 
1975). However, lineage tracing of cells expressing the WNT target 
Leucine-rich repeat containing G protein coupled Receptor 5 (Lgr5) 
clearly showed that cells at the bottom of the crypt, which are 
clearly distinct from the +4 cells, also act as SCs (Barker et al., 
2007) (Figure 5). Intestinal stem cells (ISCs) will be discussed in 
more detail in the following sections. 
 
 
 
Figure 5: Lineage tracing from Lgr5 expressing cells in mouse 
intestine. A Hierarchical organization of the intestinal epithelium: Lgr5+ 
cells reside at the bottom of the crypts and give rise to all the 
differentiated cells that populate the epithelium. B. Lineage tracing of 
Lgr5+ cells in colon and small intestine of Lgr5-eGFP-CreERT2, Rosa26-
fl-stop-fl-LacZ mice. From (Barker et al., 2007; Fuchs, 2009). 
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1.2.4 Clonogenic cultures 
 
Despite the evident advantages of the lineage tracing, the cost in 
resources and time of generation of these mutant transgenic mice 
is a limiting step of this approach. 
The recent establishment of in vitro 3D SC culture models 
represents a more rapid and economic tool to assess the 
clonogenic potential of certain cell populations, and also to perform 
detailed studies on the pathways involved in the SC biology and 
tissue architecture. The principle behind this approach resides in 
the isolation and culture of the cell population of interest. SCs are 
commonly cultured in a 3D matrix in the presence of cocktails of 
growth factors and inhibitors that mimic the SC niche of the tissue 
of origin. Only SCs are able to sustain the culture for extended 
periods of time. Moreover, the 3D SC culture should allow the 
formation of mini-organoids composed by all the types of cells 
deriving from the SC and resembling the hierarchical organization 
of the tissue of origin (Barker et al., 2010; Dong et al., 2013; Jung 
et al., 2011; Sato et al., 2009, 2011a) (Figure 6). 
The major caveat of this approach is the possibility that SCs could 
require unknown signals. It is plausible that the culture conditions 
could bias and select the growth of a subpopulation that is not 
representative of the SC population of origin. In this regard, the 
combination of in vivo and in vitro approaches is recommended. 
Finally, it’s worth mentioning that most of the functional approaches 
to study SC populations described above are based on the 
isolation of cells from the tissue of origin. The selection of a specific 
marker or combinations of markers to isolate the SCs has crucial 
importance and it has been a controversial field. In fact, the use of 
different markers can lead to the isolation of different populations 
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with different features, but may not necessarily enrich for SCs. In 
this regard, the identification of pathways and gene programs 
specific for certain cell populations together with the establishment 
of purification techniques based on Fluorescence Activated Cell 
Sorting (FACS) have allowed further refinement of the assays 
mentioned above. 
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Figure 6: Establishment of an intestinal crypt culture system. A. (a-b) 
Single isolated crypts (left panel) efficiently form large organoids within 14 
days (right panel). (c) Three-dimensional reconstructed confocal image 
after 3 weeks in culture. Lgr5-GFP stem cells (green) are localized at the 
tip of crypt-like domains. (d) Schematic representation of an intestinal 
organoid, consisting of a central lumen lined by villus-like epithelium and 
several surrounding crypt-like domains. B. Confocal images (a-d) and 
stained paraffin sections (e-h) of single intestinal SC-derived organoids 
reveal the presence of all the differentiated lineages. From (Sato et al., 
2009). 
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2. The mammalian intestine as model for adult SC 
biology 
 
2.1 Anatomy of the intestine 
 
The intestinal tract is a tubular structure that connects the end of 
the stomach to the anus. It is anatomically and functionally divided 
into two main parts: the small intestine and the large intestine or 
colon (Figure 7 A). The small intestine is composed of duodenum, 
jejunum and ileum, and is responsible for the final steps of 
digestion as well as being the primary site of food uptake. The 
colon exerts the function of water absorption and stool compaction 
for excretion. 
 
The intestinal tube is organized as concentric layers around a 
central lumen (Figure 7 B). The first layer in contact with the lumen 
is the mucosa or epithelium. Besides representing a barrier from 
mechanical and biological insults, the intestinal epithelium exerts 
the functions of absorption and secretion. The intestinal epithelium 
is monostratified and is folded into tubular crypts (crypts of 
Lieberkühn) that invaginate into the underlying mesenchyme. 
Contrary to the colon, the small intestinal epithelium also 
possesses finger-like structures that protrude into the lumen (villi) 
to maximize the intestinal surface area for absorption (Figure 7 C). 
The second layer is termed lamina propria and is composed of 
connective tissue and stromal cells. The third layer, the 
submucosa, contains blood vessels, nerves, lymphatic noduls and 
myofibroblasts. It is separated from the lamina propria by a thin 
muscle layer (muscularis mucosae) and is externally enveloped by 
a thicker smooth muscle layer, tunica muscularis externa, which is 
involved in peristaltic motions (Figure 7 B). 
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Figure 7: Anatomy of the intestinal tract. A Anatomy of the intestinal 
tract (http://www.yoursurgery.com/ProcedureDetails.cfm?BR=1&Proc=49). B. 
Representation of a transverse section of the small intestine and colon 
(http://www.vetmed.vt.edu/education/curriculum/vm8054/Labs/Lab19/Lab19.htm). 
C.  Representation of the intestinal epithelium organization along the 
proximo-distal axis. From (Clevers and Batlle, 2015). 
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2.2 Self renewal in the intestinal epithelium 
 
As mentioned before, the inner surface of the intestinal tube is lined 
by a simple epithelial monolayer. Cells in the monolayer are 
exposed to a harsh environment and thus the adult epithelium must 
undergo rapid renewal to maintain optimal function.   
 
Regeneration relies in a small group of adult SCs that reside at the 
bottommost position of the crypts of Lieberkühn. Functional 
differentiated cells occupy positions close to the lumen where they 
are required for the main functions of the intestinal tract, 
absorption, compaction and excretion of intestinal contents. To 
maximize these functions, the intestinal tube displays distinct 
morphologies along the proximo-distal axis. The small intestine is 
arranged in crypts and villi, whereas the colon consists only of 
crypts (Figure 8 A, B). 
 
Despite their distinctive morphologies, epithelial cell types of both 
the small intestine and colon are organized following a bottom-to-
top axis into three compartments: the SC compartment that is 
located at the crypt base, the transient-amplifying (TA) 
compartment that occupies the middle portion of the crypts, and the 
differentiation zone, which expands from the top third of the crypt to 
the tip of the villus (Figure 8 A, B). 
 
Renewal of the epithelial monolayer is a continuous process 
throughout the life span of an individual. Regeneration relies upon 
the activity of adult SCs that regularly divide to produce TA cells 
that are highly proliferative progenitors. The nascent TA cells divide 
2-3 times and gradually commit to the absorptive or secretory cell 
lineages while migrating upwards towards the base of the villi 
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(Marshman et al., 2002). The differentiated cells continue migrating 
upwards along the villi until they reach the tip and die. 
 
More than 300 million new epithelial cells must be generated daily 
in the small intestine to compensate for the high rate of cell death 
on the villi. The entire epithelial cell renewal cycle takes 3-5 days 
(Karam, 1999). Paneth cell turnover is the only exception. In fact, 
these cells are renewed every 3-6 weeks from secretory cell 
progenitors located at the base of the TA compartment. These 
progenitors mature into fully differentiated Paneth cells while 
following a downward migratory path to the crypt bottom (Ireland et 
al., 2005; Karam, 1999). 
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Figure 8: Epithelial self-renewal in the intestinal epithelium. A. 
Scanning electron micrograph of the small intestine (left panel). 
Longitudinal representation of the crypt-villus axis (central panel). 
Hierarchical organization of the intestinal epithelial cells (right panel). B. 
Scanning electron micrograph of the colon (left panel). Longitudinal 
representation of the crypt-villus axis (central panel). Hierarchical 
organization of the colon epithelial cells (right panel). From (Barker, 2014). 
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2.3 Differentiated cell types composing the intestinal 
epithelium 
 
2.3.1 Cell types of epithelial origin 
 
Seven differentiated cell types have been identified in the intestinal 
epithelium belonging to two main lineages, absorptive or secretory: 
Enterocytes, Goblet cells, Enteroendocrine cells, Paneth cells, Tuft 
cells, M cells and Cup cells (Figure 9) (Clevers and Batlle, 2015; 
van der Flier and Clevers, 2009; Neutra, 1998; Schonhoff et al., 
2004; Takashima et al., 2013). 
 
Absorptive lineage: 
 
- Enterocytes (or columnar cells) constitute more than 80% of the 
epithelium. They are highly polarized cells carrying an apical brush 
border that is responsible for absorbing and transporting nutrients 
across the epithelium (Takashima et al., 2013). 
 
Secretory lineage: 
 
- Goblet cells secrete protective mucins that are required for the 
movement and expulsion of gut contents (Karam, 1999). The 
proportion of goblet cells increases from the duodenum (4%) to the 
colon (16%). 
 
- Paneth cells reside at the crypt base and have a function in innate 
immunity since there are able to secrete granules containing 
specific proteins like lysozymes, antimicrobials, and defensins. 
Paneth cells are the only differentiated intestinal epithelial cell type 
that migrates downward to the crypt bottom. This 
compartmentalization is achieved through guidance mediated by 
tyrosine kinase receptors EPHB2 and EPHB3 (Batlle et al., 2002). 
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- Enteroendocrine cells are scattered as individual cells throughout 
the mucosa, representing approximately 1% of the epithelial cells. 
They coordinate gut functioning through specific peptide hormone 
secretion (Schonhoff et al., 2004). 
 
- Tuft cells are rare cells that are believed to secrete prostanoids. 
These cells are characterized by Dclk1 (or Dcamkl1) gene 
expression (Gerbe et al., 2011; Gerbe, Brulin, Makrini, 
Legraverend, & Jay, 2009; Gerbe, Legraverend, & Jay, 2012). 
 
- M cells or Microfold cells are situated over the Peyer’s patches 
(PPs), which are intraepithelial pockets characterized by high 
density of antigen-presenting cells. The M cells exert an important 
role for the mucosa immunity since they transport antigens into the 
PPs (Neutra, 1998). 
 
- Cup cells comprise up to 6% of epithelial cells in the ileum. Their 
function is still unknown. 
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Figure 9: ISCs at the crypt bottom give rise to all the intestinal 
differentiated cell types. From (Gerbe et al., 2012). 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
 23
2.3.2 Major cell types composing the intestinal lamina propria 
 
The intestinal lamina propria (Figure 10) is composed of cells of 
mesenchymal origin, in addition to immune cells: 
 
Mesenchymal cells: 
 
- Myofibroblasts are cells that possess both fibroblast and smooth 
muscle cell characteristics, and are located in close contact with 
the epithelial cells. They mediate the information flow between the 
epithelium and the mesenchymal elements of the lamina propria 
through expression and secretion of cytokines, chemokines, growth 
factors, prostaglandins, and basal lamina/extracellular matrix 
molecules (Powell et al., 2005). 
 
- Fibroblasts are the main component of the connective tissue. 
They synthesize extracellular matrix and collagen and play a critical 
role in tissue wound healing. 
 
- Endothelial cells compose the intestinal microvasculature that 
provides oxygen and nutrients. 
 
- Pericytes wrap around capillaries as single cells. They provide 
proteins to the vascular basement membrane, and communicate 
with the endothelial cells via paracrine signals. Together with the 
endothelium, pericytes contribute to angiogenesis and 
revascularization. Paracrine signals from pericytes can control 
contractility and permeability of the capillary. Pericytes and 
endothelial cells are in close contact in a similar way as the 
subepithelial myofibroblasts are with the intestinal epithelium 
(Bergers and Song, 2005). 
 
- Bone marrow-derived stromal stem cells (MSCs) have been 
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shown to modulate the immune system through the secretion of 
prostaglandin E2. Additionally, they aid vasculogenesis (Powell et 
al., 2011). 
 
- Smooth muscle cells of the muscularis mucosae are responsible 
for peristaltic contractions. In particular, the Interstitial Cells of Cajal 
(ICC) have specialized contacts with both nerves and smooth 
muscle cells, allowing them to relay information from nerves to 
muscles (Al-Shboul, 2013). 
 
Immune cells: 
 
- Resident Macrophages, Dendritic Cells (DC) and B/T 
Lymphocytes migrate in and out the tissue, providing constant 
immunosurveillance and antigen trafficking. These cells are 
normally in a resting state but, when the need arises, new 
monocytes and new lymphocytes are recruited from the circulation 
and lymphoid organs to trigger inflammation (Bogunovic et al., 
2009; Smith et al., 2011). 
 
Aside from their role as structural elements, mesenchymal cells 
also serve as resident sentinels that produce chemokines upon 
activation, initiating the recruitment of leukocytes to the site of 
tissue injury and inflammation (Pinchuk et al., 2007; Vogel et al., 
2004). 
 
All of these neighboring stromal cells are critical for the 
establishment and maintenance of the ISC niche by providing 
structural support and modulating the main pathways that regulate 
intestinal homeostasis. 
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Figure 10: Epithelial and mesenchymal elements of the intestine. (a) 
Longitudinal representation of the crypt-villus axis showing the epithelium 
and the lamina propria composed of subepithelial myofibroblasts, 
pericytes of the capillaries, mesenchymal stem cells, and smooth muscle 
cells. Fibroblasts are shown mainly in the upper portion of the villus. (b-c) 
Cross sections through villus and crypts. (d) A higher-power depiction of 
the myofibroblasts and pericytes surrounding and supporting the 
capillaries. (e) A Peyer’s patch with its vascular, lymphatic, and stromal 
elements. Lymphocytes, macrophages, dendritic cells, and 
polymorphonuclear leukocytes are not shown. From (Powell et al., 2011). 
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2.4 Signaling pathways regulating ISC homeostasis 
 
The major pathways that regulate ISC homeostasis are: WNT, 
Notch, EGF and BMP/TGFβ signaling (Figure 11). 
 
 
 
Figure 11: Major pathways regulating ISCs. A tight signaling network is 
established between SCs and the stroma to modulate the main pathways 
behind intestinal homeostasis. In particular, WNT, Notch and EGF 
signaling promote stemness and proliferation. On the other side, BMP 
signaling counteracts proliferation and promotes differentiation. From 
(Clevers and Batlle, 2015). 
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2.4.1 The WNT pathway 
 
This pathway is highly conserved throughout the animal kingdom 
(Clevers, 2006). The central player in the canonical WNT pathway 
is β-catenin. In the absence of a WNT signal, β-catenin is targeted 
for phosphorylation and consequent proteasomal degradation. The 
β-catenin phosphorylation complex consists of the tumor 
suppressors AXIN and adenomatous polyposis coli (APC) and the 
constitutively active glycogen synthase kinase 3 (GSK3) and 
casein kinase I (CKI). When WNT ligands signal through their 
Frizzled and Low-density lipoprotein Receptor–related Protein 
(LRP) co-receptors, the destruction complex is inactivated. As a 
result, β-catenin is no longer degraded and accumulates in the cell. 
The subsequent translocation of β-catenin into the nucleus results 
in the binding of β-catenin to transcription factors of the T cell 
factor/lymphocyte enhancer factor (TCF/LEF) family. TCF/LEF-β-
catenin forms an active transcriptional complex that activates 
expression of target genes. In the absence of a WNT signal, 
transcriptional repressors like Groucho bind TCF/LEF transcription 
factors (Cavallo et al., 1998) (Figure 12).  
 
 
 
 
 
 
 
INTRODUCTION 
 28
 
 
Figure 12: Components of the WNT signaling pathway. (a) In the 
absence of WNT stimulation, β-catenin levels in the cell are kept low 
through a destruction complex composed of APC, CKI, GSK3 and AXIN. 
This complex phosphorylates and targets β-catenin for proteasomal 
degradation. (b) In the presence of WNT ligands, they bind to Frizzled 
receptors and LRP co-receptors. Consequently, the destruction complex 
no longer targets β-catenin for proteasomal degradation and the β-catenin 
level rises, resulting in its translocation into the nucleus. Here β-catenin 
replaces Groucho on TCF transcription factors. Transcriptionally active β-
catenin/TCF complex activates the expression of WNT target genes. From 
(van der Flier and Clevers, 2009). 
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This pathway represents the dominant force behind the proliferative 
activity of the intestinal epithelium as many functional studies 
confirm that the WNT pathway constitutes the master switch 
between proliferation and differentiation of the intestinal epithelial 
cells. In fact, a dramatic reduction of proliferative activity in the 
crypts has been observed upon deletion of Tcf4 (Korinek et al., 
1998), depletion of β-catenin (Ireland et al., 2004), and transgenic 
expression of the secreted WNT inhibitor Dickkopf-1 (Dkk-1) 
(Kuhnert et al., 2004). On the contrary, transgenic expression of 
the WNT agonist R-spondin1 results in augmentation of crypt 
proliferation (Kim et al., 2005). 
 
Besides the maintenance of proliferation, WNT signaling is also 
required for determining the correct cell positioning in the intestinal 
epithelium. This is achieved through the regulation of the 
distribution of the tyrosine kinase receptors EPHB2 and EPHB3, 
which are targets of the β-catenin/TCF complex. Genetic deletion 
of EphB2 and EphB3 generates defects in the 
compartmentalization of crypt cells leading to Paneth cell miss-
positioning and intermingling of differentiated cells with progenitor 
cells (Batlle et al., 2002). 
 
Paneth cells are a rich source of canonical WNTs (3, 6, 9b) and, 
interestingly, they use WNT signaling for their terminal maturation 
(van Es et al., 2005; Gregorieff et al., 2005; Sato et al., 2011b).  
The stromal niche also exerts an important role in intestinal WNT 
pathway regulation. Non-canonical WNTs (2b, 4, 5a, 5b) are 
secreted by the intestinal mesenchyme (Gregorieff et al., 2005) and 
subepithelial myofibroblasts support ISC growth by secreting R-
spondins (Lei et al., 2014). 
On the other hand, microarray analysis of micro-dissected tissue 
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demonstrated a stromal source for the WNT antagonists Dkk-2, 
Dkk-3, Sfrp-1 and Sfrp-2 (Li et al., 2007). 
Therefore, mesenchymal cells have a key role in the regulation of 
WNT/β-catenin signaling, inducing this critical pathway in the stem 
and progenitor cells and preventing its abnormal activity in mature 
intestinal epithelial cells. 
 
2.4.2 The Notch pathway 
 
The Notch pathway plays a central function in intestinal cell fate 
decisions. Notch genes encode single transmembrane receptors 
that regulate a broad spectrum of differentiation processes during 
animal development (Artavanis-Tsakonas, 1999). Interaction of one 
of the four Notch receptors with any one of the five Notch ligands 
results in proteolytic cleavage of the receptor. The resulting free 
Notch intracellular domain (NICD) translocates into the nucleus 
where binds to the transcription factor RBP-Jκ (CSL or CBF1) to 
activate target gene transcription (Tamura et al., 1995). 
Like WNT signaling, the Notch pathway is essential to maintain the 
crypt compartment in its undifferentiated and proliferative state. 
Inhibition of the Notch pathway in the intestinal epithelium by 
conditional deletion of the Csl gene or through pharmacological 
inhibitors results in the complete conversion of all epithelial cells 
into goblet cells (Milano et al., 2004). Gain of function through 
specific overexpression of a constitutively active Notch1 receptor in 
the intestinal epithelium results in the opposite effect, a depletion of 
goblet cells and a reduction in enteroendocrine and Paneth cell 
differentiation (Fre et al., 2005; Stanger et al., 2005). Thus, the 
Notch pathway controls absorptive versus secretory fate decisions 
in the intestinal epithelium. 
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In particular, the direct Notch target gene Hes1 represses the 
expression of the transcription factor Math1 (Jensen et al., 2000). 
Intestines from Hes1 deficient animals show an increase in Paneth, 
goblet, and enteroendocrine cells and a decrease in absorptive 
enterocytes (Jensen et al., 2000; Suzuki et al., 2005). Intestinal 
Math1 expression is required for commitment toward the secretory 
lineage because the epithelium of Math1 mutant mice is populated 
only by enterocytes (Yang et al., 2001). 
 
2.4.3 The EGF pathway 
 
Epidermal Growth Factor (EGF) is the most described ligand of the 
family of EGF Receptors. These ligands exist as pro-proteins that 
are cleaved for their activation/secretion. When bound to their 
ligand, the EGFRs dimerize and transactivate their kinase domains. 
This active kinase domain is able to signal to several downstream 
effector pathways that overall result in mitogenic signals (Yarden 
and Shilo, 2007). In the case of the intestine, EGF is one of the 
major mitogens required for ISC growth (Sato et al., 2009). 
LRIG1, a marker for stem and early TA cells, acts as a negative 
regulator of EGF signaling. Previous research has shown that 
genetic inactivation of this gene in mouse models leads to an 
increase in the size of the ISC population (Wong et al., 2012). 
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2.4.4 The BMP pathway 
 
2.4.4.1 Components of canonical BMP signaling 
 
Bone Morphogenetic Proteins (BMPs) represent the largest 
subgroup of the TGFβ superfamily. They account for nearly two 
thirds of the ligands of the TGFβ superfamily and are characterized 
by a high degree of promiscuity with regards to interactions 
between ligands and receptors (Kim and Choe, 2011; Mueller and 
Nickel, 2012). Dimeric BMP ligands (homo- or hetero-dimers) bind 
to two copies of a heteromeric signaling complex composed of 
BMP receptor 1 (BMPRI) and BMP receptor 2 (BMPR2) (Figure 
13). There are five known BMP type 1 receptors: ALK1 (Acvrl1), 
ALK2 (ActRI), ALK3 (BMPRIA), ALK4 (ActRIb) and ALK6 
(BMPRIB). Three BMP type 2 receptors have been shown to be 
bound by BMPs: BMPR2, ActRIIa and ActRIIb (Bragdon et al., 
2011; Nohe, 2004). BMPs bind with different affinity to these 
receptors. The initial interaction occurs with the high affinity 
anchoring receptor that is the BMP type 1 receptor. Dimerization of 
the BMP type 1 and type 2 receptors results in the phosphorylation 
of the intracellular glycine/serine-rich domain (GS-box) in the BMP 
type 1 receptor by the BMP type 2 receptor. In the canonical BMP 
pathway, the activated BMP type 1 receptor recruits and 
phosphorylates the receptor-associated SMAD1, SMAD5 and 
SMAD8. Phosphorylated SMADs then form heteromeric complexes 
with a co-SMAD (SMAD4) and enter the nucleus where they 
interact with other transcription factors and regulate target gene 
expression such as the direct targets ID1, ID2 and ID3 (Figure 13) 
(Brazil et al., 2015). 
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2.4.4.2 Negative and positive regulators of BMP pathway 
 
BMP activity can be regulated by extracellular modulators including 
Noggin (NOG), Gremlins (GREM1 and GREM2), Chordin (CHRD), 
and BMP and Activin Membrane-Bound Inhibitor (BAMBI). In 
particular, NOG (Groppe et al., 2002), GREM1/2 (Topol et al., 
2000) and CHRD (Larraín et al., 2000) directly bind and dimerize 
with BMP ligands effectively blocking signal transduction upstream 
of the receptors (Figure 13). BAMBI acts as a decoy receptor as it 
resembles the BMP type 1 receptors but lacks the GS box. As a 
result, it sequesters ligands from active receptors inhibiting BMP 
signal transduction (Onichtchouk et al., 1999). 
There are also BMP intracellular modulators such as SMAD6, 
SMAD7 and SMAD Ubiquitin Regulatory Factors (SMURF1 and 
SMURF2). SMAD6 (Imamura et al., 1997) and SMAD7 
(Souchelnytskyi et al., 1998) are inhibitory SMADs as they can 
either mediate degradation of BMP type 1 receptors in the 
cytoplasm or interact with transcriptional repressors in the nucleus 
(Yan et al., 2009). SMAD7 blocks both BMP and TGFβ signaling, 
while SMAD6 acts specifically on the BMP pathway (Zhang et al., 
2007). SMURF1 and 2 are ubiquitin ligases that are recruited by 
SMAD6 and SMAD7 to target both BMP type 1 receptors and 
SMAD1/5/8 for proteasomal degradation (Murakami et al., 2003). 
Interestingly, SMAD6 is also a BMP target gene, denoting the 
existence of a feedback regulation of the pathway. 
BMP co-receptors that act as positive regulators of the pathway 
also exist. These function by potentiating the interactions between 
BMP ligands and type 1 receptors. These co-receptors are 
Endoglin (CD105), TGFBR3 and DRAGON (Barbara et al., 1999; 
Kirkbride et al., 2008; Lee et al., 2008; Samad et al., 2005; 
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Yamashita et al., 1994) 
 
 
 
Figure 13: Components of canonical BMP pathway. BMPs are 
processed by peptidases to generate mature dimers. These dimers bind 
to two copies of the BMP type I and type II receptors, generating 
heterohexameric complexes that trigger the activation of the downstream 
pathway. Regulation of the BMP pathway can occur via binding of 
extracellular antagonists (1) or in the plasma membrane via the action of 
pseudo-receptors such as BAMBI (2). Smad1/5/8 phosphorylation can 
also be inhibited by SMAD6 binding to the receptors. SMAD6 can be 
inactivated by the action of PMRT1 methyltransferase (3). Additional 
regulation of BMP signaling occurs via ubiquitin ligases such as Smurf (4), 
via miRNA- (5) and via methylation- (6) mediated control of BMP gene 
expression. From (Brazil et al., 2015). 
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2.4.4.3 BMP pathway in intestinal homeostasis 
 
The switch from proliferation to differentiation must be finely 
regulated along the crypt-villus axis. The activation of WNT, Notch 
and EGF pathways is required for the maintenance of the SC 
compartment. On the other hand, the WNT pathway must be 
counteracted at the top of the intestinal crypt in order to allow 
differentiation.  
BMP signaling seems to play a major role in normal intestinal 
homeostasis by restricting WNT activity at the bottom of the crypts 
and promoting differentiation at the top (Figure 14). Indeed, in vivo 
specific ablation of BMP signaling in the intestinal epithelium 
impairs terminal differentiation of the intestinal secretory lineage 
(Auclair et al., 2007), whereas full intestinal blockade of the BMP 
pathway results in ectopic SC niches in the villus and the eventual 
appearance of benign outgrowth called hamartomas (Haramis et 
al., 2004). As a confirmation of the above, in vitro ISC expansion 
requires inhibitors of BMP pathway such as NOG (Jung et al., 
2011; Sato et al., 2009). 
 
Active BMP signaling is commonly assessed by immune detection 
of phosphorylated SMAD1/5/8 and is observed within differentiated 
epithelial cells and throughout the stroma of the lamina propria 
(Haramis et al., 2004; Hardwick et al., 2008). Kosinski et al. 
(Kosinski et al., 2007) gave an explanation of the lack of active 
BMP signaling in the SC zone finding that myofibroblasts and 
muscularis mucosae cells in proximity to this zone secrete the BMP 
inhibitory molecules GREM1, GREM2, and CHRD1. Interestingly, a 
recent study has identified GREM1 as a marker of the cells of 
origin of the periepithelial intestinal mesenchyme, the intestinal 
reticular stem cells (iRSCs) (Worthley et al., 2015). A model has 
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been proposed in which cryptal myofibroblasts and muscularis 
mucosae cells, via localized secretion of BMP antagonists, create a 
low BMP gradient at the bottom of the crypt, contributing to the 
establishment of a SC niche where WNT signaling proceeds 
unopposed. As cells migrate up the crypt-villus axis, BMP levels 
increase, generating an environment that promotes epithelial 
differentiation (Figure 14). 
 
In the normal intestinal epithelium the study of BMPs has mainly 
focused on BMP2, BMP4 and BMP7. BMP2 has been shown to be 
expressed in terminally differentiated epithelial cells of colon and 
small intestine, whereas BMP7 was localized to myofibroblasts 
adjacent to the most terminally differentiated epithelial cells. BMP4 
expression has been detected in mesenchymal cells located 
around crypts and within villi in the small intestine (Batts et al., 
2006; van Dop et al., 2009; Haramis et al., 2004; Hardwick et al., 
2008; Kosinski et al., 2007). 
 
In particular, Hedgehog (HH) signaling is the primary determinant 
of stromal BMP synthesis and thus contributes to the establishment 
of the epithelial SC niche (Sukegawa et al., 2000). Epithelial 
synthesis of HH proteins in the adult intestine is restricted to 
differentiated cells, ensuring a lower level of BMPs within the 
proliferative zone (Figure 14) (van den Brink, 2007; Shyer et al., 
2015). Indeed, Ihh knockout mice display villus branching, aberrant 
crypt formation and increased epithelial proliferation (Kosinski et 
al., 2010). Conversely, constitutively active HH signaling results in 
premature enterocyte differentiation and depletion of SCs in the 
crypt (van Dop et al., 2009). 
 
The dichotomy between WNT and BMP finely regulates the fate of 
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intestinal epithelial cells. Interestingly, it has been described that 
WNT signals in the SC niche induce nearby fibroblasts to produce 
the BMP antagonist GREM2, inhibiting differentiation and 
promoting expansion of SCs in their microenvironment (Klapholz-
Brown et al., 2007). However it is not clear how BMP signaling 
manages to counteract the WNT-driven gene program. Kosinski et 
al. showed that treatment of normal intestinal cells with GREM1 
enhanced WNT signaling, as determined by cytoplasmic and 
nuclear translocation of β-catenin and increased WNT target gene 
expression (Kosinski et al., 2007). It has also been described that 
BMPs can antagonize WNT signaling by stabilizing Phosphatase 
and Tensin homolog (PTEN), resulting in decreased AKT activity, 
which culminates in decreased nuclear β-catenin (Waite and Eng, 
2003). Further, alternative SMAD-independent BMP signaling can 
occur when a BMP type 2 receptor initiates Mitogen-Activated 
Protein (MAP) kinase cascades (Miyazono et al., 2010). 
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Figure 14: Epithelial-mesenchymal interactions orchestrate HH, BMP 
and WNT signaling in the intestinal crypt. HH proteins produced by 
differentiated epithelial cells trigger stromal BMP synthesis. Active BMP 
signaling within the differentiated compartment contributes to 
maintenance of the differentiated state. Within the SC niche, lack of HH 
signaling leads to reduced stromal BMP synthesis. Secretion of WNTs by 
Paneth cells and myofibroblasts, in addition to promote self-renewal of 
ISCs, may also induce synthesis and secretion of BMP inhibitors by the 
underlying myofibroblasts and muscularis mucosae cells. BMP 
antagonism within the SC niche would further enhance WNT signaling. 
From (Powell et al., 2011). 
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2.5 Identification of ISCs 
 
2.5.1 Historical models of adult ISC identity 
 
Over the past decades two models of ISC identity have competed: 
the “stem cell zone model” and the “+4 model” (Figure 15). 
Based on pulse-chase experiments, the “stem cell zone model” 
proposed that the columnar cells at the base of the crypt (CBCs) 
were the stem cells (Bjerknes and Cheng, 1999; Cheng and 
Leblond, 1974). The authors described the CBCs as being actively 
phagocytic, clearing dead cells from the crypt base. Taking 
advantage of this property, they pulsed mice with tritiated thymidine 
and irradiated them. They observed that surviving CBCs contained 
radiolabelled phagosomes as a consequence of neighboring CBCs 
that had died. Initially, only CBCs were marked, but at later time 
points also the differentiated cells became radiolabelled. This was 
interpreted as CBCs being the common ancestor of the 
differentiated epithelial cells of the intestinal epithelium. 
Yet for many years the accepted identity for the ISCs was that 
proposed in the “+4 model” (Potten, 1975). This model was based 
on label retaining experiments under the assumption that crypt 
cells capable of label retention (LRCs or label retaining cells) were 
ISCs. LRCs were located in the position “+4”, immediately above 
Paneth cells rather than at the crypt base and were also highly 
sensitive to ionizing radiation (Potten, 1977). This was a SC trait 
believed to ensure that long-lived cells would not survive DNA 
damage that could eventually lead to cancer. 
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2.5.2 Identification of Lgr5 as ISC marker and validation of CBCs 
as ISCs 
 
After the cornerstone discovery that constitutive activation of the 
WNT pathway was the key driver of colorectal cancer (CRC) 
initiation (Korinek et al., 1997), the Clevers group investigated the 
physiological role of TCF4 by using engineered mouse models. 
They observed that the WNT signaling pathway was essential for 
the development and maintenance of the mouse intestine as Tcf4 
deficient mice died shortly after birth due to the lack of the 
proliferative compartment in the intestinal epithelium (Korinek et al., 
1998). They also analyzed the transcriptional program driven by 
WNT signaling in CRC cells and observed that constitutive 
activation of WNT pathway leads to the initiation of tumorigenesis 
by the acquisition of a constitutive stem/progenitor gene program in 
crypt cells (Van de Wetering et al., 2002). Consequently, they 
analyzed in detail target genes of the WNT pathway to identify 
potential ISC restricted genes.  
 
In 2007, the generation of a mouse carrying the knock-in allele 
eGFP-ires-CreERT2 under the promoter of the Lgr5 gene allowed to 
visualize restricted Lgr5 expression in CBC cells and to perform 
lineage tracing experiments in vivo that confirmed Lgr5 as a bona 
fide ISC marker (see Figure 5) (Barker et al., 2007). 
By using these Lgr5-eGFP knock-in mice, the Clevers group was 
consequently able to purify and expand single Lgr5+ cells in vitro, 
showing that Lgr5+ cells are the only clonogenic cells in the 
intestine (see Figure 6). In order to maintain these cultures, the 
authors confirmed that activation of WNT and EGF signaling was 
required, as well as the blockade of the BMP pathway (Sato et al., 
2009).  
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2.5.3 Validation of “+4 cells” as ISCs 
 
In support of the “+4 model”, several genes have been reported to 
be specifically expressed in the “+4 SCs” (Figure 15). Although 
some of these markers have been validated by in vivo lineage 
tracing, many of them seem to mark epithelial cell populations 
distinct from the LRCs originally described by Potten. This may 
reflect the existence of phenotypically distinct SC populations 
residing at the +4 position. However, the validity of some of these 
candidate +4 SC markers remains controversial, due to the fact 
that some mouse models do not faithfully report the endogenous 
expression pattern of these candidate SC markers. 
 
- BMI1: the Bmi1 gene encodes a component of the polycomb 
repressor complex. 
In situ hybridization (ISH) analyses documented Bmi1 expression 
at the +4 position, which was confirmed using a Bmi1-eGFP 
reporter mouse model (Sangiorgi and Capecchi, 2008; Tian et al., 
2012). In vivo experiments using a Bmi1-ires-CreERT2/R26R-lacZ 
mouse model revealed the presence of a Bmi1+ reserve SC 
population harboring relatively quiescent and radiation resistant 
cells that can still repopulate the intestinal epithelium after ablation 
of Lgr5+ cells (Tian et al., 2012). Additionally, in vivo ablation of the 
Bmi1+ population led to crypt loss, and Bmi1+ cells could generate 
epithelial organoids in culture (Sangiorgi and Capecchi, 2008; Yan 
et al., 2012). Functionally, it has been demonstrated that BMI1 is 
necessary for ISC self-renewal by acting downstream of Notch 
(Lopez-Arribillaga et al., 2015). 
However, further studies have documented a broad endogenous 
Bmi1 expression throughout the proliferative zone of the crypt and 
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were not able to reproduce the intestinal lineage tracing of the 
original study (Itzkovitz et al., 2011; Muñoz et al., 2012).  
 
- HOPX: The Hopx gene encodes an atypical homeobox protein 
and its expression at +4 position was shown with a Hopx-lacZ 
reporter mouse (Takeda et al., 2011). Hopx+ cells were relatively 
quiescent and radiation resistant, and they harbored the capacity to 
rapidly proliferate in response to irradiation. In vivo lineage tracing 
using a Hopx-ires-CreERT2 mouse model, showed that activation of 
the reporter gene at +4 position produced persistent, multipotent 
tracings throughout the intestine.  
Comparative expression profiling of Hopx+ cells and their crypt 
base progeny showed that Hopx+ cell descendants have higher 
expression of Lgr5 and other CBC markers. Conversely, organoid 
culture assays confirmed that isolated Lgr5+ CBCs give rise to 
Hopx+ cells ex vivo (Takeda et al., 2011). These observations 
support a model in which proliferating Lgr5+ SCs and quiescent 
Hopx+ SCs are located at distinct anatomical locations within the 
crypt and efficiently interconvert to ensure correct homeostasis. 
However, it should be noted that a different expression profile for 
Hopx was reported in a separate study (Muñoz et al., 2012). 
 
- LRIG1: The Lrig1 gene encodes a transmembrane receptor that 
functions as inhibitor of ERB proteins. 
In vivo lineage tracing using an Lrig1-ires-CreERT2 mouse model 
generated long-term tracing typical of multipotent SCs throughout 
the small intestine (Powell et al., 2012). Reporter gene activation 
was mostly observed within positions +2 to +5, but also in the lower 
portion of the TA compartment. In the colon, Lrig1 expression 
marked a small population of cells at the very bottom of the crypt, a 
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minority of which overlapped with Lgr5. The lineage tracing 
indicated that some but not all the Lrig1+ cells were cycling SCs 
contributing to daily epithelial homeostasis. The quiescent cells 
were induced to proliferate and were able to repopulate the colonic 
intestine following irradiation. An independent study also 
documented Lrig1 as being expressed in a broad gradient, with 
extensive overlap with Lgr5+ CBC stem cells (Muñoz et al., 2012). 
These Lrig1+ cells were also shown to be actively proliferating. 
Functionally, the Lrig1 intestinal knockout showed crypt hyperplasia 
after birth with the expansion of the Lgr5+ compartment. This was 
linked to deregulated ErbB expression in the SC compartment.  
Collectively, these studies suggest that LRIG1 regulates ERBB 
signaling in ISCs. However, its broad expression gradient in the 
crypts of the small intestine disqualifies it as a specific ISC marker. 
 
- TERT: it is a catalytic subunit of the telomerase enzyme. 
Elevated telomerase expression is considered to be a SC feature 
that protects against replication-induced senescence. 
Using Tert-GFP reporter mice, predominantly quiescent Tert+ cells 
were detected at +4 position (Breault et al., 2008). In vivo lineage 
tracing showed that a small fraction of Tert+ crypt cells were 
cycling SCs contributing to daily epithelial homeostasis in both 
small intestine and colon (Montgomery et al., 2011). The other 
quiescent Tert+ cells could be activated after epithelial damage. 
However, other studies detected TERT expression and telomerase 
activity in all proliferative cells of the crypt, with highest levels within 
Lgr5+ SCs (Itzkovitz et al., 2011; Schepers et al., 2011). This fits 
better with the idea that such elevated telomerase activity would 
probably benefit the highly proliferative Lgr5+ SCs. 
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Figure 15: CBC stem cells and +4 stem cells. Summary of markers and 
characteristics defining CBC SCs and +4 SCs according to up to date 
studies. From (Barker, 2014). 
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2.5.4 Intestinal plasticity and models of epithelial regeneration 
 
Despite all of the current tools, the true identity of adult ISCs is still 
controversial. 
It has been demonstrated that Lgr5+ CBC cells ensure intestinal 
epithelial homeostasis under physiological conditions (Barker et al., 
2007) (Figure 16 A). However, it has also been shown that the 
intestine can survive short-term loss of CBCs in vivo, suggesting 
the co-existence of distinct ISC pools in the niche or the ability of 
committed cells to be reconverted to SCs (Tian et al., 2012). 
In order to reconcile opposing views, the “plastic model” for ISC 
identity has been proposed. This model suggests the existence of 
an ISC niche composed of a pool of active SCs (CBCs), involved in 
daily epithelial homeostasis, and a pool of quiescent “reserve” SCs 
that can be activated upon injury (Figure 16 B, C). 
Reserve ISCs can be identified within Bmi1+ cells, since in vivo 
lineage tracing of Bmi1+ cells, following Lgr5+ CBC cells ablation, 
showed that Bmi1+ cells can repopulate the Lgr5 SC pool (Tian et 
al., 2012). Nevertheless, Bmi1, as well as other “+4 markers”, have 
been reported to have a broad expression pattern throughout the 
proliferative compartment of the crypt (Muñoz et al., 2012). 
An alternative view considers the ability of progenitor (TA) cells to 
re-acquire SC identity upon loss of the Lgr5+ population (Figure 16 
B, D). Indeed, in vitro experiments have demonstrated that 
exposure to WNT3A efficiently re-converted Lgr5- TA cells to Lgr5+ 
SCs (Sato et al., 2011b). 
This model is supported by a separate study where histone H2B-
YFP (yellow fluorescent protein) was used to identify and isolate 
LRCs in the small intestine. Authors observed a pool of LRCs 
presenting a mixed phenotype as they expressed markers of 
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Paneth cells, enteroendocrine cells, Lgr5 and +4 SC markers. 
Under physiological conditions, these cells acted as progenitors of 
Paneth and enteroendocrine cells. Upon irradiation-induced 
damage, these LRCs were converted to cycling multipotent SCs 
contributing to epithelial regeneration (Buczacki et al., 2013) 
(Figure 16 B, D). As these LRCs were characterized as being a 
subpopulation of Lgr5+ cells and the intestinal epithelium is able to 
survive to Lgr5+ SC ablation, a further Lgr5- SC population should 
exist. An independent study suggested that Paneth cells (Roth et 
al., 2012) exhibited this capability although this observation was not 
confirmed in the study performed by Buczacki et al. The colonic 
epithelium, deprived from Paneth cells and LRCs, is also still able 
to survive acute Lgr5+ cells ablation, strongly suggesting the 
existence of a further Lgr5- SC population. 
In particular, Van Es et al have shown that Notch ligand Delta-like1 
(DLL1) positive cells residing at the +5 position physiologically 
represent the progenitors of the secretory lineage. Following Lgr5+ 
cells ablation, Dll1+ cells can convert into multipotent Lgr5+ cells 
and contribute to the regeneration of the epithelium (van Es et al., 
2012) (Figure 16 B, D). 
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Figure 16: Model for intestinal epithelial regeneration. In this model, 
CBC cells are responsible for daily epithelial homeostasis (A) whereas 
more quiescent “reserve” SCs (+4 cells) can be activated following injury 
(B and C). This model also proposes that cells residing in lower positions 
of the TA compartment can acquire SC identity to ensure correct epithelial 
homeostasis in case of loss of the other SC populations (D). From 
(Barker, 2014). 
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3.  Colorectal cancer (CRC) 
 
3.1 Epidemiology of CRC 
 
CRC is one of the most prevalent tumors being the second most 
diagnosed cancer worldwide in women and the third in men. 
Respectively, it is estimated to be the fourth and third most deadly 
cancer in women and men (www.cancer.gov). 
North America and Europe are among the areas with the highest 
incidence rate. Moreover, CRC incidence rate is alarmingly 
increasing in Spain and other nations with historically low rates of 
CRC (Jemal et al., 2011). 
More than 90% of all cases occur in individuals older than 50 
years. Beside the older age, risk factors include high fat, alcohol or 
red meat intake, obesity, lack of physical activity and smoking 
(Watson and Collins, 2011). 
 
3.2 TNM staging and disease management 
 
The 5 year survival rate of CRC patients is related to the tumor 
stage at time of diagnosis, that to date is still the most robust 
predictor of clinical outcome (Figure 17). 
The staging system is referred to the TNM (Tumor extent, Nodal 
involvement and presence of Metastases) system. 
Stage 0 is the earliest detectable non-invasive malignant lesion and 
is confined to the mucosa layer. The only difference between stage 
0 and I is that a stage I CRC has broken the mucosa layer, but has 
not penetrated the muscle layer. Both stage 0 and stage I CRCs 
are surgically resected and no adjuvant therapy is usually 
indicated. These patients have low risk of relapse and a survival 
rate of 90%. 
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Stage II CRCs display invasion through the muscle layer, the 
serosa and/or adjacent tissue. The treatment involves the resection 
of a portion of the colon (colectomy) and the use of chemotherapy 
alone or in combination with other drugs. These patients have a 
survival rate around 70%. 
Stage III includes CRCs that have invaded the nearby lymph nodes 
but not distal organs, yet. The treatment includes resection of the 
local lymph nodes, colectomy and combined therapies. 
The major cause of death in patients with CRC at stage II and III is 
disease relapse that can occur even years after the end of the 
therapy. Relapses occur in form of metastasis (preferentially in liver 
and lungs) and are due to the presence of disseminated cells that 
survived therapy. 
Stage IV CRCs are large, invasive tumors that at the time of 
diagnosis have already disseminated to distant organs. When the 
tumors are unresectable, due to large metastasis or multiple 
metastases, the treatment involves a combination of therapies to 
shrink the tumor burden prior surgery. This may be followed by 
further drug combination treatments post-surgery. Tumors with 
incurable metastatic lesions are subjected to palliative treatments 
to improve the quality of life of the patient. Stage IV patients have a 
survival rate lower than 8%. 
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Figure 17: Overview of American Join Committee on Cancer TNM 
staging (7th ed.) for CRC. Survival and recurrence rate of the different 
stages of CRC. 
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3.3 Pathogenesis and genetics of CRC 
 
Approximately 75% of patients with CRC acquire the disease 
sporadically, whereas around 25% of individuals with CRC have 
some family history suggesting a hereditary contribution (Burt, 
2010). 
 
The vast majority of CRCs are initiated by the uncontrolled growth 
of colon epithelial cells that give rise to glandular clusters called 
adenomas (Figure 18). Once an adenoma has acquired sufficient 
genetic aberrations to become malignant it is referred to as an 
adenocarcinoma, which is the most common type of CRC (95%). 
The progression from a benign lesion to a fully malignant CRC is a 
process that requires many years (Vogelstein, 1996). In particular, 
genetic characterization of various stages of CRC allowed Fearon 
and Vogelstein to propose a model of CRC progression based on 
the acquisition of successive genetic alterations (Fearon and 
Vogelstein, 1990) (Figure 18). This model suggests that colon 
tumors are formed due to progressive accumulation of genetic 
alterations and that, although a preferred sequence of these 
mutations exists, the kind of mutations is the determining factor of 
tumor biology rather than the order in which the mutations appear. 
The earliest detectable lesions are aberrant crypt foci (ACF), which 
are usually associated with aberrant activation of the WNT 
signaling pathway. In 80% of the cases loss of function mutations 
in the tumor suppressor gene APC can be found (Figure 18). The 
pre-malignant lesions characteristically acquire further mutations 
through chromosomal instability (CIN). Over time, rapidly 
proliferating adenomas acquire further somatic mutations and 
progress toward malignancy. Most commonly, these further 
mutations hyper-activate key pro-tumorigenic pathways (KRAS, 
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BRAF, PI3K), and block tumor suppressor pathways (TGFβ/BMP, 
P53, PTEN) (Fearon and Vogelstein, 1990; Markowitz and 
Bertagnolli, 2009) (Figure 18). 
 
 
 
 
Figure 18: CRC progression. A Schematic representation of the major 
genetic events and tissue alterations leading to the acquisition of 
malignancy. Adapted from (Fearon and Vogelstein, 1990; Hardwick et al., 
2008) and Batlle lab ©. 
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As previously mentioned, the mutations can be inherited or 
acquired. 
75% of the cases of CRC are sporadic, which suggests a strong 
influence of the environment and ageing on promoting CRC 
(Kinzler and Vogelstein, 1996). Supporting the relevance of these 
two factors is the data that 65% of the cases are diagnosed in 
developed countries. 
The remaining 25% of CRCs show hereditary components but only 
5% of them are caused by known genetic mutations. The study of 
this kind of tumors has provided important mechanistic insights that 
have improved our knowledge about CRC initiation and 
progression. 
 
- Familial adenomatous polyposis (FAP): is a hereditary syndrome 
characterized by the formation of hundreds benign polyps in the 
colon of the patients. As a consequence, patients are at high risk of 
developing CRC (Kinzler and Vogelstein, 1996). Genetic studies 
revealed the presence of inactivating mutations in one APC allele 
in the germline of most patients. Over time, as the wild-type APC 
allele is stochastically inactivated, the WNT pathway becomes 
deregulated leading to constitutive activation of β-catenin/TCF 
complex and to the appearance of polyps (Kinzler and Vogelstein, 
1996). 
 
- Hereditary non-polyposis colon cancer (HNPCC), also referred as 
Lynch Syndrome: is an autosomal dominant pathology that also 
enhances CRC risk (Kinzler and Vogelstein, 1996). The genetic 
analysis of these patients led to the identification of mutations in 
DNA repair genes MLH1 and MSH2. This leads to microsatellite 
instability and the consequent generation of mutations in genes 
with nucleotide repeated sequences such as, amongst others, β-
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catenin. Activating mutations in β-catenin also lead to constitutive 
activation of β-catenin/TCF activity.  
 
- Juvenile Polyposis (JP): these patients possess germline 
mutations in either BMPR1A or SMAD4, thus affecting BMP and/or 
TGFβ pathways (Hardwick et al., 2008). Unlike FAP and HNPCC, 
JP patients develop cists filled polyps surrounded by non-dysplastic 
epithelium and abundant stroma (Daniels and Montgomery, 2007; 
Gammon et al., 2009). These lesions are called hamartomatous 
polyps and eventually can progress to adenomatous polyps. Thus, 
this autosomal dominant disease increases the risk of developing 
CRC (Brosens et al., 2007).  
 
Loss of function mutations in PTEN have been found in patients 
with Bannayan Riley Ruvalcaba Syndrome (BRRS) and Cowden 
Syndrome (CS), which are even more rare polyposis syndromes 
characterized by the development of hamartomas (Edelman and 
Eng, 2010). A link between BMP and PTEN has already been 
proposed (Waite and Eng, 2003). 
 
It has become increasingly clear that the mechanisms involved in 
these rare hereditary syndromes also participate in the 
development of sporadic CRC. Indeed, around 85% of sporadic 
CRCs present mutations in components of the WNT signaling 
pathway whereas about 10-15% displays defects in the DNA 
damage repair machinery. 
On the other hand, it has been speculated that the TGFβ/BMP 
pathway could have a more prominent role during later stages of 
tumor progression, during the transition from benign status 
(adenoma) to malignant status (carcinoma) (Hardwick et al., 2008). 
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3.4 WNT pathway alterations in CRC and the connection to SC 
biology 
 
As mentioned before, the WNT signaling pathway is the most 
commonly mutated pathway in CRC and the first and only genetic 
alteration observed in the earliest lesions. The genetic program 
driven by the β-catenin/TCF transcription complex in CRC was 
deciphered by generating CRC cell lines where the blockade of β-
catenin/TCF activity could be induced. By studying the expression 
of a set of putative WNT target genes in mouse and human tissues, 
it was observed that both early CRC lesions and stem/progenitor 
cells of normal intestinal crypts expressed a similar genetic 
program, suggesting the acquisition of a stem/progenitor cell 
phenotype during tumorigenesis (Batlle et al., 2002; Van de 
Wetering et al., 2002). 
WNT target genes are highly upregulated in CRC (Batlle et al., 
2005; Van der Flier et al., 2007). Among them, MYC oncogene 
regulates downstream expression of a large subset of genes (Van 
de Wetering et al., 2002). Supporting this notion, Myc ablation is 
able to rescue the phenotype imposed by Apc deletion in mice 
(Sansom et al., 2007). 
 
3.4.1 Identification of the adenoma stem cell (AdSC) hierarchy 
 
Further to the identification of Lgr5+ ISCs, the Clevers group also 
identified the cells of origin of intestinal cancer (Barker et al., 2009). 
By deleting Apc either in ISCs or in their progeny (TA and 
differentiated cells), in genetic mouse models, they observed that 
only deletion of Apc in Lgr5+ ISCs resulted in the formation of 
adenomas, whereas Apc deficiency in Lgr5- cells mainly generated 
small aberrant crypt foci. This result suggested that Lgr5+ ISCs 
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represent the cells of origin of intestinal cancer (Barker et al., 
2009). 
Of note, despite nuclear β-catenin and Myc expression (hallmarks 
of active WNT signaling) are homogeneously distributed in the 
adenoma mass, only few cells residing at the base of adenoma 
glands retained Lgr5 expression, suggesting the presence of an 
AdSC compartment and a hierarchical organization. 
To explore this hypothesis, the Clevers group performed lineage 
tracing experiments from Lgr5+ cells in Apc null mice using the 
multicolor Rosa26R-confetti tracing allele (Schepers et al., 2012). 
Upon a first tamoxifen induction and consequent activation of the 
Cre recombinase in Lgr5+ cells, the confetti reporter recombines in 
a random fashion adopting one of the four possible fluorescent 
colors. Every active color remains associated to a silent color that 
can be activated upon a second induction of tamoxifen, resulting in 
a color switch (re-tracing) (Figure 19 A). Following 24 days of re-
tracing, the newly labeled Lgr5+ cells reconstituted the adenomas 
and all cell types within it (Figure 19 B). 
 
INTRODUCTION 
 57
 
 
 
Figure 19: Lineage tracing from adenoma Lgr5+ cells. A. Possible 
outcomes of Rosa26-Confetti locus after the first tamoxifen induction 
(tracing) and the second tamoxifen induction (re-tracing). B. 24 days-
adenoma shows a few Lgr5+ newly labeled cells (blue) 2 days after re-
tracing (a). The newly labeled cells start repopulating the adenoma (b) 
and fully repopulate it after 24 days of re-tracing (c). LGR5-EGFP cells are 
shown in green. C. Adenomas maintain a hierarchical organization 
despite the SC compartment is expanded. Lgr5+ cells still reside at the 
bottom of adenoma gland intermingled with paneth cells. From (Schepers 
et al., 2012). 
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A different group identified Doublecortin-like kinase 1 (DCLK1) as a 
specific marker of AdSCs, but not normal ISCs (Nakanishi et al., 
2013). They performed lineage tracing of Dclk1+ cells and 
observed that Dclk1 marked post mitotic tuft cells in normal 
intestine, as already reported (Gerbe et al., 2009). Nevertheless, in 
adenomas, Dclk1 marked a small proportion of Lgr5+ cells that 
could generate all the adenoma cell types. Targeted depletion of 
Dclk1+ cells from adenomas using an inducible diphtheria toxin 
allele resulted in adenoma collapse. The surrounding normal tissue 
remained unaffected (Nakanishi et al., 2013). 
 
3.4.2 Colorectal cancer stem cells (CRC-SCs) 
 
In the last two decades, the modern molecular genetics have 
allowed the identification of several genomic alterations as driving 
forces of tumor initiation and progression (Hanahan, 2000). These 
findings led to the proposal of the “clonal evolution model” that 
states that any cell clone within the tumor has the same potential to 
sustain the tumor, depending on the stochastic acquisition of 
genetic mutations that would give a selective advantage to grow. 
Thus, this model assumes that cells with the same genotype 
potentially have the same ability to sustain the tumor and the clonal 
evolution is explained as a stochastic process determined by the 
environment and driven by the competition between cell clones. 
Nevertheless, in 1994 a study showed for the first time the 
presence of heterogeneity within genetically identical tumor cells. 
The authors purified cell subpopulation from human acute myeloid 
leukemia (AML) and observed that only one subpopulation was 
able to initiate and sustain the tumor when injected in 
immunocompromised mice (Lapidot et al., 1994). These findings 
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suggested the presence of a hierarchical organization in AML. In 
the follow-up study, the group demonstrated that these tumor 
initiating cells (TICs) retained the same gene program of 
hematopoietic stem cells (Bonnet and Dick, 1997). 
These pioneer studies led to the proposal of the “cancer stem cell 
model” that states that the tumor, as well as the normal tissue, is 
hierarchically organized. Therefore, only a subset of cells retaining 
self-renewal ability and multipotency can sustain the tumor growth. 
Remarkably, this model identifies the cancer stem cells as real 
relevant therapeutic targets. 
Since these initial studied performed in AML, other evidence has 
accumulated that supports the existence of a hierarchical 
organization in breast tumor (Al-Hajj et al., 2003; Liu et al., 2010), 
melanoma (Boiko et al., 2010; Schatton et al., 2008) and brain 
tumor (Chen et al., 2012). 
 
The first studies showing evidence supporting colorectal cancer 
stem cells (CRC-SCs) were published in 2007 (Dalerba et al., 
2007; O’Brien et al., 2007; Ricci-Vitiani et al., 2007). These studies 
identified CD133 and CD44 as markers of colon tumor initiating 
cells upon transplantation in immunodeficient mice. Yet, these 
analyses lack a deep investigation of these markers in the context 
of normal intestinal biology and it was unclear if they just 
segregated for a subset of aggressive tumor subpopulation, or if 
they really identified a cancer population at the base of the tumor 
hierarchy reminiscent of normal SCs. The above reasons and the 
inconsistency with follow-up studies (Kemper et al., 2010; Merlos-
Suárez et al., 2011) disqualified these molecules as CRC-SC 
markers. 
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Due to the current lack of a good antibody against LGR5, our group 
identified an alternative ISC marker that could allow SC isolation 
from both mouse and human intestine. In particular, in 2011, we 
isolated human colon SCs and mouse small intestine SCs by using 
the receptor tyrosine kinase EPHB2 (Jung et al., 2011; Merlos-
Suárez et al., 2011). 
EPHB2 plays a crucial role in intestinal crypt cell positioning and 
migration as knockout mice for this receptor, or its ligand EfnB1, 
display loss of normal and tumor cell compartmentalization (Batlle 
et al., 2002; Cortina et al., 2007). In order to guide the crypt cell 
compartmentalization, WNT signaling drives EPHB2 expression 
along the crypt axis following a decreasing gradient from the 
bottom to the top (Batlle et al., 2002). 
In normal intestine, isolated EPHB2high cells from human colon 
expressed a similar gene program to that of mouse ISCs and 
strongly overlapped with the previous described signature of 
mouse Lgr5+ cells. Moreover, EPHB2high cells could be expanded 
in vitro for extended periods of time maintaining multipotency (Jung 
et al., 2011). 
In CRC, EPHB2high cells were still enriched in ISC genes and 
identified a population of undifferentiated cells at the bottom of the 
tumor glands that possessed tumor initiation capability when 
injected into immunocompromised mice (Merlos-Suárez et al., 
2011). This study demonstrated that CRC maintains a hierarchical 
organization that resembles that of the normal intestinal epithelium 
(Figure 20). Within the tumor, only the subset of cells retaining the 
ISC gene program was able to sustain the tumor, the CRC-SCs. 
Indeed, the expression level of ISC genes in CRC correlated with 
poor prognosis. 
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In the absence of a good commercial antibody for LGR5, EPHB2 
represents the best marker, to date, to isolate normal and cancer 
ISCs, of both human and mouse origin. 
 
 
 
 
 
 
Figure 20: CRC resembles the hierarchical organization of normal 
intestine. A. Schematic representation of cell hierarchical organization in 
normal intestinal crypts. B. LGR5 ISH identifies SCs at the base of the 
crypts. C. KRT20 immunohistochemistry (IHC) shows the differentiated 
cells at the top of the crypts, close to the intestinal lumen. SC and 
differentiation compartments are mutually exclusive in normal intestinal 
epithelium. D. Schematic representation of cell hierarchical organization in 
intestinal tumor glands. E. EPHB2 IHC shows decreasing expression 
gradient from the bottom to the top of tumor glands, identifying CRC-SCs 
(EPHB2high), tumor TA cells (EPHB2medium) and tumor differentiated cells 
(EPHB2low/neg). F. LGR5 ISH identifies the CRC-SC compartment. G. 
KRT20 IHC shows the differentiated compartment. SC and differentiation 
compartments are mutually exclusive in CRC. Black and green arrows 
indicate the differentiation compartment. Red arrows indicate the SC 
compartment. Blue arrow indicates the tumor proliferative compartment 
(EPHB2medium). Str: stroma. Lu: lumen. From (Merlos-Suárez et al., 2011). 
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3.5 BMP pathway in CRC 
As discussed in section 3.3, germline mutations in the BMP 
components BMPR1A and SMAD4 lead to the formation of 
hamartomatous polyps (Figure 21, bottom scheme). This link is 
supported by a study conducted by the Clevers group where they 
demonstrated that silencing of BMP in the intestine by transgenic 
over-expression of Noggin in epithelial cells, resulted in the 
formation of Juvenile Polyposis-like polyps (Haramis et al., 2004). 
Since epithelial BMP silencing is not enough to achieve this 
phenotype (Auclair et al., 2007), it has been suggested that juvenile 
polyps may develop through the so-called “landscaper mechanism” 
where an abnormal stromal microenvironment leads to neoplastic 
transformation of the adjacent epithelium. Two studies have 
demonstrated that specific mesenchymal BMP silencing, in 
fibroblasts and T cells respectively, leads to the formation of 
hamatomatous polyps (Beppu et al., 2008; Kim et al., 2006). 
On the other hand, a study reported that the human Hereditary 
Mixed Polyposis Syndrome (HMPS), which is characterized by 
colon tumors of mixed morphology, is caused by a duplication of 
the GREM1 locus resulting in ectopic epithelial expression of this 
BMP inhibitor (Jaeger et al., 2012). A recent follow-up study 
performed in mouse models confirmed that epithelial expression of 
GREM1 disrupts the homeostatic intestinal gradients, promoting 
the acquisition of SC properties in the Lgr5- compartment (Davis et 
al., 2015). 
Although a debate exists regarding the locus driving Cre 
recombinase expression in the abovementioned studies to achieve 
specific BMP silencing in the stroma, it is clear the importance of 
BMP depletion in the development of hamartomas, regardless of 
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the compartment (epithelial or stromal) used to ablate it. 
Interestingly, genetic alterations of the BMPR1A locus occur 
predominantly in the stroma of JP patients, whereas SMAD4 
mutations involve mainly the epithelium (Brosens et al., 2007). 
In addition to JP patients, components of the BMP pathway (mainly 
SMAD4 and BMPR2) have been found mutated in 70% of sporadic 
CRCs (Kodach et al., 2008). Histopathological analysis of adenoma 
and adenocarcinoma samples indicated that loss of BMP signaling 
preferentially occurs in the adenoma to carcinoma transition 
(Kodach et al., 2008) (Figure 21, upper scheme). This suggests a 
tumor suppressive role for BMP signaling during tumor progression 
rather than at tumor initiation, similarly to what has been described 
for TGFβ. Of note, since SMAD4 is a common component of TGFβ 
and BMP signaling pathways, the role of BMP in CRC has been 
historically understated in the literature. 
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Figure 21: BMP pathway in adenoma to carcinoma progression. In 
sporadic CRC, blockade of BMP signaling is one of the molecular 
alterations involved in the acquisition of malignancy and the transition 
from adenoma to carcinoma (upper scheme). In JP patients, early loss of 
BMP signaling leads to the development of benign lesions (hamartomas) 
that predispose to loss of APC and adenomatous transformation (bottom 
scheme). From (Hardwick et al., 2008). 
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Strengthening the role of BMP in CRC, Genome Wide Association 
Studies (GWAS) of CRCs have identified four low-risk susceptibility 
variants mapping in genomic regions located near the locus 
encoding for the BMP pathway components SMAD7, GREM1, 
BMP2, BMP4 and BMP7 (Slattery et al., 2010; Tomlinson et al., 
2011). 
Importantly, BMP deregulation in CRC has also been detected at 
epigenetic level. Two studies performed in CRC cell lines and 
primary tumors reported that the promoters of BMP2 and BMP3 are 
hyper-methylated and consequently silenced in a high percentage 
of CRCs (Kodach et al., 2011; Loh et al., 2008). Indeed, treatment 
of CRC cell lines with statins, which are DNA methyltransferase 
(DNMT) inhibitors, re-activated BMP and induced tumor cell 
differentiation (Kodach et al., 2011). 
Another study showed that BMP4 treatment of isolated CRC-SCs 
induced differentiation and increased response to chemotherapy by 
activating canonical pSMAD1/5/8 dependent- and non-canonical 
PI3K/PTEN dependent-BMP pathways. Only SMAD4-defective 
tumors, also harboring phosphoinositide 3-kinase (PI3K) activating 
mutations or phosphatase and tensin homolog (PTEN) loss of 
function mutations, were not responsive to BMP4 treatment 
(Lombardo et al., 2011). 
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4. GATA transcription factors
The transcription factors of the GATA family share two zinc finger 
domains that mediate not only the DNA binding through the core 
consensus sequence A/T GATA A/G, but also the interaction with 
other proteins (Maeda et al., 2005; Merika and Orkin, 1993). With a 
few exceptions, GATA1, GATA2 and GATA3 are mainly expressed 
in the hematopoietic system (Orkin, 1998), whereas GATA4, 
GATA5 and GATA6 are termed endodermal GATA factors (Kelley 
et al., 1993; Laverriere et al., 1994; Morrisey et al., 1996). 
In general, GATA factors are broadly expressed in many tissues 
and can regulate cell expansion in addition to cell specification and 
differentiation, playing an essential role in determining cell fate. 
Indeed, deregulation of GATA factors can lead to developmental 
disorders. In particular, Gata3 null mice are embryonic lethal and 
display defects in hematopoiesis, spinal cord formation and show 
growth retardation (Pandolfi et al., 1995). Gata4 ablation is early 
embryonic lethal due to defects in heart formation (Kuo et al., 1997; 
Molkentin et al., 1997). Gata5 null mice are born with abnormalities 
in the genitourinary tract of females (Molkentin et al., 2000), 
whereas Gata6 deficient mice die before gastrulation (Koutsourakis 
et al., 1999; Morrisey et al., 1998). 
4.1 GATA factors in intestinal homeostasis 
The study of GATA factors in intestine has been mainly focused on 
GATA4 and GATA6. These two factors are co-expressed in adult 
duodenum and jejunum. However, they present a different 
distribution in the ileum where GATA4 is expressed in differentiated 
cells of the villi and GATA6 in proliferative crypt cells and also in 
INTRODUCTION 
67
mucous-secreting cells (Beuling et al., 2011; Bosse et al., 2006). In 
the colon, GATA6 is the only GATA factor expressed. 
Given that Gata4/6 constitutive knockout mice are lethal before 
birth, some groups have investigated their role in adult intestine by 
generating conditional knockout alleles in mice. Intestinal Gata4 
conditional knockout results in a shift of intestinal segment identity 
along the cefalocaudal axis (Beuling et al., 2010; Bosse et al., 
2006). Loss of Gata6 in adult intestine leads to defects in 
proliferation, migration and differentiated cell maturation (Beuling et 
al., 2012). 
4.2 GATA factors in cancer 
Given their important role in determining cell fate specification, 
GATA factors are involved in in the development of many human 
malignancies. 
GATA1 is mutated in patients affected by Megakaryoblastic 
Leukemia (Wechsler et al., 2002). GATA3 can harbor several 
mutations in breast cancer (Usary et al., 2004) and it has been 
involved in T cell lymphoma (Nawijn et al., 2001).  
The abovementioned different expression of GATA4 and GATA6 in 
the ileum has suggested a potential oncogenic role for GATA6 and 
a tumor suppressive function for GATA4. Surprisingly, although 
GATA4 and GATA5 are not expressed in normal colon, they have 
been found silenced in cell lines and primary samples of CRCs 
through hyper-methylation of their promoters. Methylation did not 
correlate with CRC staging, suggesting that methylation could be 
an early event during disease progression. Consistently, GATA4 
and GATA5 over-expression in CRC cell lines impaired proliferation 
and migration (Hellebrekers et al., 2009). On the other hand, high 
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levels of GATA4 correlate with poor prognosis in ovarian tumors 
(Anttonen et al., 2005), indicating that the role of GATA factors 
during tumorigenesis is context-dependent. 
Similarly, a tumor suppressor role for GATA6 in astrocytoma has 
been proposed (Kamnasaran et al., 2007), yet GATA6 upregulation 
has been detected in 50% of pancreatic carcinomas (Fu et al., 
2008; Kwei et al., 2008). Moreover, GATA6 is highly expressed in 
the majority of CRC cell lines, adenomas and adenocarcinomas. In 
this context, GATA6 has been proposed to promote cell invasion by 
regulating urokinase plasminogen activator gene and also to 
prevent apoptosis by silencing 15-Lox-1 gene (Haveri et al., 2008; 
Shureiqi et al., 2007). 
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5. SPARC related modular calcium binding 2 (SMOC2)
5.1 SMOC2 is a novel member of the BM-40 protein family 
SMOC2 is the last characterized member of the BM-40 protein 
family (Vannahme et al., 2003). These proteins are secreted 
extracellular matrix proteins sharing an extracellular calcium-
binding (EC) domain and a follistatin-like (FS) domain (Vannahme 
et al., 2003) (Figure 22). 
BM-40, also known as secreted protein acidic and rich in cysteine 
(SPARC) or Osteonectin, was the first member to be isolated 
originally from bone and subsequently found in a variety of other 
tissues (Lane and Sage, 1994; Termine et al., 1981). SPARC is the 
best characterized member of the family and it has been reported 
to participate in the regulation of cell-matrix interactions, influencing 
bone mineralization, wound repair and angiogenesis. In particular, 
Sparc deficient mice develop cataracts, and severe osteopenia 
(Delany et al., 2000; Gilmour et al., 1998; Yan et al., 2002). These 
mice also display defects in wound healing and in tissue 
remodeling (Basu et al., 2001; Bradshaw et al., 2002; Sangaletti et 
al., 2011; Savani et al., 2000). 
In vitro experiments showed the ability of SPARC to inhibit cell 
adhesion, spreading and proliferation and to regulate the 
expression of proteins involved in matrix turnover (Brekken and 
Sage, 2000).  
In general, the extracellular matrix (ECM) is a collection of 
extracellular molecules secreted by cells that provide structural and 
biochemical support to surrounding cells. 
In particular, ECM proteins facilitate the communication between 
the cells and their microenvironment by directly binding to cell 
INTRODUCTION 
70
surface integrins and receptors, or by mediating the binding of 
other growth factors (Bornstein, 2009). Thus, the ECM proteins can 
be involved in several physiological processes (cell migration, 
adhesion, proliferation, differentiation) (Engler et al., 2006) as well 
as pathological events (wound healing and fibrosis) (Schultz and 
Wysocki, 2009; Wight and Potter-Perigo, 2011). 
The BM-40 protein family also includes SC1/hevin, QR1, 
tsc36/Flik/FRP, testican-1, -2, -3, and SMOC1 (Figure 22). 
Interestingly, SMOC1 and SMOC2 represent a distinct subgroup of 
the family, as they share a common domain organization built from 
one FS domain, one EC domain, two thyroglobulin-like (TY) 
domains and a novel SMOC-specific domain without known 
homologs (Vannahme et al., 2003) (Figure 22). 
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Figure 22: Domain organization of BM-40 proteins. FS: Follistatin-like 
domain. TY: Thyroglobulin-like domain. SMOC: Smoc protein-specific 
domain. TCAN: Testican-specific domain. EC: Extracellular calcium 
binding domain. Triangles indicate putative glycosaminoglycan-
attachment sites. Black bars within the EC domain indicate calcium 
binding EF-hands motifs. From (Vannahme et al., 2003). 
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5.2 SMOC2 biological functions 
 
Expression analysis from different tissues of adult mice indicates a 
broad expression of Smoc2. Indeed, Smoc2 expression has been 
detected in brain, thymus, lung, heart, liver, kidney, spleen, testis, 
ovary and skeletal muscle (Vannahme et al., 2003). 
Although its structural domains have been characterized, SMOC2 
biological functions are still unknown. 
In vitro analysis of its ability to bind to blood serum proteins showed 
that SMOC2 has strong binding affinity with vitronectin which is 
involved in cell adhesion, migration and proliferation and binds 
several extracellular and membrane proteins such as integrins 
(Novinec et al., 2008). 
Experiments conducted with cell lines showed that SMOC2 
promotes attachment and migration of keratinocytes (Maier et al., 
2008), potentiates angiogenic effects of other growth factors 
(Rocnik et al., 2006), and promotes growth factor-induced fibroblast 
cell cycle progression through integrin linked kinase (ILK)-mediated 
induction of cyclin D1 (Liu et al., 2008). 
SMOC proteins are abundant in vertebrates and SMOC-like 
proteins containing a conserved TY-EC domain pair were found 
throughout the animal kingdom (Novinec et al., 2006). 
In Drosophila Melanogaster, the ortholog of SMOC2 gene is called 
Magu (or Pent) and is required for germline stem cell renewal 
through the positive regulation of BMP pathway (Li and Tower, 
2009; Zheng et al., 2011). In Drosophila, the BMP ortholog is called 
Decapentaplegic (Dpp) and represents an important morphogen 
regulating wing formation. In this context, Magu acts as an 
expander of Dpp gradient during disc growth (Hamaratoglu et al., 
2011). 
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The Xenopus ortholog of human SMOC1/2 (XSmoc1) is essential 
for correct development and acts as a BMP antagonist. 
Interestingly, XSmoc1 still antagonizes BMP activity in the 
presence of a constitutively active BMP receptor, indicating a 
mechanism of action downstream of the receptor. Authors provided 
evidences that XSmoc1 counteracted BMP activation at the level of 
SMAD1/5/8 phosphorylation, suggesting the existence of 
independent SMOC signaling (through a specific receptor or 
integrins) that converges with BMP signaling downstream the 
activated receptors (Thomas et al., 2009). 
These studies provide clues supporting the involvement of SMOC 
proteins in the regulation of the BMP pathway. Moreover, in 
contrast with other known extracellular BMP regulators that directly 
bind to BMP ligands, SMOC proteins could be signaling and 
interfering with BMP through other receptors. Supporting this 
hypothesis, the above mentioned study by Liu et al. showed that 
SMOC2 interacts with αvβ1 and αvβ6 integrins and maintains ILK 
activity. 
In another study, knockdown of Smoc2 in zebrafish showed teeth 
abnormalities reminiscent of the human phenotype of oligo- and 
microdontia. Moreover, Smoc2 depletion affected the expression of 
three major odontogenesis genes: dlx2, bmp2, and pitx2 (Bloch-
Zupan et al., 2011). 
On the other hand, Smoc1 null mice showed defects in ocular and 
limb development related to disturbed expression of genes involved 
in BMP signaling (Okada et al., 2011). 
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5.3 SMOC2 in cancer and diseases 
At the moment we started this thesis, only one study reported 
SMOC2 implication in cancer. In particular, the authors showed 
that mutagenic hyper-activation of the small GTPase Ran induced 
oncogenic transformation through SMOC2 up-regulation (Milano et 
al., 2012). 
SMOC2 is also implied in other human diseases like Oligodontia 
and Vitiligo. Recessive oligondontia is linked to homozygous loss-
of-function mutation in the SMOC2 locus (Alfawaz et al., 2013; 
Bloch-Zupan et al., 2011). Other studies point to SMOC2 as a risk 
locus for Vitiligo, a common autoimmune skin disorder (Alkhateeb 
et al., 2010; Birlea et al., 2010). 
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gene expression 
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Chapter 2: Functional characterization of the novel ISC 
gene Smoc2 
1. Identification of the ISC gene Smoc2
Besides LGR5, the secreted protein Olfactomedin-4 (OLFM4) and 
transcription factor achaete scute-like 2 (ASCL2) are other widely 
used ISC markers (Schuijers, van der Flier, van Es, & Clevers, 
2014; Laurens G. van der Flier et al., 2009b). 
To date, Ascl2 is the only ISC specific gene that has shown to be 
essential for ISC maintenance, as its conditional ablation leads to 
rapid loss of ISCs, whereas its overexpression results in ISC 
expansion (van der Flier et al., 2009). 
As discussed in section 3.4.2 of the introduction, our group took 
advantage of the EPHB2 expression gradient to isolate EPHB2high 
(ISCs), EPHB2medium (TA cells) and EPHB2low (differentiated cells) 
fractions from the intestinal epithelium (Figure 23). We observed 
that EPHB2high human colon stem cells expressed a similar gene 
program to that of mouse ISCs and could be grown in culture for 
extended periods of time, while maintaining multipotency (Jung et 
al., 2011; Merlos-Suárez et al., 2011).  
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Figure 23: Sorting of intestinal epithelial cell populations based on 
EPHB2 expression. A. EPHB2 follows a decreasing expression gradient 
from the bottom to the top of the intestinal crypt. B. Representative FACS 
profile of EPHB2 expression in the intestinal epithelium. EPHB2 
expression allows the identification of EPHB2high (SCs), EPHB2medium (TA 
cells) and EPHB2low (differentiated cells) cell populations. From (Merlos-
Suárez et al., 2011). 
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We then compared three ISC signatures: the EPHB2 ISC signature 
from mouse small intestine (Merlos-Suárez et al., 2011), the human 
EPHB2 colon SC signature (Jung et al., 2011) and the LGR5 
signature from small intestine of Lgr5-EGFP mice obtained in our 
lab (Figure 24 A). By looking at these signatures, it was evident an 
over-representation of WNT target genes, strengthening the central 
role of WNT pathway in the ISC homeostasis. We focused our 
attention on the common genes among the three signatures, 
assuming that they could have an essential role in determining 
stemness. In particular, we found 3 already described ISC genes 
(Lgr5, EphB3 and Ascl2) (Barker et al., 2007; Batlle et al., 2002; 
van der Flier et al., 2009; de Lau et al., 2011) and genes (Apcdd1, 
Mex3a, Phgdh, Slco3a1, Smoc2) still not related to ISC biology 
(Figure 24 B). 
The reported involvement of SMOC2 in the regulation of the BMP 
morphogen pathway during invertebrate development (see section 
5.2 of the introduction) together with the known relevance of BMP 
in the intestine, raised our interest in studying the role of SMOC2 in 
stemness and intestinal homeostasis. Moreover, our finding that 
SMOC2 was still highly enriched in EPHB2high CRC-SCs (Merlos-
Suárez et al., 2011), strengthened our interest in characterizing its 
function in normal and pathological conditions. 
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Figure 24: Identification of the intestinal stem cell gene Smoc2. A. 
Smoc2 is one of the common genes enriched in LGR5-derived and 
EPHB2-derived ISC signatures. B. Table with the common genes 
enriched in the three ISC signatures. 
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In parallel with our studies, the Clevers group generated gene 
expression and proteomic analysis of LGR5+ cells derived from 
Lgr5-EGFP mice (Muñoz et al., 2012). In particular, they used two 
independent microarray platforms (Affymetrix® and Agilent®) and 
Mass Spectrometry (MS)-based proteomics approach. Blue 
highlighted genes in the diagram are genes confirmed by at least 
two of these methods and represent the global mouse intestinal 
stem cell signature (Figure 25 A). 
Consistently with our data, Smoc2 was one of the most enriched 
genes in LGR5+ ISCs. Moreover, ISH analysis and in vivo lineage 
tracing of the Smoc2 locus definitively established Smoc2 as a 
novel ISC gene whose expression was restricted at the crypt base 
(Muñoz et al., 2012) (Figure 25 B). 
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Figure 25: Smoc2 marks intestinal stem cells in vivo. A. Proteomic 
and transcriptomic analyses of LGR5+ mouse ISCs identify Smoc2 as one 
of the most enriched genes. D. Smoc2 ISH of mouse small intestine (left 
panel); Smoc2-driven GFP expression at the bottom of intestinal crypts 
(central panel); lineage tracing of Smoc2 expressing cells (right panel). 
From (Muñoz et al., 2012). 
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2. SMOC2 acts as a BMP inhibitor 
 
As the literature reports the involvement of SMOC2 in the 
regulation of the BMP pathway in Drosophila, Xenopus and 
Zebrafish, we decided to analyze this possibility in mammalian 
cells. We first used HeLa cells, which are responsive to addition of 
BMPs. 
Recombinant BMP2 and recombinant SMOC2 proteins were used 
in serum-free culture conditions. SMAD1/5/8 phosphorylation was 
assessed by Western Blot as readout of BMP activation 
downstream the BMP receptors. We observed strong SMAD1/5/8 
phosphorylation already 20 minutes after rBMP2 addition and the 
SMAD1/5/8 phosphorylation was maintained over time (6 hours) 
(Figure 26 A). Recombinant SMOC2 was able to block the early 
BMP pathway activation, yet its inhibitory effect was lost over time. 
In order to exclude fast rSMOC2 degradation, we generated 
doxycycline-inducible SMOC2-FLAG HeLa cells. In this system, 
SMOC2 is produced upon doxycycline induction. We observed that 
both recombinant and overexpressed SMOC2 had the same 
dynamics of BMP repression, causing a delay in the activation 
more than a full blockade of the pathway (Figure 26 A). 
Since our organ of interest is the intestine, we performed a similar 
experiment with SW480 cells. SW480 is a CRC cell line carrying a 
mutation on SMAD4. These cells are devoid of downstream BMP 
signaling but retain the response to BMP at the level of the 
receptors and SMAD1/5/8 phosphorylation. SW480s already 
presented high basal levels of pSMAD1/5/8 (Figure 26 B), 
probably as result of autocrine BMP signaling. On this cell line we 
performed response kinetics by treating the cells at different time 
points with recombinant SMOC2 (rSMOC2) and compared effects 
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to that of recombinant NOGGIN (rNOGGIN), which is a bona fide 
BMP inhibitor (Groppe et al., 2002). Since NOGGIN is composed of 
232 amino acids and SMOC2 is composed of 457 amino acids, we 
tried to achieve an equivalent molecular amount of the two proteins 
by using rNOGGIN at a concentration of 100 ng/ml and rSMOC2 at 
a concentration of 200 ng/ml. We found that both recombinant 
proteins were able to counteract BMP pathway activation, although 
the effect of rSMOC2 was weaker and less persistent than that of 
rNOGGIN (Figure 26 B). 
BMP pathway inhibition is required to culture and maintain ISCs in 
vitro. Using a specific cocktail of growth factors and inhibitors, it is 
possible to culture ISCs in 3D matrix. By doing so, their self-
renewal capability can be preserved indefinitely and they can form 
intestinal organoids (“mini guts”) resembling the architecture of 
normal intestine with a stem, a proliferative and a differentiated 
compartment (Jung et al., 2011; Sato et al., 2009). In particular, 
rNOGGIN is commonly used to protect ISCs from BMP pathway 
activation. The removal of rNOGGIN from the culture dramatically 
impaired ISC growth and organoid formation (Figure 26 C). The 
addition of rSMOC2 to the medium partially rescued this 
phenotype, confirming that SMOC2 acts as a BMP inhibitor in 
intestinal cells, albeit with lower potency than NOGGIN. 
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Figure 26: SMOC2 acts as a BMP inhibitor. A. Western blots of 
pSMAD1/5/8 in doxycycline-inducible SMOC2-flag HeLa cells treated with 
rBMP2 (25 ng/ml) and rSMOC2 (200 ng/ml). B. Kinetics of SMAD1/5/8 
phosphorylation in SW480 treated with rSMOC2 (200 ng/ml) or rNOGGIN 
(100 ng/ml). C. Representative pictures showing the growth of intestinal 
crypts cultured with rNOGGIN or rSMOC2. Fully formed organoids were 
counted 5 days after crypt seeding and treatments. Data are mean ± SD 
of triplicates. 
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3. Characterization of intestinal Smoc2 transgenic mouse 
 
3.1 Generation of Villin-Smoc2 transgenic (TG) mouse 
 
As described in section 2.4.4.3 of the introduction, BMP is one of 
the signaling mechanisms that determine the highly regular 
patterning of the intestinal epithelium into crypts and villi. Inhibition 
of BMP signaling by transgenic expression of Noggin results in the 
formation of numerous ectopic crypt units perpendicular to the 
crypt-villus axis. These changes of architecture phenocopy the 
intestinal histopathology of patients with the cancer predisposing 
syndrome Juvenile Polyposis (JP), including the frequent 
occurrence of intraepithelial neoplasia (Haramis et al., 2004). 
We decided to confirm the role of SMOC2 as BMP inhibitor by 
generating an intestinal Smoc2 transgenic mouse. In similar 
fashion than the experiments performed by the Clevers laboratory 
to study the function of NOGGIN in vivo (Haramis et al., 2004), we 
cloned the mouse Smoc2 open reading frame downstream of a 
9Kb fragment of the promoter of the Villin1 gene, which drives 
robust expression of the transgene specifically in the intestinal 
epithelium (Pinto et al., 1999) (Figure 27 A). This construct was 
inoculated into oocytes by pronuclear injection by the mouse 
mutant facility at IRB Barcelona following standard techniques. This 
experiment yielded 36 mice, 8 of which had integrated Villin-Smoc2 
construct as assessed by PCR based genotyping on genomic DNA 
using specific primers (Figure 27 B). We established these founder 
transgenic mice by breeding with C57/Bl6 mice. All of them were 
fertile and transmitted the transgene to the progeny. We next 
analyzed Smoc2 overexpression by quantitative PCR on intestinal 
extracts and three different lines expressing different levels of the 
transgene were selected for further studies (#127, #57, #13) 
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(Figure 27 C). We confirmed high Smoc2 upregulation throughout 
the whole intestinal epithelium by ISH (Figure 27 D). Please note 
that in wild-type mice, expression of Smoc2 was restricted to the 
crypt base whereas in transgenic mice its expression extended 
throughout the crypt-villus axis. This pattern follows that of the 
Villin1 gene (Figure 27 D). 
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Figure 27: Generation of intestinal Smoc2 transgenic mouse. A. 
Structure of the Villin-Smoc2 transgene. Black arrows indicate the location 
of the forward and reverse primers used for genotyping. B. Integration of 
Villin-Smoc2 transgene was assessed by PCR. Copy-standards were 
used to assess the sensitivity of the PCR assay and estimate copy 
numbers. C. Representative RT-qPCR showing Smoc2 expression in 
intestinal RNA extracts of three different Smoc2 transgenic founders. D. 
Representative pictures showing detection of Smoc2 mRNA in intestinal 
sections of Smoc2 wild-type and transgenic mice. Dashed line indicates 
the crypt-villus boundary. Note that in Smoc2 wild-type mice, Smoc2 
mRNA is restricted to the base of the crypts where ISCs reside. Smoc2 
transgenic mice display Smoc2 expression throughout the whole 
epithelium. Magnification 10X. 
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3.2 Adult intestinal Smoc2 transgenic mice display intestinal 
gigantism 
 
Macroscopic inspection upon necropsy of adult (12 weeks) mice 
revealed that the small intestine of transgenic mice was thicker 
than that of wild-type littermates (Figure 28 A). This feature was 
consistent in all the transgenic colonies and appeared more evident 
in colony #127 and #57. The total length of small intestine was not 
affected (Figure 28 B). No macroscopic differences were detected 
in transgenic colon. The other organs had normal gross 
appearance and size equivalent to wild-type littermates. 
 
 
 
Figure 28: Transgenic intestines display increased thickness than 
wild-type intestines. Representative pictures of wild-type and transgenic 
small intestine. A. Transgenic small intestine is more voluminous than 
wild-type small intestine. B. The total length of transgenic small intestine is 
not affected. 
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Histological analysis revealed larger crypts and proportionally 
larger villi in transgenic small intestine compared to wild-type mice 
(Figure 29 A). The colon of transgenic mice had much larger 
crypts, as well (Figure 29 B). This denotes that the gigantism is 
present throughout the whole transgenic intestine and the absence 
of villi may make the phenotype macroscopically less evident in the 
colon. Moreover, there was evident abundant stromal cells and 
collagen deposition in the intravillus space of transgenic mice 
(Figure 29 C). These features were consistent among the different 
transgenic colonies and were more exacerbated in the colony #127 
displaying the highest Smoc2 over-expression. 
 
 
RESULTS 
 91
 
 
Figure 29: Histological characterization of Smoc2 transgenic 
intestine. Hematoxilin/Eosin (HE) staining shows an overall gigantism in 
small intestine (A) and colon (B) of transgenic mice. C. CollagenIV 
staining shows increased collagen deposition in the intravillus space of 
transgenic small intestine (colony #127). 
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Cell size looked equivalent in transgenic and wild-type mice, 
suggesting that the increased size on the intestine triggered by 
Smoc2 overexpression was due to increased number of cells. 
To explore this, we performed quantitative analysis by taking 
several pictures of wild-type and littermate transgenic mice 
belonging to the three transgenic colonies. Thus, the result of these 
analyses represents an average between the different Smoc2 
transgenic colonies.  
Overall, adult Smoc2 transgenic mice displayed 1.6 fold larger villi 
than Smoc2 wild-type littermates (Figure 30 A, C). Yet, crypts also 
contained 1.6 times more cells (Figure 30 B, C). We indeed found 
that transgenic mice contained about a 1.6 fold increase in 
proliferative (MKI67+) cells, thus confirming that overall proportions 
of the intestine were kept in transgenic mice (Figure 31 A). To 
study cell migration along crypt-villus axis we inoculated mice with 
BrdU so that all proliferative crypt cells were labeled. Then we 
assessed their positions along the crypt-villus axis after 72h 
(Figure 31 B). The speed of migration was also increased by about 
1.6 fold respect to wild-type mice. 
All these data suggest that Smoc2 transgenic mice display an 
overall proportionate gigantism. 
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Figure 30: Transgenic mice display higher villi and larger crypts. 
Representative pictures of wild-type and transgenic mice showing 
comparisons of the villi length (A) and the crypt depth (B) (Colony #127). 
C. Quantification of villi length and number of cells per crypt in wild-type 
and transgenic mice. Data are mean ± SD of n=20 measurements 
deriving from the three transgenic colonies and wild-type littermates. 
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Figure 31: Proliferative compartment and speed of cell migration 
along the villus is proportionally increased in Smoc2 transgenic. A. 
Representative pictures showing MKI67 positive cells in the proliferative 
compartment of the crypt (left panel) and quantification of the number of 
MKI67+ cells per crypt (right panel). B. Representative pictures showing 
BrdU positive cells 72 hours after injection (left panel). The very bright 
cells are the ones that were residing at the crypt-villus boundary at the 
moment of injection and were leaving the proliferative compartment to 
enter the differentiation compartment. These cells did not undergo many 
cell divisions and retained the whole labeling. Black arrows indicate the 
distance covered by the front of BrdU+ cells during 72 hours post-
injection. Right panel shows the quantification. Data are mean ± SD of 
n=20 measurements. Duodenum, magnification 10X. 
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Cell differentiation towards the different lineages was unaffected in 
Smoc2 transgenic mice as shown by ChromograninA 
(enteroendocrine cells) and PAS/Alcian blue (mucosecreting cells, 
enterocytes) staining (Figure 32 A, B). Less consistently than the 
observed gigantism, 30% of transgenic mice displayed Paneth cell 
miss-positioning (Figure 32 C). Nevertheless, the expression 
pattern of EPHB2, EPHB3 and EPHRINB1, whose distribution in 
the epithelium determines the correct cell positioning (Batlle et al., 
2002), was also unaffected (Figure 33). 
In the absence of evident defects in the EPHB-EPHRIN expression 
gradient, the observed Paneth cell miss-positioning could suggest 
the presence of an altered inflammatory status (Adolph et al., 
2013).  
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Figure 32: Differentiation lineages are not affected in Smoc2 
transgenic mice. A. Black arrows indicate ChromograninA positive cells 
(entoendocrine cells). B. Pas/Alcian Blue staining shows goblet cells and 
enterocytes in the villi. C. Lysozyme staining identifies Paneth cells in the 
crypt base of wild-type intestine and some miss-localized Paneth cells in 
transgenic intestine (red arrows). Duodenum, magnification 10X. 
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Figure 33: EPHRIN-EPHB expression in not altered in Smoc2 
transgenic mice. Representative pictures of EPHB2 (20X) (A), EPHB3 
(20X) (B) and EPHRINB1 (10X) (C) IHC in the duodenum of Smoc2 wild-
type and transgenic mice. On the right, is shown the expected expression 
pattern. 
 
 
RESULTS 
 98
Moreover, the levels and expression domain of the transcription 
factor MYC were equivalent in transgenic and wild-type mice 
(Figure 34). 
 
 
 
 
Figure 34: C-MYC expression is not altered in Smoc2 transgenic 
mice. A. C-MYC IHC shows the expected expression pattern restricted to 
the proliferative compartment of the intestinal crypts in both wild-type and 
transgenic mice. Jejunum, magnification 10X. B. Western Blot analysis of 
C-MYC expression in protein extracts of Smoc2 wild-type and transgenic 
crypts. 
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The Villin promoter drives expression of transgenes from 
embryonic day E16. To test whether overexpression of Smoc2 had 
effects over the development of the intestine, we also analyzed the 
intestines of newborn mice (Postnatal day 1-P1).  Macroscopically, 
the intestine of wild-type and transgenic newborn mice were 
identical. At this developmental stage (P1), crypts have not been 
formed yet. Then we analyzed the length of the villi and we found 
no differences between transgenic and wild-type littermates 
(Figure 35). 
Altogether this data suggest that Smoc2 overexpression affects 
organ size without affecting the overall organization of the 
underlying tissue. This phenomenon seems to occur during 
postnatal development. 
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Figure 35: At P1 post-natal developmental stage the Smoc2 wild-type 
and transgenic intestinal size is equal. A. Representative pictures of 
Smoc2 wild-type and transgenic duodenum (#127) of P1 mice. B. 
Quantification of the length of the villi. Data are mean ± SD of n=10 for 
each genotype (transgenic #57 and #127). 
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3.3 Intestinal Smoc2 transgenic mice display strong inhibition of 
BMP signaling 
 
We then studied the levels of BMP pathway activation in our 
Smoc2 transgenic mice. Similarly to the effect of overexpression of 
Noggin in Villin-Noggin transgenic mice (Haramis et al., 2004), 
Smoc2 overexpression triggered inhibition of BMP pathway, as 
shown by reduction in SMAD1/5 phosphorylation. Both epithelial 
and stromal cells of Smoc2 transgenic mice were negative for p-
SMAD1/5 (Figure 36). Of note, a few stromal cells located in the 
intravillus space at the tip of the villi that escaped from SMOC2 
inhibitory effect. That is in line with recent findings suggesting 
maximum BMP signals at the villus tip (Shyer et al., 2015). 
Overall, these data confirm the role of SMOC2 as inhibitor of BMP 
signaling pathway. 
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Figure 36: BMP signaling is strongly inhibited in Smoc2 transgenic 
intestine. Representative pictures of pSMAD1/5 staining on tissue 
sections from Smoc2 wild-type and transgenic (#127) mice. Duodenum, 
magnification 10X. Lower panels show the intravillus space at higher 
magnification. Black arrows indicate residual BMP activation in stromal 
cells of the villus tip in Smoc2 transgenic mice.  
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3.4 Aged Smoc2 transgenic mice can develop Juvenile Polyposis-
like polyps 
 
We found that in old mice (8-10 months) the gigantism and the 
disorganization of stromal cells was exacerbated compared to 
young mice (2-3 months), suggesting that gigantism of the intestine 
progresses over time (Figure 37). 
 
 
 
Figure 37: Smoc2 transgenic phenotype increases by ageing. 
Representative pictures of Smoc2 wild-type (left panel), young Smoc2 
transgenic (middle panel) and old Smoc2 transgenic (right panel) 
duodenum. Dashed boxes are shown at higher magnification in the lower 
panels. Black arrows indicate the stromal cell composition in the intravillus 
space. 
 
 
 
 
RESULTS 
 104
A large percentage of Smoc2 transgenic mice displayed the 
presence of fecal blood and prolapses by ageing (Figure 38 A, B). 
Moreover, we noticed that 35% of old (5-10 months) transgenic 
mice deriving from colony #127 spontaneously developed polyps in 
the colon. At histological levels, these polyps appeared 
hyperplastic and presented the typical features of polyps arising in 
patients with Juvenile Polyposis syndrome, including the presence 
of big cysts and abundance of stromal cells (Figure 39). As 
expected, these polyps were mainly negative for SMAD1/5 
phosphorylation (Figure 39). 
 
 
 
 
Figure 38: Smoc2 transgenic mice display prolapse by ageing. A. 
Representative pictures of the anus of old Smoc2 wild-type and 
transgenic mice (10 months old). B. Percentages of old transgenic mice 
from colony #127 developing prolapse and polyps in the colon. 
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Figure 39: Old Smoc2 transgenic mice develop benign hyperplastic 
polyps. Representative pictures of colonic hyperplastic polyps found in 
Smoc2 transgenic colon. The upper panels show trichromic staining (left 
panel at 10X and right panel at 20X). Bottom right panel shows HE 
staining, at magnification 20X. Bottom left panel shows almost negative 
pSMAD1/5 staining (magnification 10X). Black arrows indicate abundant 
stroma infiltration. Red arrows indicate cysts. 
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Polyps developed by Juvenile Polyposis patients and by Villin-
Noggin transgenic mice display no nuclear β-catenin accumulation. 
However, a fraction of these polyps develop aggressive features 
including dysplasia and WNT pathway activation (Brosens et al., 
2011; Chow and Macrae, 2005).  It has been described that 
hyperplastic polyps that arise as result of BMP signaling inhibition 
have increased chances to lose the Apc gene and evolve towards 
adenomatous polyps (see section 3.3 of the introduction). This 
process was reproduced in Villin-Smoc2 transgenic mice. 
Embedded within hyperplastic polyps, we found areas of dysplasia 
and nuclear β-catenin accumulation that resemble classical 
adenomas (Figure 40). 
From these results we conclude that Smoc2 overexpression 
triggers a Juvenile Polyposis-like phenotype in mice. This 
phenotype is largely reminiscent of that present in Villin-Noggin 
transgenic mice (Haramis et al., 2004). 
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Figure 40: Benign hyperplastic polyps of Smoc2 transgenic mice 
predisposes to adenoma transformation. Upper panels show β-catenin 
staining. The majority of the lesions are negative for nuclear β-catenin. 
Dashed box indicate adenomatous areas with nuclear β-catenin defining 
zones with mutagenic WNT activation. Lower panels show pSMAD1/5 
staining. BMP signaling is strongly inhibited also in the adenomatous area 
(dashed box). 
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3.5 In vitro growth of Smoc2 transgenic intestinal crypts 
 
We next explored whether gigantism present in the intestine of 
Smoc2 transgenic mice was a cell-autonomous effect occurring in 
epithelial cells. To this end, we cultured intestinal crypts derived 
from Smoc2 wild-type and transgenic mice. At the moment of 
seeding there was obvious difference in size between the crypts of 
the two genotypes. However, as the culture evolved, sizes of 
organoids were normalized (Figure 41 A).  Smoc2 wild-type and 
transgenic crypts formed organoids of equivalent dimensions 
despite the fact that Smoc2 overexpression was kept in culture 
(Figure 41 B). 
This observation suggests that the effect of Smoc2 over crypt size 
is not cell autonomous and more likely depends on interaction with 
stromal cells. 
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Figure 41: In vitro culture of intestinal crypts derived from Smoc2 
wild-type and transgenic mice. A. Representative pictures of Smoc2 
wild-type and transgenic intestinal crypts 6 hours after ex vivo extraction 
and 4 days after seeding. B. Representative RT-qPCR analysis of Smoc2 
expression in Smoc2 wild-type and transgenic cultured crypts. 
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We next analyzed the in vitro growth of Smoc2 wild-type and 
transgenic crypts and their dependency on BMP signaling. In the 
presence of rNOGGIN, Smoc2 transgenic crypts grew to similar 
extent that crypts derived from wild-type mice (Figure 42 A, B). 
Removal of rNOGGIN induced a sharp loss of organoid growth. 
Smoc2 overexpression facilitated organoid formation in this 
condition but it was not sufficient to fully rescue the effect (Figure 
42 A, B). Of note, whereas levels of Smoc2 transgenic 
overexpression in vivo are in the range of 800-3000 fold, transgenic 
crypts cultured in vitro expressed only 10 to 50 times more Smoc2 
than crypts derived from wild-type mice (Figure 41 B). This 
observation may suggest that intestinal epithelial cells require high 
SMOC2 levels to inhibit BMP signaling. These findings are also in 
line with the results obtained in cell lines (Section 2) indicating that 
SMOC2 has weaker activity than NOGGIN as BMP inhibitor. 
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Figure 42: In vitro culture of Smoc2 transgenic crypts displays 
dependency on BMP pathway inhibition. A. Representative pictures of 
in vitro cultured organoids derived from Smoc2 wild-type and transgenic 
crypts in the presence or absence of rNOGGIN (100 ng/ml). B. 
Quantification of organoid formation. Formed organoids were counted 5 
days after crypt seeding. Data are mean ± SD of triplicates. 
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3.6 Smoc2 overexpression enhances polyp formation and size in 
Apc mutant mice 
 
We finally analyzed the effect of Smoc2 overexpression during 
intestinal tumorigenesis. To this purpose, we crossed the Smoc2 
transgenic mice (#127 and #13) with Apcmin mice. Apcmin mice carry 
a truncating mutation at codon 850 of the Apc gene and 
spontaneously develop multiple adenomas in small intestine and 
colon (Moser et al., 1990). 
Apcmin, Smoc2 wild-type and transgenic mice where sacrificed at 
the age of 4 months and polyps were counted. Smoc2 transgenic 
mice developed more polyps than Smoc2 wild-type littermates and 
the phenotype was much more severe in colony #127 displaying 
the highest Smoc2 overexpression (Figure 43 A). Indeed, the 
strength of the phenotype followed the extent of Smoc2 
overexpression in the different Smoc2 transgenic colonies. 
Transgenic polyps were also larger (Figure 43 A). Histological 
analysis demonstrated robust BMP inhibition in adenoma arising in 
Smoc2 transgenic mice (Figure 43 B).  
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Figure 43: Smoc2 overexpression enhances polyp formation in Apc 
mutant mice. A. Polyp counting (left panel) and polyp size distribution 
(right panel) in colon and small intestine of Apcmin, Smoc2 wild-type and 
transgenic mice. Data are mean ± s.e.m of measurements (n=8-12 mice 
per genotype). Statistics are done by Student’s t-test. ****P<0,0001; 
*P<0,05 B. β-catenin and pSMAD1/5 IHC in polyps of APCmin, Smoc2 
wild-type and Smoc2 transgenic mice. 
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We also cultured adenoma stem cells (AdSCs) and tested the 
ability of rSMOC2 to block BMP pathway activation in these cells. 
Upon rNOGGIN removal or rBMP4 addition, Western Blot against 
pSMAD1/5/8 revealed that rSMOC2 was able to efficiently 
counteract BMP pathway activation in adenoma cultures at least at 
short time points after BMP induction (Figure 44 A). This effect 
triggered a significant rescue of adenoma organoid growth (Figure 
44 B, C). We also observed significant inhibition in expression of 
BMP target genes such as Apcdd1, Id1, Id3 and Smad6 (Figure 44 
D). 
Overall, our results indicate that blockade of BMP signaling by 
Smoc2 overexpression exacerbates the formation of adenomas 
induced by constitutive activation of the WNT pathway. These 
results are in concordance with a tumor suppressor role for BMP 
signaling in the intestine as previously shown (Whissell et al., 
2014). Our data also point that upon overexpression, SMOC2 acts 
as a BMP inhibitor for intestinal epithelial cells.  
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Figure 44: rSMOC2 protects AdSCs from BMP activation in vitro. A. 
Western blot of pSMAD1/5/8 on AdSCs treated with rBMP4 (25 ng/ml) 
and rSMOC2 (200 ng/ml). B. Representative pictures of spheres grown 
from AdSCs cultured with rNOGGIN (100 ng/ml) or rSMOC2 200 ng/ml). 
C. Quantification of sphere formation 6 days after sphere disaggregation 
and single cell seeding. Data are mean ± s.e.m. of triplicates. Statistics 
are done by Student’s t-test. *P<0,05; ***P<0,001 D. BMP target gene 
expression detected by RT-qPCR on RNA extracts deriving from AdSCs 
cultured with rNOGGIN or rSMOC2. 
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4. Characterization of intestinal Smoc2 conditional KO mouse 
 
4.1 Generation of a Smoc2 conditional KO (cKO) allele 
 
Based on our observations in transgenic mice, we hypothesized 
that SMOC2 could act as a BMP inhibitor in ISCs. Together with 
the other BMP inhibitors present in the niche, SMOC2 may 
contribute to maintain low BMP signaling levels in the ISC niche 
which is required for self-renewal. However, because SMOC2 
appears to be a weaker BMP inhibitor than NOGGIN, experiments 
of overexpression in transgenic mice may also trigger non-specific 
effects. 
To test the physiological roles of SMOC2 in intestinal epithelium 
homeostasis, we generated a new mouse model that enabled 
tissue specific ablation of Smoc2 in adult mice (see methods for 
details). Briefly, we inserted by homologous recombination in 
mouse ES cells loxP sites flanking the second exon of the mouse 
Smoc2 locus, which encodes the FS domain, a key functional 
domain of the protein shared by all members of BM-40 protein 
family (Vannahme et al., 2002) (Figure 45 A). Recombination of 
loxP sites will cause not only the deletion of exon 2 but also a 
frameshift and the introduction of a STOP codon in exon 4.  
Correct targeting of this construct in ES cells was assessed by 
long-range PCR (LR-PCR), followed by Southern Blot (Figure 45 
B). The positive clones were re-expanded and Neo cassette was 
removed by expressing FlpO recombinase. Clones with excised 
Neo cassette were identified by PCR. We then re-confirmed correct 
Neo cassette removal by Southern blot. The corrected targeted ES 
cell clones were then inoculated into blastocysts following standard 
protocols to obtain chimeric mice (see methods for details). Those 
were crossed with C57/Bl6 mice and offspring bearing the Smoc2 
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targeted allele were confirmed by standard genotyping (Figure 45 
C). The Smoc2 conditional KO mouse colony was then established 
and backcrossed to C57/Bl6 background for at least 6 generations 
before any experimental procedure. 
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Figure 45: Generation of Smoc2 conditional KO mouse. A. Schematic 
representation of mouse SMOC2 protein and Smoc2 locus. LoxP sites are 
flanking the exon 2 in the targeted allele. Purple arrows indicate the 
position of the specific primers used for genotyping. B. Southern blots of 
the 5’ and 3’ region of Smoc2 locus. 5’ and 3’ probes were used to assess 
gDNA after Acc65I digestion. C. PCR strategy to identify loxP and FRT 
sites. WT: wild-type allele; T: targeted allele. 
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4.2 Conditional ablation of Smoc2 in the intestinal epithelium 
 
To ablate Smoc2 expression in the intestinal epithelium we chose 
the well described Villin Cre-ERT2 transgenic mouse line. This Cre 
strain enables strong deletion of floxed genes in intestinal crypts 
and villi, including the ISC compartment (El Marjou et al., 2004). 
Figure 46 shows the intestine-specific and inducible deletion of the 
exon 2 of Smoc2 both at the level of gDNA and mRNA. Seven days 
after tamoxifen treatment the mRNA levels of Smoc2 were reduced 
100 fold in the intestinal epithelium of Villin-CreERT2 Smoc2flox⁄flox 
mice (from here onwards called Smoc2∆IEC mice) compared to 
Villin-CreERT2 Smoc2+⁄+ mice (from here onwards called 
Smoc2CON). 
We have been unable to detect Smoc2 by Western Blot. 
Commercially available antibodies are either unable to detect the 
protein or they detect several unspecific bands of diverse sizes. 
Nevertheless, the strong decrease of Smoc2 at the mRNA level 
suggests that the gene function is completely ablated in this mouse 
model. 
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Figure 46: Intestinal deletion of Smoc2. A. Diagram of the targeted and 
the recombined allele of Smoc2 cKO. B. Analysis of Tamoxifen injected 
mice bearing the Villin Cre-ERT2 transgene and either the wild-type or the 
floxed allele of Smoc2. The left panel shows the PCR on gDNA to assess 
recombination and the right panel shows the mRNA levels of Smoc2 in 
purified intestinal crypts 7 days after tamoxifen injection. Data are mean ± 
SD of n=3 mice for each genotype. 
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4.3 BMP pathway is not altered in Smoc2 KO intestinal crypts 
 
Several works indicate that the BMP pathway is kept off at the crypt 
base allowing the maintenance of the ISC compartment (Haramis 
et al., 2004; Kosinski et al., 2007). As the cells migrate upwards 
along the crypt-villus axis, they progressively encounter stronger 
BMP signals that trigger their differentiation. 
Deletion of Smoc2 in the intestinal epithelium did not cause 
changes in Inhibitor of Differentiation (Id) genes, which are BMP 
canonical targets genes (Figure 47 A). Moreover, we did not detect 
expression changes neither of Lgr5 (Figure 47 A) nor of other 
known ISC markers (not shown). These experiments were 
performed on intestinal epithelial cells from purified crypts (see 
methods for details).  
By IHC, we demonstrated that pSMAD1/5 showed negative 
staining in the crypts, as previously reported. Smoc2 KO crypts did 
not display increased pSMAD1/5 staining (Figure 47 B). 
All together, these data indicate that Smoc2 depletion in intestinal 
epithelial cells does not alter BMP signaling. 
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Figure 47: BMP pathway activation in intestinal crypts of Smoc2∆IEC 
and Smoc2CON. A. RT-qPCR analysis of expression of Lgr5 and BMP 
target genes in intestinal crypts purified from Smoc2∆IEC and Smoc2CON 
mice 7 days after tamoxifen induction. Data are mean ± SD of n=3 mice 
for each genotype. B. IHC with pSMAD1/5 antibodies in intestinal crypts of 
adult Smoc2∆IEC and Smoc2CON mice. Black arrows indicate positive BMP 
signaling in the epithelial cells of the villus and in the stromal cells of the 
intravillus space. On the right, is shown the expected expression pattern.
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4.4 Smoc2 epithelial depletion has no effect on intestinal biology 
 
We next studied the overall architecture and the different cell 
compartments in the Smoc2 KO intestinal epithelium. At the 
histological level, we could not find any obvious morphological or 
structural defects in Smoc2∆IEC mice when compared to their 
control littermates. EPHB2, a marker for stem cells and crypt 
progenitors showed the expected decreasing gradient from the 
crypt bottom to the top (Figure 48 A). MKI67 and KRT20 
distinguished the proliferative from the differentiated compartment 
and presented a mutually exclusive expression pattern (Figure 48 
B, C).  
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Figure 48: Impact of epithelial Smoc2 depletion on intestinal 
homeostasis. A. EPHB2 IHC on intestinal sections of Smoc2∆IEC and 
Smoc2CON mice. Insets show crypts at higher magnification. B. C. KRT20 
and MKI67 IHC on intestinal sections of Smoc2∆IEC and Smoc2CON mice. 
On the right, is shown the expected expression pattern. Duodenum, 
magnification 10X. 
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The Villin-CreERT2 driver does not enable full deletion of the floxed 
gene, resulting in a percentage of epithelial cells still retaining full 
expression of the floxed gene (El Marjou et al., 2004). In fact, we 
observed that Smoc2 levels were strongly reduced (100 fold) after 
tamoxifen induction, but still detectable. This opens three possible 
scenarios: in the case that Smoc2 depleted SCs would suffer a 
disadvantage from Smoc2 loss, we should observe a progressive 
loss of Smoc2 downregulation due to positive selection of Smoc2 
expressing cells that would repopulate the crypt; in the case that 
Smoc2 depleted SCs would gain an advantage from Smoc2 loss, 
these cells would replace the Smoc2 expressing cells and we 
should observe increased reduction of Smoc2 levels over time; in 
the case that Smoc2 depletion would not give neither advantage 
nor disadvantage to the cells, we should expect stable Smoc2 
downregulation over time. 
We then verified the extent and the persistency of Smoc2 mRNA 
downregulation at early and late time points after tamoxifen 
induction in Smoc2∆IEC mice. We found that the gene deletion was 
stable over 7 months, suggesting that Smoc2 deficient ISCs were 
neither negatively nor positively selected (Figure 49). 
All these data pointed out that Smoc2 is dispensable for normal 
intestinal homeostasis. 
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Figure 49: Smoc2 downregulation in Smoc2∆IEC mice remains stable 
over time. mRNA levels of Smoc2 were detected by RT-qPCR on RNA 
extracts of intestinal crypts purified from Smoc2∆IEC and Smoc2CON mice 7 
days and 7 months after tamoxifen injection. Data are mean ± SD of n=3 
mice for each genotype. 
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4.5 Intestinal Smoc2 conditional KO in Apc mutant mice does not 
affect tumorigenesis 
 
Our data demonstrate that specific Smoc2 depletion in the 
epithelium does not affect the intestinal homeostasis per se. We 
then explored the role of SMOC2 during intestinal tumorigenesis. 
Unpublished data from our lab demonstrate that the expression of 
SMOC2 in intestinal cells is driven by β-catenin/TCF4 (Whissell, 
unpublished). Indeed, the inducible blockade of the WNT cascade 
in CRC cell lines defines specific WNT ON and WNT OFF gene 
programs, respectively characterized by genes that are activated 
by WNT (SC genes) and genes that are normally repressed by 
WNT (differentiation genes). We found that SMOC2 was positively 
regulated by WNT (Figure 50 A).  
Consistently, we observed that, upon mutagenic activation of WNT, 
Smoc2 expression pattern in mouse Apc mutant crypts was 
expanded mirroring the expansion of the adenoma stem cell 
compartment (Figure 50 B). 
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Figure 50: Smoc2 is a WNT target gene upregulated during 
tumorigenesis. A. Cluster analysis showing relative changes in the 
expression levels of the WNT ON and the WNT OFF programs in CRC 
cell lines 36 hours after WNT blockade compared to control cells 
(Whissell, unpublished). Note that SMOC2 is downregulated in the 
majority of CRC cell lines upon WNT blockade. B. Representative pictures 
of Smoc2 ISH in Apc wild-type crypts and Apc mutant crypts. Black 
arrows indicate Smoc2 expression restricted to the bottom of wild-type 
crypts and an expansion of Smoc2 expression pattern upon mutagenic 
WNT activation. 
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To investigate SMOC2 function during tumorigenesis, we 
generated compound mice that carry Smoc2 flox/flox or wild-type 
alleles combined with an Apc floxed allele in heterozygosis (Villin-
CreERT2; Smoc2fl/fl or Smoc2+/+; Apcfl/+) (Figure 51 A). In this 
setting, the Villin-CreERT2 driver triggers induction of the loss of one 
Apc allele in combination with loss of Smoc2 in the whole intestinal 
epithelium. As it occurs in patients with FAP syndrome (see section 
3.3 of the introduction), these mice develop loss of heterozygosity 
of the Apc locus spontaneously over time. This triggers the 
formation of intestinal adenomas.  
Mice of the two genotypes presented identical survival curves and 
died within 10 months after tamoxifen induction (Figure 51 B). In a 
second experiment, we sacrificed the mice 4 months after induction 
with tamoxifen and we counted the total number of polyps 
developed in small intestine and colon of the two genotypes. As an 
average, control Apcfl/+ littermates (Villin-CreERT2; Smoc2+/+; Apcfl/+) 
developed 25 polyps in the small intestine and colon (Figure 51 C). 
Villin-creERT2; Smoc2fl/fl; Apcfl/+ developed equivalent number of 
adenomas. We neither observed differences in the size of the 
tumors that arose in both genotypes (Figure 51 C). 
All together, these data imply that epithelial Smoc2 expression is 
dispensable for intestinal homeostasis and that it is not required for 
the development of adenomas upon Apc inactivation. 
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Figure 51: Effect of epithelial Smoc2 depletion in Apc mutant mice. 
A. Experimental design. B. Survival curve of Apcfl/+; Villin-CreERT2; 
Smoc2+/+ or Smoc2fl/fl mice after tamoxifen injection. N=7 Smoc2+/+ mice; 
N=6 Smoc2fl/fl mice. Differences are not statistically significant. C. Polyp 
counting in small intestine and colon and polyp size distribution in Apcfl/+; 
Villin-CreERT2; Smoc2+/+ or Smoc2fl/fl mice 4 months after tamoxifen 
injection. Each dot in the left panel represents one measurement for one 
mouse. N=18 Smoc2+/+ mice; N=16 Smoc2fl/fl mice. Differences are not 
statistically significant. 
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4.6 A stromal Smoc2 source compensates downregulation of 
Smoc2 in the epithelium of Smoc2∆IEC mice 
 
The complete lack of phenotype in the Smoc2 mutant intestinal 
epithelium prompted us to investigate the possibility that an 
additional source of SMOC2 from stromal cells may compensate 
this deficiency. We thus investigated Smoc2 expression in whole 
intestinal extracts of Smoc2∆IEC mice that include epithelial and 
stromal cells, such as fibroblasts, leukocytes, blood vessels, 
smooth muscle cells and nerve cells. Indeed, we observed that 
overall Smoc2 mRNA levels did not change in the intestine of 
Smoc2∆IEC mice, suggesting the existence of a Smoc2 extra-
epithelial source (Figure 52 A). We next measured Smoc2 specific 
gene expression in samples of homogenized total intestine 
compared to epithelium-depleted intestine (submucosa). For these 
experiments, we removed the epithelium by following the crypt 
extraction protocol described in the method section. We confirmed 
that the submucosa compartment showed high enrichment of 
general stroma genes (Cd45: pan-leukocyte marker; Cd31: 
endothelial marker; IgfBP7: fibroblast marker). Inversely, epithelial 
markers were lowly expressed in the submucosa (EpCAM: general 
epithelial marker; Krt20, Aqp3, DefCR, Cryptidin: epithelial 
differentiation markers; Olfm4: ISC marker). Smoc2 mRNA level did 
not decrease upon removal of the epithelium, thus confirming the 
presence of a Smoc2 extra-source that maintains high general 
Smoc2 expression in the intestine of Smoc2∆IEC mice (Figure 52 
B). The lack of a suitable SMOC2 antibody did not allow us to test 
this hypothesis on intestinal tissue sections by IHC or by Western 
Blot on total protein extracts. To overcome this limitation we used 
ISH, which showed high Smoc2 mRNA enrichment in ISCs as well 
as in scattered cells in the submucosa layer (Figure 52 C). These 
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stromal Smoc2 positive cells may likely represent fibroblast, 
endothelial cells, muscle cells or macrophages. Unfortunately, the 
resolution limits of this technique did not allow us to identify the 
precise cell types expressing Smoc2 in the stroma. 
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Figure 52: Smoc2 extra-epithelial source. A. Detection of Smoc2 
expression by RT-qPCR on RNA extracts of total small intestine of 
Smoc2∆IEC and Smoc2CON mice. Data are mean ± SD of n=3 mice for each 
genotype. B. Epithelial gene depletion and stromal gene enrichment in 
intestinal submucosa compared to total intestine. Genes were measured 
by RT-qPCR in total small intestine and in intestinal submucosa of Smoc2 
wild-type mice. Please note that Smoc2 expression did not change in 
epithelium-depleted intestinal tissue. C. Smoc2 mRNA detection in mouse 
intestinal section by ISH using a specific full length probe. Dashed line 
indicates the epithelium-submucosa boundary. Red arrows indicate 
Smoc2 mRNA at the bottom of the intestinal crypts where ISCs reside. 
Black arrows indicate Smoc2 positive cells in the submucosa. 
 
 
 
 
 
 
 
RESULTS 
 134
We also dissected large polyps arising in Villin-CreERT2; Smoc2fl/fl; 
Apcfl/+ or in control Villin-CreERT2; Smoc2+/+; Apcfl/+ mice and 
analyzed Smoc2 expression. We analyzed either the protruding 
part of the polyp, which is mainly composed by epithelial Apc 
mutant cells that express high levels of Smoc2 as result of WNT 
pathway activation, or macro-dissected samples that include polyp 
plus submucosa (Figure 53 A). This experiment revealed large 
downregulation of Smoc2 in the protruding region of polyps from 
Villin-CreERT2; Smoc2fl/fl; Apcfl/+ mice (Figure 53 B). In contrast, in 
samples that comprised polyp and submucosa, there was an 
evident compensation in Smoc2 levels of about 10 fold (Figure 53 
B). 
Overall, these data suggest that stromal expression compensates 
Smoc2 deficiency in epithelial cells. This compensation is complete 
in the normal intestine whereas it is less evident in large polyps that 
display a higher ratio of epithelial versus stromal cells. 
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Figure 53: Smoc2 extra-epithelial source in adenoma. A. HE staining 
of an adenomatous polyp composed of polyp glands plus the submucosa. 
B. Smoc2 expression detected by RT-qPCR on RNA extracts deriving 
from the protruding part of the polyp alone or the polyp plus submucosa. 
Data are mean ± SD of n=3 mice for each genotype (Villin-CreERT2; 
Smoc2+/+; Apcfl/+ and Villin-CreERT2; Smoc2fl/fl; Apcfl/+). 
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5. Characterization of Smoc2 full KO mouse 
 
5.1 Generation of Smoc2 null allele 
 
Considering the lack of phenotype resulting from the conditional 
ablation of Smoc2 in the adult intestinal epithelium and the 
possibility of compensation by stromal cells expressing Smoc2, we 
generated mice null for Smoc2 in all tissues. To this end, we 
crossed Smoc2flox/flox mice with a transgenic Sox2-Cre line (Hayashi 
et al., 2002). This Cre line turned the conditional allele into a null 
allele in all the cells of the embryo including the germline. We 
selected mice bearing the Smoc2∆ allele in heterozygosis from this 
intercross and further breed them to obtain the Smoc2 full KO mice 
(Smoc2∆/∆). Mutant mice were identified by standard genotyping 
(Figure 54). 
 
 
 
Figure 54: Generation of Smoc2 full KO mouse. A. Diagram showing 
wild-type and null Smoc2 alleles. Black arrows indicate the position of the 
specific primers used for genotyping. B. PCR to assess Smoc2 null allele. 
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5.2 Complete Smoc2 ablation does not affect intestinal 
homeostasis 
 
Smoc2∆⁄∆ mice were born following mendelian ratio. Young and old 
mice did not display any gross abnormality and they were fertile. In 
order to confirm the lack of phenotype, we analyzed the intestine of 
Smoc2+/+ and Smoc2∆⁄∆ mice. Gross histological analysis revealed 
no obvious alteration in young or old Smoc2 mutant mice (Figure 
55).  
 
 
 
Figure 55: Old Smoc2∆⁄∆ mice do not display histological alterations. 
Representative pictures showing HE of intestinal sections of Smoc2+/+ (left 
panel), young Smoc2∆⁄∆ (middle panel) and old Smoc2∆⁄∆ (right panel) 
mice. Duodenum, magnification 10X. 
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Our quantitative analysis included length of the villi and the number 
of cells per crypt as well as the extent of proliferative compartment 
by counting MKI67 positive cells per crypt (Figure 56). We also 
assessed differentiation towards multiple lineages by 
ChromograninA staining (enteroendocrine cells), PAS/Alcian blue 
staining (mucosecreting cells and enterocytes), and Lysozyme 
staining (Paneth cells) (Figure 57). Finally, we measured cell 
migration along the crypt-villus axis. We did not find differences in 
any of these parameters in Smoc2∆⁄∆ mice compared to Smoc2+/+ 
littermates (Figure 58). 
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Figure 56: Smoc2∆⁄∆ mice do not show intestinal abnormalities. A. 
Representative pictures of E-Cadherin staining in Smoc2+/+ and Smoc2∆⁄∆ 
intestinal sections (left panel). Duodenum, magnification 10X. 
Quantification (right panel) of the length of the villi. Data are mean ± SD of 
n=20 measurements for each genotype. B. Representative pictures of E-
Cadherin staining in Smoc2+/+ and Smoc2∆⁄∆ intestinal crypts (left panel). 
Quantification (right panel) of the number of cells per crypt. Data are 
mean ± SD of n=20 measurements for each genotype. C. Representative 
pictures of MKI67 staining in Smoc2+/+ and Smoc2∆⁄∆ intestinal sections 
(left panel). Duodenum, magnification 10X. Quantification (right panel) of 
the number of MKI67 positive cells per crypt (proliferative cells). Data are 
mean ± SD of n=20 measurements for each genotype. 
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Figure 57: Differentiation towards multiple lineages is not affected in 
Smoc2∆⁄∆ mice. Representative pictures of ChromograninA staining 
(enteroendocrine cells) (A), Pas/Alcian blue staining (goblet cells and 
enterocytes) (B) and Lysozyme staining (Paneth cells) (C) in intestinal 
sections of Smoc2+/+ and Smoc2∆⁄∆ mice. Black arrows indicate 
enteroendocrine cells. Duodenum, magnification 10X. 
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Figure 58: Cell migration along the crypt-villus axis is not affected in 
Smoc2∆⁄∆ intestine. Representative pictures showing BrdU staining 72 
hours post-injection in Smoc2+/+ and Smoc2∆⁄∆ duodenum. Black arrows 
indicate the equal distance covered by the BrdU positive cell front in both 
genotypes. Magnification 10X. Lower panel shows the quantification. Data 
are mean ± SD of n=20 measurements for each genotype.  
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The above results prompted us to search for compensation by 
Smoc1 in the intestine of Smoc2∆⁄∆ mice. Our data indicated that 
Smoc1 was expressed at very low levels in the intestine, displaying 
cycle threshold (ct) value 33 compared to Smoc2 (ct value: 25) 
(Figure 59 A). Moreover, its levels did not change upon deletion of 
Smoc2 (Figure 59 B). Sparc, a related gene, was also expressed 
at equivalent levels in the intestine of Smoc2∆⁄∆ mice compared to 
Smoc2+/+ littermates (ct value: 28). We also measured intestinal 
BMP inhibitors (Grem1, Grem2, Chordin) in total intestine, which 
were expressed yet they did not change significantly in Smoc2 
deficient mice (ct value: 28) (Figure 59 B). 
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Figure 59: Expression levels of Bm-40 related genes and BMP 
inhibitors in Smoc2∆⁄∆ intestine. A. Comparison between Smoc2 and 
Smoc1 expression levels measured by RT-qPCR in total intestinal RNA 
extracts from wild-type mice. Note that Smoc1 is 150 fold less expressed 
than Smoc2. Data are mean ± SD of n=3 mice for each genotype. B. 
Expression levels of Bm-40 genes (Smoc1 and Sparc) and known 
intestinal BMP inhibitors detected by RT-qPCR in total intestinal RNA 
extracts from Smoc2+/+ and Smoc2∆⁄∆ mice. Data are mean ± SD of n=3 
mice for each genotype. 
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5.3 Full Smoc2 ablation does not affect intestinal BMP signaling 
 
We first verified Smoc2 mRNA levels in purified epithelial cells from 
crypts or whole tissue extracts of Smoc2∆/∆ mice. As expected, 
Smoc2 was barely detectable in both cases (Figure 60 A, B). We 
then measured expression levels of SC markers and BMP target 
genes. In purified epithelial cells from crypts we did not detect 
evident changes in BMP target gene expression (Apcdd1, Id3), in 
markers of stemness (Lgr5) or differentiation (Krt20) (Figure 60 A). 
BMP target gene expression was also unaffected in total intestine 
samples (Id1, Id3, Apcdd1, Smad6) (Figure 60 B). 
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Figure 60: Complete Smoc2 ablation does not affect intestinal BMP 
signaling. Gene expression analysis by RT-qPCR of purified intestinal 
crypt extracts (A) and total intestinal extracts (B) from Smoc2+/+ and 
Smoc2∆⁄∆ mice. Data are mean ± SD of n=3 mice for each genotype. 
 
 
 
RESULTS 
 146
Furthermore, histological analysis showed equivalent pSMAD1/5 
patterns in Smoc2+⁄+ and Smoc2∆⁄∆ mice. In both genotypes there 
was a decreasing gradient of BMP pathway activation from the tip 
of the villi towards the bottom of the crypts. In addition, some 
stromal cells located in the intravillus space present in both 
Smoc2+⁄+ and Smoc2∆⁄∆ intestines displayed positive pSMAD1/5 
accumulation (Figure 61). 
These observations imply that during adult intestinal homeostasis, 
Smoc2 is dispensable for protecting ISCs from BMP pathway 
activation. We speculate that this is probably due to high 
abundance of other BMP inhibitors secreted by the stroma 
underlying the crypts (Kosinski et al., 2007). 
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Figure 61: BMP signaling distribution is not affected in Smoc2∆⁄∆ 
intestine. pSMAD1/5 staining on intestinal sections of Smoc2+/+ and 
Smoc2∆⁄∆ mice (upper panels). Jejunum, magnification 10X. Lower panels 
show the crypt-villus junction at higher magnification. Dashed line defines 
the crypt-villus boundary. Black arrows indicate scattered pSMAD1/5 
positive cells in the intravillus space. On the right, is shown the expected 
pSMAD1/5 pattern in the epithelial cells.  
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5.4 Smoc2 depletion does not affect either BMP signaling or ISC 
self-renewal capability 
 
To definitely confirm SMOC2 dispensability for ISC maintenance, 
we cultured intestinal crypts from Smoc2+/+ and Smoc2∆⁄∆ mice in 
3D conditions. As already commented in section 2 and in the 
introduction, robust inhibition of BMP signals is required to culture 
ISCs. In the presence of rNOGGIN, Smoc2+/+ and Smoc2∆⁄∆ mouse-
derived crypts were able to grow equally and were maintained over 
time (Figure 62 A, B). In order to exclude that rNOGGIN was 
masking the contribution of SMOC2, we followed organoid growth 
upon rNOGGIN dilution. We observed that the removal of 
rNOGGIN from the culture dramatically impaired the organoid 
growth and, upon rNOGGIN dilution, Smoc2+/+ and Smoc2∆⁄∆ 
organoids suffered equal growth reduction (Figure 62 C). 
Our data indicate that in this context, the absence or presence of 
endogenous SMOC2 does not impinge on ISC growth. 
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Figure 62: In vitro growth of ISCs derived from Smoc2+/+ and 
Smoc2∆⁄∆ mice. A. Representative pictures of organoids grown from 
Smoc2+/+ and Smoc2∆⁄∆ purified intestinal crypts in the presence of 
rNOGGIN. B. Assessment of clonogenic potential of Smoc2+/+ and 
Smoc2∆⁄∆ ISCs cultured with rNOGGIN (100ng/ml). Formed organoids 
were counted 5 days after disaggregation and seeding and the whole 
process was repeated over passaging. Data are mean ± SD of n=5 
measurements for each genotype. C. Progressive reduction of organoid 
formation in Smoc2+/+ and Smoc2∆⁄∆ ISC cultures when subjected to 
increasing rNOGGIN dilutions. Data are mean ± SD of triplicates. 
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5.5 Full Smoc2 ablation in Apc mutant mice enhances survival and 
reduces polyp formation and size 
 
Considering the lack of intestinal phenotypes resulting from full 
Smoc2 deficiency, we decided to analyze the effect of Smoc2 
depletion in pathological settings. We generated Villin-CreERT2; 
Smoc2∆⁄∆; Apcfl/+ mice and control Villin-CreERT2; Smoc2+⁄+; Apcfl/+ 
littermates. We challenged them with tamoxifen and performed 
survival and polyp formation studies (Figure 63 A). These 
experiments revealed a significant enhancement of survival in 
Smoc2 deficient mice (Figure 63 B). Polyp counting confirmed 
reduced polyp number and size in Smoc2∆⁄∆ mice (Figure 63 C). 
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Figure 63: Effect of full Smoc2 ablation in Apc mutant mice. A. 
Experimental design. B. Survival curve of Villin-CreERT2; Smoc2∆⁄∆; Apcfl/+ 
mice and control Villin-CreERT2; Smoc2+⁄+; Apcfl/+ mice after tamoxifen 
injection. N=7 Villin-CreERT2; Smoc2+⁄+; Apcfl/+ mice and 6 Villin-CreERT2; 
Smoc2∆⁄∆; Apcfl/+ mice. Statistics are done using the log-rank test. C. Polyp 
counting (upper panel) and polyp size distribution (bottom panel) in small 
intestine and colon of Villin-CreERT2; Smoc2∆⁄∆; Apcfl/+ mice and control 
Villin-CreERT2; Smoc2+⁄+; Apcfl/+ mice 6 months after tamoxifen induction. 
Each dot in the upper panel represents one measurement (one mouse). 
Data are mean ± s.e.m. of n=13 Villin-CreERT2; Smoc2+⁄+; Apcfl/+ mice and 
7 Villin-CreERT2; Smoc2∆⁄∆; Apcfl/+ mice. Statistics are done by Student’s t-
test. *P<0,05. Lower panel shows size distribution of all the polyps 
counted in the two genotypes and represented in the upper panel. 
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5.6 Effect of Smoc2 deficiency on inflammation 
 
Inflammation exacerbates intestinal tumorigenesis in mouse 
models and in humans (Balzola et al., 2013; Zaki et al., 2011). 
Likewise, blockade of inflammatory pathways is linked to 
decreased incidence of CRC in patients and experimental models. 
We thus tested the intestinal inflammatory response in Smoc2+⁄+ 
and Smoc2∆⁄∆ mice. Treatment of mice with Dextran Sulfate Sodium 
(DSS) induces mechanical stress on colon epithelial surface, which 
triggers inflammation and colitis-like disease in the colon. This 
process progresses in specific steps: epithelium destruction, 
stromal infiltration and inflammation, de novo crypt formation and 
fission, repopulation and restoration of the normal epithelial layer. 
We subjected the mice to sub-lethal DSS exposure during five 
days. We assessed the efficiency of DSS-induced damage by 
checking appearance of fecal blood during the treatment. 
Subsequently, we tracked the recovery process by measuring the 
body weight loss and by analyzing the histology of the colonic 
mucosa at different time points (Figure 64 A). Three independent 
experiments showed that Smoc2∆⁄∆ mice lost less weight and 
recovered faster than littermates Smoc2+⁄+ mice (Figure 64 C). The 
histological analysis revealed that after five days of DSS treatment 
both genotypes presented an altered architecture of the intestinal 
epithelial layer. At this stage, there was no obvious inflammation 
(Figure 64 B) and all mice were positive to the fecal blood test. 
Two days after DSS removal, we observed massive stromal 
infiltration and inflammation in Smoc2+⁄+ mice, whereas this 
response was attenuated in Smoc2∆⁄∆ mice that had already 
undergone active intestinal regeneration and de novo crypt 
formation. Seven days after the removal of DSS from drinking 
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water, Smoc2∆⁄∆ mice had almost fully recovered, whereas Smoc2+⁄+ 
mice were still in the process of tissue reconstruction (Figure 64 
B). These results imply that, upon damage, Smoc2∆⁄∆ mice are less 
prone to undergo inflammation. We checked whether loss of 
Smoc2 affects intestinal permeability, since an altered permeability 
could modulate the exposure of the mucosa to the gut microbiota 
and determine the extent of inflammation upon damage. To this 
end, we administered FITC-dextran by oral gavage and quantified 
the amount of absorbed FITC-dextran 4 hours later by measuring 
the correspondent absorbance in blood samples. Yet, we could not 
observe differences (Figure 64 D). We hypothesize that the 
resistance to DSS-induced colitis could be due to different 
recruitment or activation of pro-inflammatory cells at sites of 
damage. 
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Figure 64: Full Smoc2 ablation attenuates colonic colitis. A. 
Experimental design. B. Histological analysis of intestinal recovery after 
DSS removal. Red arrows indicate stromal infiltration at the inflamed sites. 
Black arrows indicate de novo crypt formation. C. Graphical 
representation of body weight loss. Data are mean ± SD of three 
independent experiments. N=10 mice per genotype per experiment. D. 
Measurement of intestinal permeability of healthy Smoc2+/+ and Smoc2∆⁄∆ 
mice. Data are mean ± s.e.m. of n=6 mice for each genotype. 
 
RESULTS 
 155
5.7 BMP inhibition accelerates tumorigenesis and fully rescues 
polyp formation capability in Smoc2 full KO mice 
 
We next returned to the analysis of tumorigenesis. In this case, we 
combined loss of Apc with short period of DSS treatment after 
tamoxifen induction (Figure 65 A). DSS-induced colitis in the Apc 
mutated background increases tumor burden in the colon and has 
the advantage of shortening the duration of the experiment. This 
setting also enables to study the combined effects of Smoc2 loss in 
tumorigenesis and inflammation. As shown in Figure 65 B, Smoc2 
ablation significantly extended mice survival in this experimental 
setting.  
 
 
 
 
 
 
 
RESULTS 
 156
 
 
Figure 65: Effect of full Smoc2 ablation in Apc mutant mice treated 
with DSS. A. Experimental design. B. Survival curve of Villin-CreERT2; 
Smoc2∆⁄∆; Apcfl/+ mice and control Villin-CreERT2; Smoc2+⁄+; Apcfl/+ mice 
after tamoxifen injection and DSS treatment. N=9 Villin-CreERT2; 
Smoc2+⁄+; Apcfl/+ mice and 7 Villin-CreERT2; Smoc2∆⁄∆; Apcfl/+ mice. 
Statistics are done using log-rank test. 
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In order to understand if the polyp reduction observed in Apcflox/+, 
Smoc2∆⁄∆ mice is driven by BMP signaling upregulation, we 
repeated the previous experimental setting but introducing a new 
branch of LDN-193189 treatment. LDN-193189 is a specific 
BMPR1 inhibitor that has been previously used to inhibit 
systemically BMP signaling (Cuny et al., 2008; Yu et al., 2008) (see 
results-chapter 1). Treatment of control mice with LDN-193189 
massively increased tumor burden and mice became moribund 
after 1 month approximately (Figure 66 A, B). IHC for pSMAD1/5 
confirmed inhibition of BMP signaling (Figure 66 C). These results 
are consistent with a role for BMP signaling as a tumor suppressor 
during the onset of intestinal tumorigenesis as previously shown by 
us and several others (Haramis et al., 2004; Jaeger et al., 2012; 
Lombardo et al., 2011; Whissell et al., 2014). 
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Figure 66: Blockade of BMP signaling accelerates colon 
tumorigenesis. A. Quantification of adenomatous area in the colon of 
Villin-CreERT2; Apcfl/+ mice with or without LDN-193189 treatment 
following tamoxifen and DSS administration. All the mice were sacrificed 1 
month after tamoxifen injection, when the LDN-treated ones became 
moribund. Each dot represents one mouse. Data are mean ± s.e.m. of 
n=5 untreated mice and n=4 LDN-treated mice. Statistics are done by 
Student’s t-test. ***P<0,001 B. Representative pictures of untreated and 
LDN-treated colon. Black arrows indicate tumor burden. C. pSMAD1/5 
IHC on control and LDN-treated mice. Note the presence of small 
pSMAD1/5 positive polyps in untreated mice (upper panel) whereas LDN-
treated mice (lower panel) display big polyps negative for BMP signaling. 
Black arrows indicate pSMAD1/5 positive polyp in the colon of untreated 
mice. Green arrows and red arrow respectively indicate stromal infiltration 
and the presence of cysts in LDN-treated mice, features resembling 
juvenile polyps. Magnification 10X.  
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Based on these results, we decided to sacrifice LDN-treated mice 
at 1 month whereas untreated mice were analyzed 1 further month 
later to enable polyp growth (Figure 67 A). As shown in previous 
experiments, untreated Villin-CreERT2; Smoc2∆⁄∆; Apcfl/+ mice 
developed fewer tumors than control littermates (Figure 67 B, C). 
Interestingly, Villin-CreERT2; Smoc2∆⁄∆; Apcfl/+ and Villin-CreERT2; 
Smoc2+⁄+; Apcfl/+ mice treated with LDN-193189 developed 
equivalent numbers of tumors (Figure 67 B, C). 
Thus, SMOC2 acts as a tumor promoter in the intestine by blocking 
BMP signaling.  
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Figure 67: BMP drives the reduction in tumorigenesis of Smoc2∆⁄∆ 
mice. A. Experimental design. B. Calculation of the adenomatous area in 
the colon of Villin-CreERT2; Smoc2∆⁄∆; Apcfl/+ mice and control Villin-
CreERT2; Smoc2+⁄+; Apcfl/+ mice after tamoxifen, DSS and LDN treatment. 
Each dot represents one mouse. Data are mean ± s.e.m. of n=5 to 7 mice 
for each genotype and treatment. Statistics are done by Student’s t-test. 
**P<0,01 C. Representative pictures of the colon of the four different 
conditions. LDN-treated mice were sacrificed 1 month after tamoxifen 
induction, whereas untreated mice were sacrificed 2 months after 
tamoxifen induction. Black arrows indicate tumor burden. 
RESULTS 
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5.8 Smoc2∆⁄∆ adenomas do not display increased BMP activation or 
reduction of AdSC compartment 
 
It has been proved that the cells of origin of intestinal adenomas 
are LGR5 positive ISCs (Barker et al., 2009). In turn, adenomas 
contain a population of LGR5 expressing cells at the base of the 
adenoma glands that act as bona fide tumor stem cells (i.e. 
Adenoma Stem Cells). We thus repeated the analysis of tumor 
formation but depleting Smoc2 specifically in ISCs. To this end, we 
used the Lgr5-GFP-IRES-CreERT2 driver that also allows tracking 
ISCs and adenoma stem cells (AdSCs) in vivo by means of GFP 
knock-in downstream the Lgr5 promoter. For this experiments we 
compared Lgr5-CreERT2; Smoc2∆⁄∆; Apcfl/fl mice with Lgr5-CreERT2; 
Smoc2+⁄+; Apcfl/fl mice (Figure 68 A). As expected, we observed 
strong reduction in tumor burden in Smoc2∆⁄∆ mice (Figure 68 B). 
However, the size and distribution of AdSC compartment in Smoc2 
deficient polyps were identical to that of control mice, as shown by 
GFP staining (Figure 68 C). Likewise, we did not observe 
expansion of pSMAD1/5 positive compartment in Smoc2∆⁄∆ polyps, 
which was restricted to an area close to the lumen as we previously 
described (Whissell et al., 2014). It thus appears that the BMP 
gradient is maintained in Smoc2 mutant polyps. Therefore, the 
bottom adenoma glands where AdSCs reside remain protected 
from BMP signaling in both genotypes (Figure 68 C). These data 
suggest that the adenoma epithelial compartment may not be the 
direct target of SMOC2-driven BMP inhibition. 
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Figure 68: BMP and AdSC compartment are not altered in Smoc2∆⁄∆ 
mice. A. Experimental design. B. Polyp counting (upper panel) and size 
distribution (lower panel) in the colon of LGR5-GFP-CreERT2; Smoc2∆⁄∆; 
Apcfl/fl mice and control LGR5-GFP-CreERT2; Smoc2+⁄+; Apcfl/fl mice 
sacrificed 2 months after tamoxifen injection and DSS treatment. Each dot 
in the upper panel represents one mouse. Data are mean ± s.e.m. of n=6 
LGR5-GFP-CreERT2; Smoc2+⁄+; Apcfl/fl mice and 7 LGR5-GFP-CreERT2; 
Smoc2∆⁄∆; Apcfl/fl mice. Statistics are done by Student’s t-test. ***P<0,001 
C. Representative pictures of GFP IHC (Lgr5-GFP) (upper panels) and 
pSMAD1/5 IHC (lower panels) in polyps of LGR5-GFP-CreERT2; 
Smoc2∆⁄∆; Apcfl/fl mice and control LGR5-GFP-CreERT2; Smoc2+⁄+; Apcfl/fl 
mice. Black arrows in the upper panels indicate GFP positive cells 
corresponding to the AdSC compartment at the bottom of the adenoma 
glands adjacent to the stroma. In both genotypes, PSMAD1/5 stains the 
differentiated compartment of adenomas which is negative for GFP 
staining. 
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5.9 Smoc2 proficient and deficient AdSCs are equally sensitive to 
BMP pathway activation 
 
In both Smoc2+⁄+ and Smoc2∆⁄∆ adenoma cultures, we observed 
considerable growth reduction upon rNOGGIN removal and 
consequent BMP pathway activation (Figure 69 B). In the absence 
of rNOGGIN, AdSCs clonogenic potential was progressively 
reduced as shown by loss of organoid forming capability over 
passaging in both genotypes (Figure 69 C). In concordance with 
this result, BMP target genes were equally upregulated in Smoc2+⁄+ 
and Smoc2∆⁄∆ adenoma cultured in the absence of rNOGGIN 
(Figure 69 D). These data suggest that endogenous Smoc2 
ablation does not exacerbate AdSC response to BMP activation. 
That leads us to conclude that SMOC2 does not exert a relevant 
role in protecting AdSCs from BMP and make us exclude adenoma 
epithelial cells as a major SMOC2 responsive target. 
Based on this finding, we can assert that SMOC2 does not act in a 
cell-autonomous manner. It may rather impinge on adenoma 
growth through the inhibition of BMP in other stromal cell 
subpopulations that in turn could affect adenoma initiation and 
growth.  
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Figure 69: Smoc2 deficient AdSCs are not more sensitive to BMP 
exposure in vitro. A. Experimental design. B. Representative pictures of 
colonic AdSC cultures derived from Villin-CreERT2; Smoc2∆⁄∆; Apcfl/fl mice 
and control Villin-CreERT2; Smoc2+⁄+; Apcfl/fl mice recombined in vivo with 
tamoxifen. Upon rNOGGIN removal, AdSCs from both genotypes undergo 
growth reduction. Overall, the adenoma spheres are smaller and black 
arrows indicate apoptotic spheres. C. Progressive loss of AdSC 
clonogenic capability upon rNOGGIN removal from both Smoc2+⁄+ and 
Smoc2∆⁄∆ adenoma cultures. Data are mean ± SD of triplicates. D. RT-
qPCR analysis of BMP target gene expression in Smoc2+⁄+ and Smoc2∆⁄∆ 
AdSCs cultured with or without rNOGGIN.  
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5.10 Gene expression analysis of stromal subpopulations sorted 
from Smoc2+⁄+ and Smoc2∆⁄∆ polyps 
 
Our in vitro experiments demonstrate that epithelial cells are not 
the major direct targets of SMOC2 pro-tumorigenic effect. In 
addition, our preliminary analysis of DSS-induced colitis suggests a 
role for SMOC2 in controlling inflammation. 
Important to understand the rationale behind the experiments 
described below is the fact that previous published data had shown 
that SMOC2 synergizes with vascular endothelial growth factor to 
stimulate endothelial angiogenesis in vitro (Rocnik et al., 2006). 
Furthermore, while we were developing these experiments, a 
manuscript revealed that the member of the SMOC2 family, 
SMOC1, binds directly the TGFβ auxiliary receptor Endoglin 
(CD105) and promotes endothelial cell proliferation and 
angiogenesis (Awwad et al., 2015). In addition, a previous study 
had also reported the capacity of SPARC to interact with Endoglin 
(Rivera and Brekken, 2011). Endoglin is a TGFβ binding protein 
expressed on the surface of endothelial cells. Loss-of-function 
mutations in the human Endoglin gene (ENG) cause Hereditary 
Hemorrhagic Telangiectasia (HHT1), a disease characterized by 
vascular malformations (Damjanovich et al., 2011). Moreover, mice 
lacking Eng die from defective vascular development (Li et al., 
1999). 
However, Endoglin expression is not restricted to endothelial cells. 
It has been reported that although Endoglin is absent from 
peripheral blood monocytes, it is expressed in differentiated 
monocytes (Lastres et al., 1992). 
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These data prompted us to focus on the response of stromal cells 
to Smoc2 deficiency, particularly CD105+ cells. We studied 
different cells types present in adenomas arising in Villin-CreERT2; 
Smoc2∆⁄∆; Apcfl/+ mice and control Villin-CreERT2; Smoc2+/+ Apcfl/+ 
mice. For these experiments, we macroscopically dissected large 
adenomas and we enzymatically dissociated them to single cells. 
We them labeled cells with specific surface markers and 
subsequently proceeded with FACS isolation. In particular, we 
purified epithelial cells (EpCAM+/CD45-/CD105-), CD105 
expressing endothelial cells (EpCAM-/CD45-/CD105+), CD105 
expressing immune cells (EpCAM-/CD45+/CD105+) and general 
leukocyte populations (EpCAM-/CD45+/CD105-). Because of the 
low numbers of cells obtained from these samples, we used a 
method to amplify cDNA that has been developed by the 
Functional Genomics core facility at our institution (Gonzalez-Roca 
et al., 2010). The robustness and reliability of this amplification 
method has been widely validated and used in previous studies by 
the Genomics core facility and by our laboratory (Calon et al., 
2012). 
By RT-qPCR analysis of amplified material we confirmed the 
enrichment for the markers used for cell sorting in the different cell 
fractions (Cd105, Cd45, EpCAM). Please note that each marker 
was upregulated between 10 and 1000 fold in each particular 
population, which validates this methodology (Figure 70). 
 
 
 
RESULTS 
 168
 
 
 
Figure 70: Cd105, Cd45 and EpCAM expression in sorted cell 
population from adenomas of Smoc2+/+ and Smoc2∆⁄∆ mice. Cd105 (A), 
Cd45 (B) and EpCAM (C) expression was assessed by RT-qPCR on the 
different populations purified from Smoc2+/+ and Smoc2∆⁄∆ adenomas. For 
each fraction, data are mean ± SD of n=2 mice for each genotype. 
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We also characterized the identity of the CD45+/CD105+ and 
CD45-/CD105+ cell populations. CD45+/CD105+ expressed 
elevated levels of differentiated tissue resident macrophage marker 
genes compared to general leukocyte CD45+/CD105- fraction. 
Those include Cx3cr1, Cd206, Cd11c and Cd68. On the contrary, 
Gr1, which is a marker of undifferentiated monocytes was relatively 
less expressed on CD45+/CD105+ (Figure 71 A). 
The CD45-/CD105+ cells expressed elevated levels of Cd31, a 
specific marker for endothelial cells (Figure 71 B). Therefore, 
CD45+/CD105+ cells were enriched in macrophages whereas 
CD45-/CD105+ fraction was composed of endothelial cells. 
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Figure 71: Characterization of CD45+/CD105+ and CD45-/CD105+ cell 
populations. A. Comparison of gene expression between 
CD45+/CD105+ and CD45+/CD105- cell populations derived from Smoc2 
wild-type adenomas. B. Detection of Cd31 expression in Endoglin-
expressing cell populations (CD45-/CD105+ and CD45+/CD105+) derived 
from Smoc2 wild-type adenomas. Gene expression was assessed by RT-
qPCR analysis. 
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Finally we found that Smoc2 was almost undetectable in 
CD45+/CD105- fraction. On the contrary, Smoc2 was highly 
expressed in CD105 positive cell populations, both CD45-/CD105+ 
and CD45+/CD105+ (Figure 72). This finding confirmed our 
previous observations suggesting that Smoc2 was expressed in 
stromal cells. These stromal populations co-express Endoglin 
(CD105+) and appear to be tissue resident macrophages and 
endothelial cells.  
 
 
 
Figure 72: Smoc2 expression in sorted cell populations. Smoc2 
expression was assessed by RT-qPCR in the cell populations sorted from 
Smoc2 wild-type adenomas. 
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As already mentioned, we tested several commercial antibodies 
against SMOC2 and none of them allowed the detection of the 
protein neither by Western Blot nor by IHC. The recent publication 
by Shvab et al. showed nice SMOC2 staining in ISCs of human 
samples of normal mucosa and CRC. Neither this antibody showed 
SMOC2 specific signal in mouse samples. Nevertheless, the 
analysis of SMOC2 IHC on human samples revealed stromal 
SMOC2 positive cells besides the expected positive SCs. In 
particular, anatomopathologists from Hospital del Mar in Barcelona 
confirmed strong SMOC2 signal in SCs and immune cells resident 
in the tissue and inside the blood vessels. The shape and the 
distribution of these cells resembled those of macrophages. 
Furthermore, intermediate signal was detected in endothelial and 
nerve cells. Fibroblasts and muscle cells were classified negative 
for SMOC2 expression (Figure 73). These observations confirm 
our findings achieved by purification of cell populations and 
detection of Smoc2 mRNA levels by RT-qPCR. 
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Figure 73: SMOC2 expression in human samples of normal intestinal 
mucosa and CRC. IHC showing SMOC2 expression in human intestinal 
normal mucosa (a, b, c) and CRC (d) at magnification 20X. Panel c’ and b’ 
respectively show higher magnification of SMOC2 positive ISCs and 
SMOC2 positive immune cells inside a blood vessel. Black arrows 
indicate SMOC2 positive SCs at the base of normal intestinal crypts. Blue 
arrows indicate intermediate SMOC2 signal in nerves. Red arrows 
indicate intermediate SMOC2 signal in endothelial cells of blood vessels. 
Green arrows indicate tissue resident macrophages or monocytes in the 
blood vessels. 
 
 
 
 
 
 
 
 
  
RESULTS 
 174
5.11 Expression profiling of CD105+ cell populations 
 
We next compared the global expression profiles of CD45-/CD105+ 
and CD45+/CD105+ cell populations isolated from Villin-CreERT2; 
Smoc2∆⁄∆; Apcfl/+ adenomas and control Villin-CreERT2; Smoc2+/+ 
Apcfl/+ adenomas. To this end, we hybridized samples in duplicate 
(i.e. purified populations obtained from 2 mice of each genotype) 
on Affymetrix® microarrays.  
Principal Component Analysis (PCA) showed high segregation 
between the two fractions and similar identity between duplicates 
(Figure 74). 
 
 
Figure 74: Gene expression profile of CD45-/CD105+ and 
CD45+/CD105+ cell populations sorted from Smoc2+/+ and Smoc2∆⁄∆ 
adenomas. PCA of CD45-/CD105+ and CD45+/CD105+ cell populations 
sorted from Smoc2+/+ and Smoc2∆⁄∆ adenomas and profiled on Affymetrix® 
microarrays. N=2 for each genotype and fraction. 
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In CD45+/CD105+ cells, we identified 77 genes consistently 
upregulated and 44 genes consistently downregulated in Villin-
CreERT2; Smoc2∆⁄∆; Apcfl/+ mice compared to control Villin-CreERT2; 
Smoc2+/+; Apcfl/+ mice (cutoff: 2 fold; p<0.05). In CD45-/CD105+ 
cells, we identified 27 genes consistently upregulated and 102 
genes consistently downregulated in Villin-CreERT2; Smoc2∆⁄∆; 
Apcfl/+ mice compared to control Villin-CreERT2; Smoc2+/+; Apcfl/+ 
mice (cutoff: 2 fold; p<0.05). Top genes for each comparison are 
listed in the following tables.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
 176
Downregulated genes in Smoc2∆/∆ 
CD45-/CD105+ cell population 
 
Gene.Symbol FC P.Value 
Cxcl9 -5,68 0,00 
Mfap4 -4,74 0,00 
Il1rl1 -4,43 0,09 
Bmp7 -4,28 0,00 
Il1rn -4,14 0,00 
Pdgfra -4,03 0,00 
Serpina3n -3,88 0,06 
Lgi2 -3,63 0,01 
Fgfr2 -3,55 0,00 
Col6a4 -3,41 0,01 
Lama1 -3,37 0,00 
Rgs2 -3,36 0,01 
Sycn -3,24 0,14 
Rgs2 -3,22 0,01 
Igf1 -3,18 0,02 
Sprr1a -3,16 0,10 
Scube1 -3,10 0,00 
Lamb3 -3,09 0,02 
Col6a4 -3,04 0,01 
Smoc1 -2,98 0,02 
Fndc1 -2,89 0,00 
Rbp4 -2,89 0,13 
Tnfrsf9 -2,86 0,09 
Cdca7l -2,86 0,01 
Ereg -2,84 0,19 
Rgs2 -2,78 0,01 
Fgf7 -2,68 0,02 
Sema3c -2,66 0,02 
Krt20 -2,66 0,14 
Pdgfra -2,64 0,07 
Cwh43 -2,64 0,14 
Foxf2 -2,63 0,00 
Spon1 -2,61 0,00 
Plau -2,58 0,06 
Lamc2 -2,58 0,15 
Pcdh7 -2,55 0,00 
Cldn4 -2,54 0,00 
Gpm6b -2,54 0,01 
Igfbp5 -2,54 0,03 
Ccrl1 -2,54 0,05 
Ptgs2 -2,53 0,21 
Inhba -2,51 0,05 
Spon1 -2,49 0,00 
Muc3 -2,47 0,10 
Wnt5a -2,47 0,04 
Bmp2 -2,45 0,08 
Bmp5 -2,44 0,00 
Dio2 -2,43 0,25 
Lum -2,41 0,05 
Krt8 -2,41 0,11 
Dsg2 -2,37 0,01 
Mmp12 -2,35 0,19 
Fzd2 -2,34 0,12 
Pmepa1 -2,33 0,00 
Tubgcp6 -2,31 0,00 
Rnd3 -2,30 0,01 
Nrg1 -2,30 0,03 
Pcdh7 -2,29 0,01 
Krt8 -2,29 0,10 
Hgf -2,27 0,01 
Wnt5a -2,27 0,01 
Gpm6b -2,26 0,08 
Tmem190 -2,24 0,01 
Aldh1a3 -2,22 0,11 
Csgalnact1 -2,22 0,09 
U90926 -2,22 0,00 
Dpep1 -2,20 0,00 
Atp1a3 -2,19 0,00 
Ncam1 -2,18 0,00 
Col12a1 -2,18 0,00 
Tmem119 -2,16 0,01 
Bmp4 -2,15 0,00 
Col12a1 -2,14 0,00 
Ptch1 -2,13 0,00 
Dpt -2,12 0,00 
Cpxm2 -2,10 0,00 
Sycn -2,10 0,23 
Grem1 -2,10 0,07 
Akr1b8 -2,09 0,09 
Aldh1a3 -2,09 0,09 
Ckmt1 -2,08 0,00 
Syt13 -2,08 0,01 
Wls -2,08 0,03 
Hhip -2,08 0,14 
Dpep1 -2,07 0,01 
Aldh1a3 -2,06 0,31 
Ptges -2,06 0,15 
Sema3c -2,05 0,00 
Ptgfrn -2,05 0,01 
Mmp9 -2,04 0,03 
Srprb /// Trf -2,04 0,00 
Wfdc2 -2,03 0,18 
Tubb4a -2,03 0,00 
Lrp1 -2,02 0,07 
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Gm14446 -2,02 0,08 
Ccdc80 -2,02 0,00 
Fosb -2,01 0,29 
Serpina3g -2,01 0,02 
Vegfa -2,01 0,06 
Serpind1 -2,01 0,01 
Smox -2,01 0,02 
Egln3 -2,00 0,00 
Gna13 -2,00 0,00 
 
Upregulated genes in Smoc2∆/∆ 
CD45-/CD105+ cell population 
 
Gene.Symbol FC P.Value 
Lyz1 5,05 0,06 
Defa4 4,72 0,13 
Defa-rs2 4,61 0,16 
Cox8a 4,57 0,00 
Defa15 4,34 0,16 
H2-Aa 4,19 0,00 
Cldn2 3,17 0,17 
S100a8 3,05 0,06 
Spink4 2,69 0,09 
Cers6 2,60 0,01 
S100a9 2,45 0,08 
Idh1 2,44 0,00 
Lyz2 2,37 0,04 
Spock2 2,30 0,30 
Slc30a2 2,17 0,24 
Atp1b1 2,16 0,18 
Galnt15 2,15 0,04 
Flt4 2,15 0,01 
Tigd3 2,12 0,00 
Lyve1 2,09 0,01 
Insig1 2,08 0,01 
Pcdh17 2,06 0,02 
Rnf157 2,05 0,01 
Sephs2 2,02 0,00 
Wfdc18 2,02 0,01 
Adi1 2,01 0,04 
Gimap8 2,01 0,13 
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Downregulated genes in Smoc2∆/∆ 
CD45+/CD105+ cell population 
 
Gene.Symbol FC P.Value 
Mcpt1 -7,08 0,15 
Igkv6-15 -5,30 0,13 
Saa1 -4,81 0,04 
Mcpt2 -4,81 0,12 
Ppbp -4,72 0,00 
Ccl1 -4,29 0,16 
Klrc1 -4,03 0,00 
Gzmb -3,98 0,03 
Saa1 -3,06 0,04 
Cp -2,97 0,01 
Zg16 -2,95 0,00 
Col1a1 -2,91 0,02 
Folr2 -2,69 0,00 
Spic -2,69 0,00 
Dmbt1 -2,63 0,30 
Zg16 -2,63 0,01 
Cbr2 -2,61 0,00 
Fcrla -2,53 0,09 
Fap -2,46 0,00 
Tpsab1 -2,45 0,14 
Col1a1 -2,45 0,02 
Ccl22 -2,43 0,05 
Col1a2 -2,39 0,05 
Fcrls -2,37 0,00 
Cxcl13 -2,35 0,09 
Igfbp5 -2,34 0,20 
Ccl4 -2,33 0,05 
Apold1 -2,28 0,08 
F2r -2,28 0,02 
Crabp2 -2,27 0,00 
Hspa1b -2,17 0,11 
Nkg7 -2,16 0,17 
Slc2a3 -2,12 0,00 
Col3a1 -2,11 0,02 
Mmp9 -2,10 0,02 
Rbm39 -2,10 0,12 
Lypd8 -2,10 0,23 
Prkar1b -2,09 0,00 
Col6a1 -2,08 0,03 
Fosb -2,08 0,01 
Maf -2,07 0,00 
Timp1 -2,05 0,04 
Ccl3 -2,04 0,04 
Cp -2,01 0,04 
Fpr1 -2,01 0,05 
Upregulated genes in Smoc2∆/∆ 
CD45+/CD105+ cell population 
 
Gene.Symbol FC P.Value 
Igk-V1/v9-120 5,82 0,17 
Hbb-b2 5,46 0,02 
Apcdd1 4,76 0,07 
Igk-V21 4,55 0,22 
Dsp 3,65 0,00 
Igh-VJ558 3,64 0,13 
Plagl1 3,25 0,06 
Apcdd1 3,01 0,14 
Mt4 3,00 0,03 
Lgr5 2,84 0,10 
Ang4 2,83 0,13 
Mmp15 2,81 0,01 
Mal2 2,75 0,00 
Tenm4 2,73 0,01 
Cyb561 2,65 0,00 
Mpzl2 2,55 0,01 
Reg3g 2,55 0,00 
Lamb3 2,54 0,00 
Reg3b 2,53 0,43 
Ptn 2,52 0,14 
Fat1 2,52 0,02 
Foxa3 2,51 0,01 
Ddr1 2,51 0,00 
Cep170b 2,49 0,00 
Nav2 2,49 0,00 
Sox9 2,47 0,01 
Atp1b1 2,47 0,00 
Defa-rs7 2,46 0,32 
Mpzl2 2,40 0,00 
Tsc22d1 2,39 0,00 
Wif1 2,39 0,01 
Cdc20 2,38 0,02 
Pvrl3 2,37 0,00 
Cldn2 2,37 0,00 
Slc30a2 2,35 0,11 
Krt18 2,35 0,00 
Dsp 2,33 0,00 
Lmo7 2,25 0,00 
Dsg2 2,24 0,00 
Lama5 2,24 0,00 
Reg4 2,23 0,24 
Ppap2a 2,22 0,03 
Neo1 2,22 0,00 
Nkd1 2,21 0,03 
Fam83h 2,21 0,01 
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Rrm2 2,19 0,00 
Cdh13 2,19 0,08 
Alox12 2,18 0,02 
Ctxn1 2,18 0,01 
Prox1 2,17 0,04 
Syne4 2,15 0,05 
Gm9817 2,14 0,02 
Gpc4 2,13 0,02 
Prom1 2,12 0,00 
Nhsl1 2,12 0,09 
Spink3 2,12 0,19 
Krt7 2,09 0,00 
Mmp7 2,09 0,27 
Trip13 2,09 0,00 
Aldh1l1 2,09 0,00 
Perp 2,09 0,04 
Rnf43 2,08 0,02 
Ppap2a 2,07 0,02 
Irf6 2,06 0,03 
Cd24a 2,05 0,01 
Fgfr4 2,04 0,04 
Elovl6 2,04 0,00 
Sectm1a 2,03 0,05 
Cd24a 2,03 0,00 
Dsg2 2,03 0,00 
Iigp1 2,03 0,18 
Vwa2 2,03 0,02 
Atp1b1 2,02 0,03 
Cdh13 2,01 0,12 
Asprv1 2,01 0,06 
Sox21 2,01 0,00 
Mid1 2,00 0,00 
Cldn4 2,00 0,01 
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Gene Set Enrichment Analysis (GSEA) revealed that Smoc2 
deficiency in CD45+/CD105+ cells negatively correlated with 
chemokine signaling pathway, natural killer cell-mediated 
cytotoxicity, T cell migration and dendritic cell differentiation 
(Figures 75 A). In CD45-/CD105+ cells, lack of Smoc2 was 
negatively correlating with extracellular matrix organization and 
Insulin-like Growth Factor (IGF) receptor signaling pathway 
(Figures 75 B). 
These data suggest that the lack of Smoc2 triggers multiple 
responses in Endoglin positive populations of adenomas. 
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Figure 75: GSEA of profiled CD45+/CD105+ and CD45-/CD105+ cell 
populations sorted from Smoc2+/+ and Smoc2∆⁄∆ adenomas. A. 
CD45+/CD105+ cells from Smoc2∆⁄∆ adenomas negatively associate with 
inflammation related processes (such as chemokine signaling, natural 
killer cell cytotoxicity, T cell migration and dendritic cell differentiation) 
compared to Smoc2+⁄+ adenomas B. CD45-/CD105+ cells from Smoc2∆⁄∆ 
adenomas negatively correlate with extracellular matrix remodeling 
processes and IGFR signaling pathway. Pos: positive correlation; Neg: 
negative correlation. 
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5.12 IGF1 is downregulated in Smoc2 deficient CD45-/CD105+ 
cells through BMP signaling 
 
Among the pathways silenced in cells lacking Smoc2, we focused 
our attention on the IGF1 pathway. The rationale is the following: 
first, changes in Igf1 may explain the enlarged intestines present in 
Smoc2 transgenic mice. Second, IGF1 could act as a mitogen for 
AdSCs. Third, IGF1 plays important roles in regulation of 
inflammatory response (Heemskerk et al., 1999). The expression 
profiling experiments described above indicated that in CD45-
/CD105+ cells purified from adenomas, lack of Smoc2 induced 
downregulation of Igf1 as well as of other genes regulating IGF1 
signaling (IgfBP5). We thus sought to confirm these findings. To 
this end, we purified CD45-/CD105+ cells from an additional cohort 
of mice (n=4) following the methodology described above. We 
included in this experiment mice treated acutely with the BMPR1 
inhibitor LDN-193189. RT-qPCR analysis showed increased levels 
of canonical BMP target genes such as Id1 and Smad6 in Smoc2 
deficient cells. In turn, levels of these BMP target genes were 
reduced in Smoc2∆⁄∆ cells obtained from mice treated with LDN-
193189 (Figure 76 A). We also confirmed the observation that Igf1 
mRNA levels were downregulated in CD45-/CD105+ cells that 
lacked Smoc2. Consistently with regulation by the BMP pathway, 
treatment with LDN-193189 induced a large upregulation of Igf1 
(Figure 76 B).      
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Figure 76: Gene expression analysis of CD45-/105+ cell population 
purified from Smoc2+/+ and Smoc2∆⁄∆ adenomas. A. BMP target gene 
expression was detected by RT-qPCR in CD45-/105+ cells sorted from 
Smoc2+/+ and Smoc2∆⁄∆ adenomas. B. Igf1 expression was detected by 
RT-qPCR in CD45-/105+ cells sorted from Smoc2+/+ and Smoc2∆⁄∆ 
adenomas. Each dot represents one measurement deriving from a pool of 
polyps of one mouse. Data are mean ± s.e.m. 
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5.13 IGF1 does not have a direct effect on adenoma growth 
 
IGF1 is a primary mediator of the effects of Growth Hormone (GH). 
GH is made in the anterior pituitary gland, is released into the blood 
stream, and then stimulates the liver to produce IGF1. IGF1 then 
stimulates systemic body growth, and has growth-promoting effects 
on almost every cell in the body. 
Its primary action is mediated by binding to its specific receptor, the 
insulin-like growth factor 1 receptor (IGF1R), which is present on 
many cell types in many tissues. Binding to the IGF1R, a receptor 
tyrosine kinase, initiates intracellular signaling. Upon several 
external and internal stimuli, IGF1 can be produced by extra-
systemic sources, especially tissue resident macrophages and 
endothelial cells. 
Since endothelial CD105+ cells derived from Smoc2∆⁄∆ polyps 
displayed a reduction in Igf1 expression possibly mediated by BMP 
signaling, we wondered if reduced IGF1 production by these 
stromal cells could be the direct cause of the reduced adenoma 
growth observed in Smoc2∆⁄∆ mice. To test this possibility, we 
cultured adenomas from Villin-CreERT2; Apcfl/fl mice as organoids in 
the presence of recombinant IGF1 (rIGF1). Because EGF and 
Insulin are included in the media, we also set experiments in which 
we removed these supplements.  Contrary to what was expected, 
we could not observe any growth promotion by rIGF1. Even in the 
absence of Insulin and EGF, rIGF1 failed to support adenoma 
growth (Figure 77 A). Cell stimulation with IGF1 can generally 
trigger three possible outcomes: cell proliferation through MAPK 
pathway, cell migration through RAC signaling and enhancement of 
cell survival through PI3K/AKT pathway (Stewart and Rotwein, 
1996). Western Blot against pAKT showed a mild increase of AKT 
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phosphorylation in AdSCs upon rIGF treatment (Figure 77 B). 
These preliminary data suggest that, in the context of intestinal 
adenomas, IGF1 has no direct mitogenic effect on epithelial cells. 
Most likely, IGF1 must impinge on adenoma growth by modulating 
the survival pathway or through different mechanisms that involve 
the stroma. 
 
 
 
Figure 77: IGF1 effect on AdSC culture. A. Mouse colon AdSCs were 
purified from a Villin-CreERT2; APCfl/fl mouse injected in vivo with 
tamoxifen and cultured in the absence of insulin. The addition of diluted 
EGF (50 pg/ml compared to control 50ng/ml) in the media determined an 
evident reduction of the growth that was not rescued by rIGF1 addition 
(100ng/ml). B. Western Blot on cultured AdSCs shows mild enhancement 
of AKT phosphorylation in the presence of rIGF1. 
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Discussion 
 
Chapter 1: The transcription factor GATA6 enables self-
renewal of colon adenoma stem cells by repressing BMP 
gene expression 
 
In normal mucosa, Lgr5+ cells reside at the base of the crypt and 
are able to both self-renew and give rise to all cell lineages of the 
intestinal tract throughout life (Barker et al., 2007). In a follow-up 
study, Lgr5+ cells were pinpointed as the cells of origin of CRC 
(Barker et al., 2009). In adenomas, Lgr5+ cells localize at the base 
of tumor glands and behave as AdSCs giving rise to the rest of 
tumor differentiated cell types that reside in closer proximity to the 
intestinal lumen (Schepers et al., 2012). Data from our laboratory 
support that late stage CRCs also rely on tumor SC for long term 
growth (Merlos-Suárez et al., 2011). Researchers are focusing 
great efforts on understanding the main pathways and regulators 
imposing hierarchies in benign and malignant lesions of the colon. 
 
Screening for genes that regulate stemness in CRC 
 
We used a bioinformatic approach based on the algorithm 
ARACNe to identify regulators of the tumor stem cell phenotype. In 
particular, we focused on genes directly associated to LGR5. An 
shRNA screening of LGR5 neighbors in the ARACNe network led 
to the identification of the transcription factor GATA6 as positive 
regulator of LGR5 expression in CRC cells. By ChIP-seq analysis 
we showed direct binding of GATA6 to the LGR5 proximal 
promoter. Consistent with our findings, previous work had also 
shown that modulation of GATA6 directly affects LGR5 expression 
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in differentiating embryonal carcinoma P19 cells (Alexandrovich et 
al., 2008). 
 
Additionally, we also showed that GATA6 regulated the expression 
of another ISC gene Cldn2. Previous transcriptomic analysis had 
shown enrichment of Cldn2 in mouse (Muñoz et al., 2012) and 
human (Jung et al., 2011) ISCs. We demonstrated that the protein 
levels of CLDN2 are highly restricted to ISCs and AdSCs. In 
adenoma, CLDN2 expression mirrors the expression pattern of 
Lgr5. As CLDN2 is a tight junction protein localized in the cell 
surface, it may represent a novel ISC marker for normal and tumor 
stem cell isolation and characterization. Several studies positively 
correlate CLDN2 to cancer severity (Dhawan et al., 2011; Kinugasa 
et al., 2007). CLDN2 has been found upregulated in CRC and 
correlates with cancer progression (Dhawan et al., 2011). 
Moreover, CLDN2 has been shown to play a key role in the tropism 
of metastatic breast cancer cells. In particular, CLDN2 allows 
breast cancer cells to adhere to hepatocytes and home to the liver 
(Tabaries et al., 2011). Interestingly, a recent study showed that 
invasion and migration of CRC cell lines was decreased by GATA6 
knockdown and enhanced by aberrant GATA6 expression that was 
associated with metastasis and poor overall survival (Shen et al., 
2013). These observations suggest an interesting functional 
connection between CRC-SCs and liver metastasis. 
 
Gata6 deficiency impairs the expansion of AdSCs through 
upregulation of BMP pathway 
 
A considerable amount of evidence indicates that BMP signaling 
counteracts WNT signaling in the intestinal crypt. BMP signals 
along the crypt axis triggers cell differentiation (Auclair et al., 2007; 
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Haramis et al., 2004; Kosinski et al., 2010). Molecules secreted by 
the stromal cells underlying the crypt base maintain low levels of 
BMP signaling and functional SC compartment. Inversely, loss of 
this inhibitory effect in the upper region of the crypt triggers BMP 
activation and consequent epithelial cell differentiation (Haramis et 
al., 2004; Kosinski et al., 2007). Consistent with these 
observations, BMP inhibitors are required for the long-term culture 
of normal mouse and human ISC (Jung et al., 2011; Sato et al., 
2009). In cultured AdSCs, we showed that recombinant BMP2 or 
BMP4 or Gata6 deletion resulted in BMP target upregulation and 
loss of self-renewal. By supplementing culture media with the BMP 
antagonists DMH1 or NOGGIN, we re-established AdSC 
clonogenicity. These data demonstrates that the transcription factor 
GATA6 controls BMP signaling. 
 
In vivo, BMP4 has been shown to be expressed in the epithelial 
compartment of mouse small intestinal adenomas and it was 
proposed to exert an autocrine protective function to limit self-
renewal and tumor progression (Farrall et al., 2012). Our study 
confirmed that, upon aberrant WNT activation, the BMP pathway is 
activated in colon adenomas. Furthermore, we reported that BMP 
pathway activation does not follow a homogeneous pattern but it 
was switched on in the upper third of the adenoma glands. 
Reminiscent of normal intestine, the stromal cells underlying the 
base of adenoma glands may secrete BMP inhibitors that maintain 
AdSCs protected from BMP. As well as in normal intestine, BMP 
may be one of the major signaling pathways imposing cell 
compartmentalization and a SC hierarchy. In Gata6 deficient 
adenoma, these compartments were perturbed as evidenced by an 
expansion of pSMAD1/5/8 and ID1 positive cell front into the AdSC 
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compartment. Gata6 deficiency enforced BMP pathway activation 
at the base of adenoma glands, reducing the size of the AdSC 
compartment, demonstrated by decreased expression of ISC 
markers (Lgr5, CLDN2, EPHB3). As a consequence, Apc mutant 
Gata6 null mice displayed reduced tumor growth and enhanced 
survival. Consistently, polyp formation in Gata6 null mice was 
rescued by LDN-193189-induced BMP inhibition. 
 
Linking BMP signaling, Gata6 expression and CRC 
susceptibility 
 
By ChIP-seq analysis, we showed that GATA6 positively regulates 
BMP4 expression in CRC cells by direct binding to distal enhancer 
regions of the BMP4 locus. One of these regions mapped to an 
SNP (rs1957636) which had been previously associated to CRC 
susceptibility (Tomlinson et al., 2011). We focused on this GATA6-
bound BMP4 enhancer region and confirmed direct GATA6 
interaction by chromosome conformation capture experiments. 
Remarkably, in the same region, we identified binding sequences 
also for β-catenin/TCF4 complex. RT-qPCR and ChIP-seq analysis 
performed in GATA6 deficient CRC cell line indicated that β-
catenin/TCF4 and GATA6 inversely regulated BMP4 expression by 
competing for the binding to the same BMP4 enhancer region. 
  
We hypothesize that the presence of SNPs at these regulatory 
regions could modulate the transcriptional circuit regulated by 
GATA6 and consequent BMP4 levels, influencing the expansion of 
AdSCs during tumorigenesis. Therefore, SNPs in the GATA6-
bound BMP4 enhancer region could be associated to CRC 
susceptibility. We further inspected linkage disequilibrium blocks at 
this genomic location and identified three more SNPs (rs1951674, 
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rs713424 and rs728425) located within GATA6-binding and in 
linkage disequilibrium with rs1957636. Although, these SNPs do 
not modify GATA6 core binding sequences themselves, the binding 
of GATA6 co-factors could be affected. In fact, GATA6 interaction 
with other transcription factors as well as epigenetic factors could 
explain the broad variety of divergent roles exerted by GATA6 
depending on the cellular context, developmental and disease 
stage. 
 
WNT/BMP regulatory interaction in CRC 
 
We show that GATA6 can act as transcriptional repressor (BMP4) 
and transcriptional activator (LGR5) by binding to distal enhancer 
regions (BMP4) or to proximal promoters (LGR5). By doing so, 
GATA6 represses or promotes WNT target genes (BMP4 and 
LGR5 respectively) in adenoma, adding complexity to the 
WNT/BMP dichotomy. BMP4 was already found to be a WNT 
target gene in CRC cell lines (Kim et al., 2002; Scholer-Dahirel et 
al., 2011; Van de Wetering et al., 2002). In turn, activated BMP 
signaling counteracts WNT signaling through mechanisms that 
have still not been deeply explored. It has been reported that 
conditional Smad4 deletion in Apc mutant mice increased tumor 
burden as consequent abrogation of BMP-mediated regulation of β-
catenin expression (Freeman et al., 2012). In our study we provide 
evidence of a WNT/BMP regulatory interaction by reporting high 
upregulation of WNT inhibitor genes (Apcdd1, Dkk2, Dkk3, Nkd1, 
Notum, Wif1 and Znrf3) in response to BMP activation in Gata6 null 
AdSC culture. Adding complexity to this regulatory network, 
Apcdd1 is also a WNT target gene restricted to ISCs (Jung et al., 
2011; Merlos-Suárez et al., 2011; Muñoz et al., 2012) and it has 
been reported to have a negative impact on WNT signaling 
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activation (Shimomura et al., 2010). All the other WNT inhibitors 
have been reported to act upstream the WNT receptor. Therefore, 
it is unlikely that they exert a major role in suppressing 
tumorigenesis in our model system where aberrant WNT signaling 
activation is caused by a loss-of-function Apc mutation. Fittingly, 
we observed that neither addition of recombinant WNT3a in the 
media nor overexpression of Lgr5 could rescue the growth of 
Gata6 null AdSCs. All the gathered observations indicate flexibility 
of BMP and WNT signaling pathway that can reciprocally modulate 
the output of their gene programs depending on the context. 
 
Histological analysis of BMP signaling has associated the loss of 
BMP activation at the adenoma to carcinoma transition. Fittingly, 
70% of CRCs display loss-of-function BMP pathway mutations, 
whereas sporadic adenomas generally do not present BMP 
alterations (Kodach et al., 2008). In agreement with these 
observations, BMP ligands have been shown to impinge growth of 
CRC cell lines that are still responsive to BMP signaling (Beck et 
al., 2006; Hardwick et al., 2008, 2004). Moreover, Lombardo et al. 
showed that BMP4 induces differentiation of CRC-SCs and 
increases their sensitivity to chemotherapy in mouse xenografts 
(Lombardo et al., 2011). In the normal intestine and pre-malignant 
lesions, BMP acts as a molecular break to maintain correct tissue 
homeostasis and impede SC over-growth. Supporting this notion, 
silencing of BMP in epithelial and stromal intestinal compartments 
lead to Juvenile Polyposis, a syndrome that predisposes to CRC 
(Beppu et al., 2008; Haramis et al., 2004; Kim et al., 2006). Thus, 
GATA6 expression in adenomas might be a determining factor to 
maintain low levels of BMP signaling and enable disease 
progression. 
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Chapter 2: Functional characterization of the novel ISC 
gene Smoc2 
 
After the identification of the gene program regulating intestinal 
SCs (Korinek et al., 1997), the current major effort of researchers in 
the field is addressing the role of specific markers in determining 
stemness. The second chapter of this thesis focuses on the 
functional characterization of Smoc2, a novel ISC gene. At the 
beginning of this study, we identified the gene by comparing three 
published ISC signatures based on EPHB2 and Lgr5-GFP cell 
sorting from mouse and human intestinal epithelium (Jung et al., 
2011; Merlos-Suárez et al., 2011; Muñoz et al., 2012). During the 
development of this thesis, the Clevers group provided definitive 
proof that Smoc2 marks ISCs in vivo (Muñoz et al., 2012). We will 
now discuss the different lines of evidence we gathered for the 
function of this novel ISC marker. 
 
SMOC2 in the regulation of BMP pathway 
 
At the moment we started to investigate the function of SMOC2, 
several studies had reported a role of Smoc2 in the modulation of 
the BMP morphogen gradient during Drosophila, Zebrafish and 
Xenopus development (Bloch-Zupan et al., 2011; Hamaratoglu et 
al., 2011; Thomas et al., 2009). Importantly, BMP is one of the 
major pathways orchestrating adult intestinal homeostasis by 
opposing to the WNT pathway (Kosinski et al., 2007) (see section 
2.4.4.3 of the introduction). We initially hypothesized that SMOC2 
could be a factor secreted by the ISCs to negatively regulate BMP 
signaling in the ISC niche, and ensure ISC maintenance. 
Interestingly, our laboratory found that SMOC2 is positively 
regulated by WNT pathway (Whissell, unpublished). Thus, we 
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predicted that SMOC2 could be an important SC factor in the 
dichotomy between WNT and BMP signals that maintain the 
balance for correct intestinal homeostasis. In order to address the 
role of SMOC2 in the regulation of the BMP pathway in mammals, 
we first confirmed SMOC2-mediated BMP inhibition in mammalian 
cell lines and intestinal primary cultures. However SMOC2 showed 
a weaker effect than the bona fide BMP inhibitor NOGGIN. These 
results provided the first indication supporting a role of SMOC2 as 
BMP inhibitor in intestinal epithelial cells. We then generated 
mouse models in order to study the specific effect of Smoc2 
upregulation and Smoc2 depletion in adult intestine. 
 
Characterization of Smoc2 transgenic mouse 
 
The definitive proof demonstrating the importance of BMP inhibition 
to maintain the undifferentiated state at the intestinal crypt base 
was given by a study performed by the Clevers group (Haramis et 
al., 2004). Authors demonstrated that BMP silencing in the intestine 
by transgenic overexpression of the BMP inhibitor Noggin in the 
epithelium led to the formation of ectopic proliferative crypts in the 
differentiated compartment. Three month old mice developed 
benign hamartomas resembling human Juvenile Polyposis 
Syndrome. These lesions can progress and eventually become 
adenomatous. In a similar fashion, we generated mice 
overexpressing Smoc2 throughout the whole intestinal epithelium. 
Consistently with our in vitro data, Smoc2 transgenic mice 
displayed BMP inhibition in epithelial and stromal intestinal cells. 
Aged (5-10 months) Smoc2 transgenic mice with very high Smoc2 
overexpression spontaneously developed JP-like hamartomas and 
some adenomas. Strengthening a role for SMOC2 during 
tumorigenesis, we found that Smoc2 overexpression in mice 
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lacking one Apc allele exacerbated the development of adenomas. 
These results confirmed the BMP inhibitory effect exerted by 
SMOC2. In addition, in vivo results also support a weaker effect of 
SMOC2 compared to NOGGIN. This finding is consistent with our 
in vitro experiments. These observations could be explained by 
possibly different inhibitory mechanism adopted by the two 
proteins. Whereas it has been demonstrated that NOGGIN 
specifically blocks BMP activation by directly binding and 
sequestering BMP ligands (Groppe et al., 2002), the mechanism of 
action of SMOC2 is unknown. Although the main functional 
domains composing SMOC2 have been characterized based on 
their homology with those of other known proteins (Vannahme et 
al., 2003), their function remains speculative (Vannahme et al., 
2002) and no proof of specific interaction with other proteins has 
been demonstrated. Most likely, SMOC2 could interfere with BMP 
activation downstream of the BMP receptor by signaling through 
independent receptors or integrins and converging with the BMP 
pathway at the level of pSMAD1/5/8. In fact, it has been shown that 
SMOC2 is still able to counteract SMAD1/5/8 phosphorylation in 
the presence of a constitutive active BMP type 1 receptor (Thomas 
et al., 2009). Moreover, it has been reported the capacity of 
SMOC2 to enhance cell cycle progression by binding to αvβ1 and 
αvβ6 integrins and by signaling through ILK (Liu et al., 2008). 
 
The above evidences open to the possibility that SMOC2 could 
have broader functions not only restricted to the inhibition of BMP. 
Supporting this notion and contrary to the observation in Noggin 
transgenic mice (Haramis et al., 2004), Smoc2 transgenic mice did 
not display ectopic crypts along the villi and correct intestinal 
homeostasis was apparently maintained. Instead, mice developed 
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gigantism affecting all the cell compartments of small intestinal and 
colonic epithelium. Interestingly, a study reported the crucial role of 
drosophila BMP (Dpp) in driving the scaling of the wing imaginal 
disc under the guidance of SMOC2 (Pent) (Ben-Zvi et al., 2011). 
Scaling is a general property of developmental systems that ensure 
the proportionate adjustment of signaling patterns with the organ 
size. The proportionate gigantism displayed by Smoc2 transgenic 
mice led us to speculate an involvement of SMOC2 in 
developmental organ scaling. Nevertheless, the histological 
analysis of the intestine of new born Smoc2 transgenic mice did not 
show any size abnormality, even though the Villin promoter drives 
the overexpression of Smoc2 transgene already from embryonic 
day E16. On the contrary, Smoc2 transgenic mice were born 
normal. The gigantism is clearly evident in 2 months old mice and 
is exacerbated in older mice, suggesting a progressive evolution of 
the SMOC2-driven phenotype. 
 
We further investigated the effect of Smoc2 overexpression on self-
renewal and clonogenic potential of ISCs by culturing in 3D matrix 
Smoc2 wild-type and transgenic purified crypts. In the absence of 
BMP inhibition in the culture, Smoc2 overexpression provoked a 
mild enhancement of ISC growth rate that was not sufficient to 
sustain the culture over time. Surprisingly, Smoc2 overexpression 
in cultured transgenic crypts was in the range of 20-50 fold instead 
of the massive Smoc2 overexpression detected in vivo (up to 3000 
fold). This observation could explain the failure of Smoc2 
transgenic ISCs to sustain their growth in culture in the absence of 
BMP inhibition. It also suggests a weak BMP-inhibitory activity of 
SMOC2 and provides an explanation for the requirement of high 
SMOC2 abundance to achieve full BMP blockade. Importantly, we 
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observed that the original difference in size of Smoc2 transgenic 
intestinal crypts was not maintained in culture, since Smoc2 wild-
type and Smoc2 transgenic purified crypts gave rise to organoids of 
equal size in the presence of strong BMP inhibition. This 
observation suggests again that Smoc2 overexpression in vitro 
may not be sufficient to sustain the phenotype. On the other hand, 
this observation opens the possibility that the gigantism of the 
intestinal epithelium is not due to a cell-autonomous effect but 
rather depends on the contribution of stromal components 
responsive to SMOC2. 
 
Characterization of Smoc2 conditional KO mouse 
 
Our experiments with Smoc2 transgenic mice demonstrate that 
high levels of SMOC2 inhibit BMP activation in the intestine and 
cause a predisposition for adenoma growth. Nevertheless, Smoc2 
transgenic overexpression throughout the whole intestinal 
epithelium does not represent a physiological condition and 
therefore can lead to non-specific effects. In order to address the 
physiological role of SMOC2 in the intestinal epithelium, we 
generated Smoc2 conditional KO mice where we could induce 
specific Smoc2 ablation in the adult intestinal epithelium. Gene 
expression and histological analysis did not reveal any alteration in 
intestinal homeostasis of Smoc2 intestinal epithelial KO mice. 
Moreover, BMP signaling was not affected. 
 
Given the fact that Smoc2 is a target of WNT signaling and as a 
result it is upregulated upon mutagenic WNT activation during 
tumor initiation, we decided to study the effect of Smoc2 depletion 
in the intestinal epithelium of Apc mutant mice. We could not 
observe any difference in mice life span and in the incidence of 
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polyp burden in Smoc2 intestinal epithelial KO mice compared to 
control wild-type mice. Surprisingly, we found that the Smoc2 levels 
in total intestine did not decrease in Smoc2 intestinal epithelial KO 
mice. This first observation together with further analysis confirmed 
the presence of an extra-epithelial source of SMOC2 that 
contributes to Smoc2 expression following Smoc2 depletion in the 
epithelium. We proved this compensatory effect both in normal 
intestine and in the tumorigenic setting. These results suggest the 
lack of a SMOC2 epithelial cell-autonomous effect. Instead, they 
suggest that the maintenance of physiological SMOC2 levels in the 
intestinal crypt niche may ensure the correct intestinal 
homeostasis, regardless the source of SMOC2 (epithelial or 
stromal). 
 
Characterization of Smoc2 null mouse 
 
In order to overcome the compensatory effect driven by stromal 
SMOC2 secretion, we generated Smoc2 null mice. These mice 
presented almost undetectable Smoc2 both in the epithelium and in 
total intestine. Yet, we could not detect any alteration in intestinal 
homeostasis. Supporting our findings, the Clevers group reported 
that homozygous Smoc2 knock-in mice, constituting functional 
Smoc2 null mice, did not show any intestinal nor gross non-
intestinal phenotype (Muñoz et al., 2012). Furthermore, intestinal 
BMP signaling remained unaffected in Smoc2 null intestine. It has 
been reported that BMP inhibitors are secreted by the stromal cells 
underlying the intestinal crypts to protect ISCs from BMP exposure 
(Kosinski et al., 2007). We sought to investigate the expression 
levels of these known intestinal BMP inhibitors (Grem1, Grem2, 
Chordin) as well as of SMOC2 related genes (Smoc1, Sparc). At 
transcriptional level, Smoc2 was the most highly expressed among 
DISCUSSION 
 199
these genes in total intestine, whereas the levels of these genes 
were not altered in Smoc2 null intestine. These data suggest that 
these genes are not upregulated in response to Smoc2 ablation, 
yet their basal levels can be sufficient to compensate the lack of 
SMOC2 and maintain low BMP signaling in the SC niche. In order 
to analyze the effect of SMOC2 loss on ISC maintenance in the 
absence of compensatory molecules, we cultured intestinal crypts 
purified from Smoc2 null and wild-type mice. We observed equal 
growth rate in the presence of BMP inhibition and equal 
progressive growth reduction upon BMP exposure. These results 
definitively demonstrate epithelial SMOC2 dispensability for ISC 
maintenance.  
 
As described in chapter 1 of the result section (Whissell et al., 
2014), BMP4 is upregulated in response to mutagenic WNT 
activation and exerts a protective role against adenoma 
progression. However, AdSCs are still protected from this massive 
BMP activation by stromal BMP inhibitors present in the tumor SC 
niche. In this context, the balance between BMP promoting and 
inhibitory signals can determine the extent of tumorigenic 
progression. Therefore, we sought to address the effect of 
complete Smoc2 ablation in the intestine of Apc mutant mice. We 
observed that full Smoc2 deficiency enhanced survival of Apc 
mutant mice by reducing the polyp burden, suggesting a pro-
tumorigenic role of SMOC2. These findings support our previous 
results in Smoc2 transgenic mice. Indeed, Smoc2 overexpression 
enhances tumorigenesis whereas Smoc2 deficiency has anti-
tumorigenic effect. Consistent with this notion, a recent study 
showed preferential SMOC2 expression at the invasive front of 
CRC samples (Shvab et al., 2015). In this context, SMOC2 was 
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essential for L1CAM-mediated induction of aggressive/invasive 
properties. SMOC2 upregulation induced a more mesenchymal-like 
phenotype and increased liver metastasis. Additionally, 
strengthening the relevance of SMOC2 in the tumorigenic process, 
we had previously found that SMOC2 is one of the most enriched 
genes in CRC-SCs (Merlos-Suárez et al., 2011). 
 
We investigated the role of SMOC2 during the first steps of 
tumorigenesis in the context of adenoma initiation and growth. We 
observed that complete Smoc2 ablation reduced tumorigenesis in 
Apc mutant mice. On the contrary, Smoc2 epithelial depletion had 
no effect on intestinal tumorigenesis of Apc mutant mice, although 
Smoc2 KO macroadenomas displayed strong Smoc2 
downregulation as result of the consequent increase of the ratio 
between epithelial (Smoc2 deficient) and stromal (Smoc2 
proficient) compartments. This observation suggests that either 
residual SMOC2 in the conditional KO intestine is sufficient to 
sustain an effective pro-tumorigenic activity, or SMOC2 plays a 
crucial role at adenoma initiation. If this would be the case, then the 
complete lack of SMOC2 in Smoc2 null mice should restrain the 
transition from small aberrant crypt lesions to large adenomas. On 
the contrary, Smoc2 epithelial depletion in the intestine of 
conditional KO mice would be fully compensated by stromal 
SMOC2 secretion, ensuring tumor initiation and further 
progression. 
 
Inflammation is a key factor during intestinal tumorigenesis. Indeed, 
the extent and the quality of the inflammatory events can strongly 
affect the tumorigenic process. An altered inflammatory status can 
contribute both to the first stage of neoplastic transformation 
(initiation) and enhance malignancy in later stage tumors (Candido 
DISCUSSION 
 201
and Hagemann, 2013; Dobrovolskaia and Kozlov, 2005). 
Interestingly, we observed that Smoc2 null mice responded better 
than wild-type littermates to DSS-induced colonic colitis. Whereas 
we observed equivalent extent of the damage in the two genotypes 
following DSS treatment, Smoc2 null mice were more prone to 
recover upon DSS removal. The histological analysis confirmed 
that Smoc2 null intestine underwent less inflammation and 
regenerated faster than wild-type intestine. This result suggests 
that SMOC2 could exert a pro-inflammatory role. Interestingly, it 
has been reported that SPARC, a SMOC2 family member, 
exacerbated colonic inflammation by modulating macrophage 
recruitment (Ng et al., 2013). SPARC null mice displayed reduced 
inflammation and reduced macrophage recruitment following 
removal of DSS treatment. 
 
All these evidences prompted us to investigate the effect of 
SMOC2 in a setting where we combine DSS treatment (which 
triggers inflammation) with loss of Apc. By using both Villin-
CreERT2 and Lgr5-GFP-CreERT2 drivers, we observed 
enhancement of survival and reduction in polyp formation in Smoc2 
null mice. In order to address whether the anti-tumorigenic effect 
observed in Smoc2 null mice was attributed to lack of BMP 
inhibition and consequent BMP signaling hyperactivation, we 
combined Apc depletion and DSS treatment with LDN-193189 
administration. We observed that LDN-driven specific BMP 
inhibition accelerated the tumorigenic process in Smoc2 wild-type 
mice and fully rescued adenoma formation in Smoc2 null mice. 
This result demonstrates that BMP inhibition recovers adenoma 
formation capability in Smoc2 null mice. 
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The above observation implies that SMOC2 acts by inhibiting BMP 
signaling during tumor formation. Yet, the histological analysis of 
Smoc2 null adenomas showed neither an expansion of the BMP 
positive differentiated compartment nor a reduction of AdSC 
compartment. Therefore, we conclude that adenoma epithelial cells 
are not the direct targets of SMOC2-driven BMP regulation. In 
order to reinforce this result, we cultured in 3D matrix AdSCs 
derived from Apc mutant, Smoc2 null or wild-type mice. In the 
presence of robust BMP inhibition in the culture media, AdSCs of 
the two genotypes showed equal clonogenic potential. Upon BMP 
exposure, Smoc2 null and wild-type AdSCs suffered equal growth 
reduction and equivalent upregulation of BMP target genes. 
Therefore, lack of SMOC2 does not exacerbate the response of 
AdSCs to BMP activation, confirming that SMOC2 does not protect 
AdSCs from BMP but it must impinge on adenoma growth through 
another mechanism that likely involves stromal cells. 
 
Of note, although the data gathered from Smoc2 KO mice indicates 
that epithelial cells are not the major targets of endogenous 
SMOC2, Smoc2 transgenic mice showed strong BMP signaling 
inhibition also in epithelial cells. Consistently, we observed that 
recombinant SMOC2 protein promoted in vitro growth of normal 
intestinal crypts as well as of AdSCs upon BMP exposure. We 
speculate that in vitro treatment with rSMOC2 provides a non-
physiological amount of SMOC2 molecules that mimic the 
abundance of SMOC2 in the intestinal epithelium of transgenic 
mice. In both contexts, epithelial cells showed responsiveness to 
SMOC2. These data lead us to hypothesize that intestinal cells 
(epithelial and stromal) could have a “SMOC2-responsiveness 
threshold”, depending on SMOC2 protein abundance. Based on 
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our data, stromal cells are most likely the targets of endogenous 
SMOC2 activity. 
 
SMOC2 is expressed by and target Endoglin (CD105) positive 
endothelial cells 
 
We next focused our effort to understand the role of SMOC2 in the 
stromal component of adenomas. In particular, several studies 
correlating BM-40 proteins with vascular cell biology caught our 
attention. It has been already reported a role of SMOC2 in the 
stimulation of endothelial angiogenesis in vitro by synergizing with 
vascular endothelial growth factor (VEGF) (Rocnik et al., 2006). 
Moreover, Sparc null mice exhibited decreased pericyte-associated 
vessels in an orthotopic model of pancreatic cancer (Brekken et al., 
2003). The same authors also demonstrated that SPARC promotes 
pericyte migration by binding to the TGFβ co-receptor Endoglin 
(CD105) and by diminishing TGFβ activity (Rivera and Brekken, 
2011). Additionally, a very recent paper showed that SMOC1 is 
expressed by endothelial cells and promotes their proliferation by 
binding Endoglin in an autocrine fashion. In particular, they showed 
that SMOC1-Endoglin interaction blocked TGFβ signaling through 
ALK5 receptor and promoted BMP9/10 signaling through ALK1 
receptor, thus inducing angiogenesis (Awwad et al., 2015). 
 
Both the ALK1- and ALK5-mediated signaling can be activated 
within endothelium (Goumans et al., 2009).  ALK1 phosphorylates 
target SMADs (SMAD1, SMAD5, and SMAD8) through a similar 
mechanism as ALK5 phosphorylates SMAD2 and SMAD3 (Chen 
and Massagué, 1999) (Figure 78). 
The homodimeric Endoglin (CD105) lacks kinase activity but 
modulates BMP and TGFβ signaling. Endoglin not only interacts 
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with ALK1 to promote downstream SMAD1/5/8 activation, it also 
disrupts ALK5-mediated signaling (Goumans et al., 2003). 
Moreover, Endoglin is able to bind directly to BMPs 
(Scharpfenecker et al., 2007) (Figure 78). 
 
The requirement of Endoglin for endothelial cell proliferation and 
survival is illustrated by the fact that endothelial cell lines could not 
be derived from homozygous Endoglin-deficient matrix-embedded 
endothelial cells (MEECs) (Lebrin et al., 2004). Conversely, 
overexpression of either wild-type Endoglin or ALK1 increases cell 
proliferation in MEECs. Similar pro-angiogenic and pro-proliferative 
features of Endoglin are also evident in an in vivo model of 
angiogenesis involving retinal vasculature. Endoglin heterozygous 
deficiency impairs angiogenesis in this model, due to reduced 
proliferation of the endothelial cells compared to wild-type cells 
(Park et al., 2013). Mouse tumor models showed that lack of 
Endoglin expression facilitates migration through the endothelial 
cell barrier (Anderberg et al., 2013). This indicates that the 
Endoglin/ALK1 signaling axis is a key component for endothelial 
cell integrity. However, the ability of both ALK1 and ALK5 to 
exceptionally bind to TGFβ in the endothelium depending on the 
cell context, adds complexity regarding the possible outcomes of 
TGFβ/BMP signaling (Jonker, 2014; Scharpfenecker et al., 2007) 
(Figure 78). 
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Figure 78: TGFβ and BMP9 signaling pathways involving Endoglin and 
ALK1 in endothelial cells. From (Jonker, 2014). 
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Endoglin is predominantly expressed on cellular lineages within the 
vascular system and is overexpressed on proliferating endothelial 
cells. Several studies indicate that Endoglin is involved in the 
development of blood vessels and that it represents a powerful 
marker of neovascularization in various types of tumors, including 
colon cancer (Minhajat et al., 2006a, 2006b; Saad et al., 2004). 
Indeed, Endoglin is emerging as a prime vascular target of anti-
angiogenic cancer therapy (Jonker, 2014). However, Endoglin 
expression is not restricted to endothelial cells. It has been 
reported that although Endoglin is absent from peripheral blood 
monocytes, it is expressed in differentiated monocytes (Lastres et 
al., 1992) and smooth muscle cells (Ma et al., 2000; Mancini et al., 
2009; Middleton et al., 2005). 
 
Considering this interesting network involving BM-40 proteins and 
Endoglin-mediated regulation of TGFβ/BMP signaling in endothelial 
cells, we sought to purify Endoglin positive cells from Smoc2 null 
and wild-type adenomas. In particular, we found two Endoglin 
positive cell populations: CD45-/CD105+ cells that represent 
endothelial cells, and CD45+/CD105+ cells which are enriched in 
specific markers of tissue resident macrophages. Interestingly, 
these two fractions expressed high levels of Smoc2. This finding is 
in line with previous observations regarding the existence of an 
extra-epithelial source of SMOC2. We then profiled the gene 
expression of these two cell populations purified from Smoc2 null 
and wild-type adenomas. GSEA analysis showed negative 
correlation of Smoc2 null Endoglin positive macrophages with 
several processes involved in inflammation. On the other hand, 
Smoc2 null Endoglin positive endothelial cells showed negative 
correlation with genes related to ECM organization and IGF 
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receptor signaling pathway. It is known that inflammation is 
characterized by ECM remodeling to allow immune cells migration 
and recruitment, as well as by collagen deposition that can lead to 
fibrosis. We hypothesized that many of these events could be 
orchestrated by IGF1 that has been reported to be involved in 
several epithelial and stromal responses. 
 
Connecting SMOC2 with IGF1 signaling 
 
Our results indicate that lack of Smoc2 induces upregulation of 
BMP signaling in adenoma endothelial cells, which in turn 
negatively regulate Igf1 expression. By specific and acute blockade 
of BMP, endothelial Igf1 expression was reestablished. These 
findings suggest a novel IGF1 regulatory circuit in adenoma 
endothelial cells which is mediated by BMP signaling and is 
perturbed upon Smoc2 ablation. 
 
IGF1 is essential for normal pre- and post-natal growth and 
development (Clemmons, 2007). Somatic growth in mammals is 
controlled by the regulated release of GH, which acts systemically 
through the controlled production of IGF1 by the liver. IGF1 then 
circulates to target organs acting in an endocrine manner (Le Roith 
et al., 2001). Yet, conditional liver-specific Igf1 KO mice showed 
that abolished levels of liver Igf1 mRNA and significant reduction in 
circulating IGF1 did not lead to differences in body weights. These 
study suggest that extra-hepatic sources of IGF1, acting in an 
autocrine/paracrine manner, are important for postnatal growth and 
development (Sjögren et al., 1999; Yakar et al., 1999). 
 
Most IGF1 actions are mediated by its binding to the IGF1 receptor, 
a tyrosine kinase consisting of two heterodimers that has significant 
homology with the insulin receptor (Garrett et al., 1998). 
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Additionally, several proteins such as IGFBP1, IGFBP2, IGFBP3, 
IGFBP4, IGFBP5 and IGFBP6 may inhibit or potentiate IGF1 
actions. IGF1 receptor signaling involves autophosphorylation and 
subsequent tyrosine phosphorylation of insulin receptor substrate 
(IRS) (Tsuruzoe et al., 2001). IRS serves as a docking protein and 
can activate multiple signaling pathways, including PI3K/AKT 
pathway and MAPK pathway (Le Roith et al., 2001; Saltiel and 
Kahn, 2001). The activation of these signaling pathways triggers 
differential biological processes, including cell growth, 
differentiation, migration, and survival (Stewart and Rotwein, 1996) 
(Figure 79). 
 
 
Figure 79: Possible outcomes of IGF1 signaling in the cell. From 
(Delafontaine et al., 2004). 
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IGF1 in blood vessels 
 
Endothelial cells (ECs) are involved in IGF1 physiology and in turn 
they are targets of IGF1 actions. It has been reported that vascular 
smooth muscle cells (VSMCs) and ECs respectively express high 
and low levels of IGF1. The IGF1 receptor is highly expressed by 
both VSMCs and ECs from large and small vessels, suggesting 
that these cells are responsive to IGF1 (Delafontaine et al., 2004). 
Indeed, several studies report that IGF1 regulates migration and 
angiogenesis (Kondo et al., 2003; Nicosia et al., 1994; Shigematsu 
et al., 1999) and enhances inflammatory and vasodilatory 
responses in ECs (Che et al., 2002).  
 
In particular, hypoxia is a major angiogenic stimulus, and hypoxia 
inducible factors (HIFs) regulate transcription of key angiogenic 
genes, including VEGF (Semenza, 2012). IGF1 stimulate HIF1A 
expression (Hoeben et al., 2004), and induces VEGF synthesis 
(Stearns et al., 2005; Warren et al., 1996). Interestingly, it has been 
reported that Smoc2 was positively regulated by hypoxia in 
mesenchymal stem cells (Basciano et al., 2011). Furthermore, a 
recent study showed that both Smoc2 and Igf1 were upregulated in 
adipose tissue-derived stromal cells in response to serum 
deprivation (Tratwal et al., 2015), a condition that mimics in some 
aspects lack of vasculature and hypoxia. 
 
Furthermore, there is substantial interest in the role of the IGF 
system in cardiovascular disease. Many studies suggest that IGF1 
may be pro-atherogenic, because it promotes vascular smooth 
muscle cell proliferation and migration, and its expression is 
increased in atherosclerotic plaques (Clemmons, 2007). 
Interestingly, Smoc2 was found upregulated during neointima 
formation in a rat carotid endarterectomy model, suggesting that 
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SMOC2 might be involved in the progression of atherosclerosis 
(Nishimoto et al., 2002). 
 
Up to date, no evidences about direct BMP-mediated regulation of 
IGF1 have been reported. Yet, the literature offers extensive 
studies regarding the role of BMP in EC functions. Beyond its 
importance in embryonic development, BMP pathway plays a 
crucial role in vascular disorders including hereditary hemorrhagic 
telangiectasia (HHT) and peripheral arterial hypertension (PAH) 
(Cai et al., 2012). Although the BMP family is often considered pro-
angiogenic, several studies highlight how the context affects 
whether a BMP ligand acts as pro- or anti-angiogenic. Indeed, 
different EC types exhibit varying responses to the same BMP 
ligands. These differences may be due to the differential 
expression of co-receptors that mediate BMP internalization (Dyer 
et al., 2014). Recent studies have shown that the BMP pathway 
also affects processes such as the endothelial response to hypoxia 
and inflammatory stimuli (Kim et al., 2013), strengthening the 
significance of BMP pathway in maintaining vascular homeostasis. 
 
In our experimental system, we found that ECs are target of 
SMOC2-driven BMP deregulation and source of IGF1. At 
histological level, we have no clear evidence pointing to affected 
EC proliferation and angiogenesis in Smoc2 null adenomas. 
Nevertheless, our initial results indicate that several pro-mitogenic 
factors (Fgf7, FgfR2, VegfA, Hgf) appear downregulated in Smoc2 
null ECs. Further analysis will be required to assess the status of 
vascular cells in Smoc2 null adenomas. We also hypothesize that 
endothelium-secreted IGF1 may also exert paracrine functions on 
other cell types. 
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IGF1 in epithelial cells 
 
IGF1 has been demonstrated to have mitogenic effects on cultured 
intestinal epithelial cells (Duncan et al., 1994; Simmons et al., 
1995, 1999). Evidences suggest that mesenchymal cells, including  
myofibroblasts and smooth muscle cells, are primary sources of 
locally expressed IGF1 in the intestine. Indeed, in the normal 
intestine, IGF1 is expressed in scattered cells in the pericryptal 
regions and the lamina propria (Pucilowska et al., 2000a; Winesett 
et al., 1995). Situations of increased growth of the mucosal 
epithelium, such as adaptive growth following bowel resection, are 
accompanied by increased local Igf1 mRNA expression in 
mesenchymal cells in the lamina propria or muscularis propria 
(Mantell et al., 1995; Winesett et al., 1995; Zeeh et al., 1998; 
Zimmermann et al., 1993). These findings provide correlative 
evidence for paracrine actions of mesenchymal cell-derived IGF1 
on the intestinal epithelium. Smp8-Igf1 transgenic mice expressing 
rat Igf1 under transcriptional control of the murine alpha-Sma 
promoter exhibit normal levels of circulating IGF1 and high levels of 
transgene expression in smooth muscle in the small intestine 
(Wang et al., 1997). These mice display increased length and 
weight of the small intestine associated with increased thickness of 
the muscularis propria (Wang et al., 1997). In a follow-up study, 
authors observed an increase in crypt cell mitosis and mucosal 
mass in the ileum of Smp8-Igf1 mice. Therefore, local Igf1 
overexpression in intestinal mesenchymal cells has paracrine 
actions in vivo to stimulate growth of the mucosal epithelium 
(Williams et al., 2002). However, it is intriguing that this paracrine 
effect is limited to the ileum. Some studies suggest that locally 
expressed IGF1 may have segment-specific effects on mucosal 
growth (Gillingham et al., 2000). In a similar fashion, Igf1 
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transgenic mice driving the expression of the transgene in the 
epithelium (particularly in the villi) by used of the Metallothionein 1 
promoter, display increased intestinal mass with higher villus and 
deeper crypts (Ohneda et al., 1997) (Figure 80). 
 
 
 
Figure 80: Histological sections (autoradiograph under bright field) of 
wild-type and Mt1-Igf1 transgenic jejunum. From (Ohneda et al., 1997). 
 
 
 
The above-described Igf1 transgenic models resemble the Smoc2 
transgenic model in terms of general increase of mucosal mass. 
Therefore, we speculate that increased levels of stromal IGF1 
driven by Smoc2 overexpression could explain the proportionate 
gigantism observed in Smoc2 transgenic mice. 
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The pro-proliferative effect of IGF1 prompted us to investigate the 
role of IGF1 on the growth of adenoma epithelial cells. Indeed, we 
hypothesized that reduced EC production of IGF1 in Smoc2 null 
adenoma could negatively impinge on adenoma growth. However, 
we could not observe any growth promotion upon rIGF1 treatment. 
Further experiments are required to exclude or validate a direct 
IGF1 effect on adenoma epithelial cells. 
 
The role of the IGF1 system on precancerous lesions (such as 
adenomatous polyps) has not been widely investigated. A recent 
study found a significant positive correlation between serum IGF1 
and mucosal IGF1R mRNA in patients with adenomatous polyps 
(Zhang et al., 2013). IGF1 and its receptor may be activated before 
carcinogenesis, and may promote the growth and malignant 
transformation of adenomatous polyps. High levels of IGF1 have 
been also found in CRC patients (Jiang et al., 2014). Moreover, it 
has been reported that one SNP in IGF2 significantly increased risk 
of development of distal adenoma (Levine et al., 2012). 
Furthermore, the IGF1 system has been involved in the hypoxia-
induced cancer progression and metastasis (Guise, 2013; 
Nurwidya et al., 2014). 
 
IGF1 in inflammation 
 
The pathogenesis of CRC is associated to inflammation. Indeed, 
patients affected by Inflammatory Bowel Disease (IBD), a group of 
inflammatory conditions of colon and small intestine, have 
increased risk of developing CRC (Nieminen et al., 2014). Many 
evidences suggest a dual role for IGF1 during intestinal 
inflammation (Theiss et al., 2004). In a study aimed to analyze the 
relationship between serum levels of components of IGF1 system 
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and interleukins (IL1β and IL6) in IBD patients, authors found that 
IGF1 and IGFBP2 levels were co-related to ILs levels, disease 
activity and anatomical distribution (Street et al., 2004). A recent 
paper showed that epithelial-secreted IGF1 modulates the 
monocytes behavior to inhibit inflammation in intestine (Ge et al., 
2015). Another study assessed IGF1 mRNA and protein levels in 
Crohn's disease (CD) and ulcerative colitis (UC) using ISH and IHC 
(Lawrance et al., 2001). Authors observed that in CD, increased 
IGF1 mRNA expression was transmural, affecting the full thickness 
of the bowel wall. In UC, IGF1 increase was confined to the lamina 
propria and submucosa. In both cases, the distribution of IGF1 
protein matched mRNA expression and coincided with the 
distribution of the inflammatory infiltrate. An increase in the 
collagen type 3 in both CD and UC also coincided with the inflamed 
sites. These findings suggest that IGF1 is involved in intestinal 
ECM remodeling in IBD. ECM remodeling is essential for regulating 
immune cell recruitment during inflammation. Interestingly, IGF1 
plays a crucial role in the migration of macrophages at sites of 
inflammation (Furundzija et al., 2010). ECM organization and 
collagen deposition play also a crucial role during fibrosis. Fibrosis 
is associated to an irreversible healing response to chronic 
inflammation and injury (Speca et al., 2012). In particular, it 
involves muscularis overgrowth, excessive collagen deposition and 
mesenchymal cell hyperplasia within the lamina propria, muscularis 
mucosa, submucosa, muscularis propria, and serosa (Pucilowska 
et al., 2000b). While having potentially beneficial effects to promote 
mucosal repair and growth (Williams et al., 2001), considerable 
evidences suggest that local IGF1 can act in a paracrine and/or 
autocrine manner and mediate an excessive wound-healing 
response that leads to fibrosis during intestinal inflammation 
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(Pucilowska et al., 2000a; Simmons et al., 1999; Zimmermann et 
al., 1997). 
 
IGF1 functions are broad and context-dependent. It is possible that 
SMOC2 regulates a variety of processes depending on the target 
cell type and on the context, as well. Our observations that Smoc2 
is expressed by and acts on ECs together with reported evidences 
that its levels are regulated by hypoxia and nutrient deprivation, 
lead us to speculate that SMOC2 may have an active role in 
angiogenesis and/or tumor cell intra- and extravasation during late 
stage events of tumorigenesis. In the context of tumor initiation, our 
current data indicate that SMOC2 could also regulate the tumor-
associated inflammatory process through IGF1 that has been 
reported to be involved in ECM remodeling and immune cell 
recruitment (Figure 81). 
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Figure 81: Working hypothesis for the biological function of SMOC2 
during adenoma progression. Dashed arrows indicate hypothetical 
mechanisms that have still to be proved. 
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Conclusions 
 
Chapter 1 
 
1. The transcription factor GATA6 directly regulates LGR5 
expression. 
 
2. GATA6 is the only GATA factor expressed in the colon. 
 
3. Gata6 deletion in an Apc null background leads to prolonged 
survival and a lower tumor burden. 
 
4. Gata6 deletion in colon AdSCs results in increased BMP 
signaling. 
 
5. BMP inhibitors rescue the morphology and the proliferative and 
clonogenic potential of Gata6 null adenoma organoids. 
 
6. In vivo, mutagenic WNT activation induces protective activation 
of BMP pathway in the differentiated compartment of adenoma. 
Gata6 null adenomas exhibit an expansion of BMP activation in the 
SC compartment. 
 
7. In vivo treatment of mice with BMP inhibitor LDN-193189 
increases tumor burden and rescues the Gata6 null phenotype. 
 
8. GATA6 regulates BMP4 gene expression through distal 
enhancer elements. 
 
9. GATA6 inhibits β-catenin/TCF4 binding to BMP4 R.31 enhancer. 
 
10. GATA6 competes with β-catenin/TCF4 complex for the 
regulation of BMP signaling during tumorigenesis.
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Chapter 2 
 
1. The analysis of human and mouse ISC signatures identifies 
Smoc2 as a novel ISC gene. 
 
2. SMOC2 acts as a BMP inhibitor in mammalian cell lines and 
primary intestinal cell cultures. 
 
3. Transgenic Smoc2 overexpression in intestinal epithelium leads 
to proportionate gigantism and triggers robust BMP inhibition in 
both epithelial and stromal compartments. 
 
4. Aged Smoc2 transgenic mice spontaneously develop 
hamartomatous polyps resembling those arising in patients with 
Juvenile Polyposis syndrome. 
 
5. Smoc2 overexpression in Apc mutant background enhances 
polyp formation. 
 
6. Conditional Smoc2 ablation in the intestinal epithelium does not 
affect either normal intestinal homeostasis or tumorigenesis in mice 
with an Apc mutant background. 
 
7. A stromal source of SMOC2 maintains high SMOC2 levels upon 
epithelial Smoc2 depletion. 
 
8. Complete Smoc2 depletion does not affect intestinal 
homeostasis or BMP signaling. 
 
9. Intestinal SMOC2 is dispensable for ISC self-renewal and 
clonogenicity. 
 
10. Complete Smoc2 deficiency prolongs survival and decreases 
tumor burden in an Apc mutant background. 
 
11. Smoc2 null mice undergo less inflammation and recover faster 
after DSS-induced colitis. 
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12. Endogenous SMOC2 does not target epithelial cells and does 
not contribute to protect AdSCs from BMP activation. 
 
13. In adenomas, Smoc2 is expressed by Endoglin positive 
endothelial cells (CD105+/CD31+) and resident macrophages 
(CD105+/CD45+). 
 
14. Smoc2 null macrophages (CD105+/CD45+) show decreased 
levels of genes related to inflammation.  
 
15. Smoc2 null endothelial cells (CD105+/CD31+) show reduced 
expression of ECM related genes and of IGF1 pathway 
components. 
 
16. BMP regulates Igf1 mRNA levels in Endoglin-positive 
endothelial cells.  
 
17. In vitro treatment with IGF1 does not promote AdSC 
proliferation. 
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General conclusions and perspectives 
 
The unifying theme behind this thesis has been to understand 
stemness in the intestine, and how this is related to homeostasis 
and tumor initiation. In particular, we selected two genes, the LGR5 
transcriptional regulator GATA6 and the novel ISC gene SMOC2, 
and studied their involvement in defining the stem cell phenotype. 
Both lines of investigation converged in the regulation of BMP 
signaling in intestine. In this thesis, we provide evidence that BMP 
is subjected to a complex regulatory network during tumor initiation. 
Also in the context of adenoma, WNT and BMP pathways interact 
and reciprocally modulate their outcomes, imposing hierarchies. 
Chapter 1 identifies a transcriptional regulatory circuit in the 
epithelium of adenoma where WNT and GATA6 compete for the 
regulation of BMPs. This newly discovered link between GATA6, 
BMP and WNT signaling pathways may have important 
implications to understand risk of CRC in the population. Moreover, 
dissecting the mechanisms that impose cell hierarchies on tumor 
cells may help to identify new therapeutic targets.  
Chapter 2 is focused on addressing the role of the novel WNT 
target ISC gene SMOC2. Despite our first hypothesis, SMOC2 
revealed to be dispensable for normal ISC maintenance and its 
expression was not only restricted to epithelial SC compartment. 
SMOC2 is secreted by both epithelial and stromal cells, with 
relevant functions in pathological settings. We have now started 
analyzing the functions of SMOC2 in endothelial cells and 
macrophages. The association between SMOC2, BMP signaling 
and IGF1 deserves further attention and it might reveal unexpected 
links between inflammation and tissue growth during colon tumor 
formation.
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Methods 
 
Standard cell culture and treatments 
 
All cell lines were cultured in standard conditions in DMEM (Gibco), 
supplemented with 10% FBS (Gibco). For the lentivirus-transduced 
cells, puromycin (Invivogen, 2 µg/mL) was added to the standard 
media to select the stable expression of the transgene. For 
transgene induction Doxycycline (Sigma) was used at 1 µg/mL and 
left in the culture media for the intended time of the experiment. All 
the cell lines used in this study were obtained from the ATCC 
(HEK-293T, HeLa, SW480). 
Human recombinant BMPs (Peprotech) were added at 25 ng/ml; 
human recombinant NOGGIN (Peprotech) was used at 100 ng/ml, 
human recombinant SMOC2 (R&D) was used at 200 ng/ml. Of 
note, rSMOC2 activation required 30 minutes of pre-incubation 
before adding rBMPs. 
 
Lentivirus production and generation of HeLa cells over-
expressing SMOC2 
 
The entire human SMOC2 ORF was amplified removing the stop 
codon and adding the FLAG-tag at the 3’. The SMOC2-FLAG 
construct was then amplified with Gateway adaptors and 
recombined into the pDONR221 vector. Finally, the SMOC2-FLAG 
was recombined into the lentiviral inducible vector pTRIPz 
Gateway. 
All PCR reactions involved in the cloning were performed with the 
PFU Turbo polymerase (Agilent) following the manufacturer’s 
instructions. All Gateway reactions were done following the 
manufacturer’s protocol (Invitrogen). 
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To generate stable expressing HeLas, cells were infected with 
lentiviral particles that contained the DNA of SMOC2-FLAG. 
Replication-deficient lentiviral particles were produced in HEK-293T 
cells by cotransfection of SMOC2-FLAG construct with the viral 
envelope vector (pCAGGS_VSVG), packaging vector 
(pCAG_KGPIR) and retrotranscriptase vector (pCAG_RTR2) in the 
following proportions (Hanawa et al., 2002): 50% lentiviral vector 
containing SMOC2-FLAG construct, 10% envelope vector, 30% 
packaging vector and 10% retrotranscriptase vector. Total DNA 
content was 0.2 µg/cm2. Polyethylenimine (PEI) (Polysciences 
Inc.) was used as transfection reagent at 1 µg/cm2. DNA and PEI 
were mixed at 1:5 ratio and diluted in 150 mM NaCl up to 21 
µl/cm2, incubated at room temperature for 20 minutes and added 
to HEK-293T cells. HEK-293T supernatant containing the viral 
particles was collected at 48h and 72h post-transfection, filtered 
through 0.22 µm filter and supplemented with 8 µg/ml polybrene 
(Fluka) before being added to the media of cells to be infected (0.1 
ml/cm2 of virus supernatant). Cells were selected by resistance to 
puromycin (2 µg/ml). 
 
Generation of the Smoc2 conditional KO (cKO) mouse 
model 
 
Mouse Smoc2 gene is composed of 13 exons. To ensure the 
ablation of SMOC2 functionality, loxP sites were designed to flank 
the coding region of exon 2. The targeting vector was generated by 
Genebridges. The vector was verified by restriction enzyme 
digestion as well as sequencing. The vector was electroporated 
into W4 mouse embryonic stem cells (mESCs) and stably 
transfected cells were selected with G418. After this, single 
colonies were picked and triplicate plates of resistant clones were 
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generated. The clones were then screened by long range PCR by 
using the Sequal Prep Kit (Invitrogen). Positive clones were then 
expanded and further analyzed by Southern Blot to ensure correct 
and unique genomic integration. The clones verified by Southern 
were then transfected with an FlpO-bearing plasmid to remove the 
Neomycin resistance. Single clones were picked and screened by 
PCR for recombination and presence of both loxP sites. Positive 
clones were then expanded and analyzed by Southern once again 
to ensure the appropriate integration of the cassette, as well as to 
independently confirm the deletion of the Neomycin resistance 
cassette. Finally, positive clones were selected and blastocyst 
injection was done to generate chimeras. The chimeras with 
successful germline transmission were bred with C57/Bl6 mice and 
the offspring were used to generate the final colonies of mice. 
 
Generation of Smoc2 transgenic (TG) mouse 
 
Mouse Smoc2 ORF was amplified from Smoc2 IMAGE cDNA clone 
4191849 (Thermoscientific). NcoI restriction site was inserted 
before the ATG and NotI restriction site was inserted after the stop 
codon. NcoI-Smoc2-NotI construct was cloned in frame 
downstream of the last 2Kb Villin promoter fragment contained in a 
pGENT vector. The 2kb Villin-Smoc2 construct was cut out with 
BamHI/NotI digestion and eventually cloned in a pBLUESCRIPT 
KS vector downstream of a 7Kb Villin promoter fragment. Mouse 
oocytes were injected with this plasmid carrying 9Kb Villin-Smoc2 
construct. The random integration of the transgene was assessed 
by genotyping the new born mice. We established several founder 
transgenic mouse colonies by breeding with C57/Bl6 mice. 
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Mouse models and genotyping 
 
For inducible intestinal Smoc2 deletion in the adult mouse, Villin 
Cre-ERT2; Smoc2+/+ and Villin Cre-ERT2; Smoc2fl/fl mice were used. 
Villin Cre-ERT2 mice have been previously described and were 
obtained from Sylvie Robine. 
For full Smoc2 KO mice, Sox2-Cre mice were crossed with 
Smoc2flox/flox mice to establish a Smoc2 null (∆) allele. The 
Smoc2∆/+ mice were intercrossed and the Sox2-Cre was removed 
by selecting mice. Sox2-Cre mice have been previously described 
and were obtained from Ángel Nebreda. 
For inducible intestinal tumorigenesis, Villin Cre-ERT2; Apcfll+; 
Smoc2+/+ and Villin Cre-ERT2; Apcfl/+; Smoc2fl/fl or Smoc2∆/∆ mice 
were used. 
In a similar experiment, inducible intestinal tumorigenesis was 
achieved by using Lgr5 Cre-ERT2; Apcfllfl; Smoc2+/+ and Lgr5 Cre-
ERT2; Apcfl/fl; Smoc2∆/∆ mice. Lgr5 Cre-ERT2 mice have been 
previously described and were obtained from Hans Clevers. 
For the study of tumorigenesis in Smoc2 overexpressing mice, 
APCmin; Smoc2 WT and APCmin; Smoc2 TG mice were used. 
For the study of adenoma growth in vitro, extracted crypts from 
Villin Cre-ERT2; Apcfllfl; Smoc2+/+ and Villin Cre-ERT2; Apcfl/fl; 
Smoc2∆/∆ mice were used. 
All mice were genotyped with standard PCR protocols. 
 
Mouse treatments 
 
Tamoxifen (Sigma): tamoxifen was dissolved in 100% ethanol 
(1/10th of the final volume) at 55ºC. Once completely dissolved, 
solution was immediately combined with 9/10th of corn oil. 
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Villin CreERT2 mice received daily intraperitoneal injection of 
tamoxifen at a dose of 80 mg/kg body weight over a period of 4 
days. 
Lgr5 CreERT2 mice were injected once at a dose of 8 mg/kg body 
weight. 
Dextran Sodium Sulfate (DSS) (Cymit Quimica): DSS was 
administered at 2% in drinking water over a period of 5 days. 
LDN-193189 (Shanghai Biochem): LDN was dissolved in citric 
buffer (pH 3.1) at 3 mg/ml. Mice received two oral doses of LDN 
daily (morning and evening; 35 mg/kg body weight each). Controls 
received citric buffer alone with the same regime. 
Bromodeoxyuridine (BrdU) (Sigma): BrdU was dissolved in HBSS 
and mice were injected with 125 mg/kg body weight 2 hours before 
sacrifice. Actively replicating cells were then detected by anti-BrdU 
immunohistochemistry. 
Fluorescein isothiocyanate conjugated dextran (FITC-dextran) 
(Sigma): FITC-dextran was dissolved in PBS and administered by 
oral gavage at a dose of 44 mg/100g body weight. 
 
Survival analysis  
 
Kaplan-Meier survival curves were produced using the log rank 
test. Statistical analyses were performed using GraphPad Prism 
(GraphPad Software Inc.). 
 
Colon tumor burden analysis 
 
For the analysis of tumor burden, polyps were manually counted 
and the diameter was measured under the microscope the day 
after intestine fixation. 
In LDN experiments, due to the massive uncountable polyp burden, 
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the percentage of tumor area was quantified as previously 
described in method section of Chapter 1 (Whissell et al., 2014). 
 
Intestinal permeability assay 
 
Intestinal permeability assay protocol was adapted from (Gupta 
and Nebreda, 2014, http://www.bio-protocol.org/e1289). Briefly, 
mice were food starved overnight. The morning after, FITC-dextran 
was administered by oral gavage (Bertola et al., 2013). After 4 
hours, mice were anesthetized and blood was collected by 
intracardiac puncture. The blood was transferred to Microtainer 
SST tubes (BD) and the serum was separated following the 
manufacturer’s instruction. Serum was diluted with an equal 
volume of PBS and 100ul of diluted serum were transferred to 96-
well microplate (Corning) in duplicate. The FITC concentration in 
the serum was determined by spectrophoto-fluorimetry with an 
excitation of 485 nm and an emission of 528 nm using a standard 
curve generated with serially diluted FITC-dextran concentrations. 
Serum from mice not administered with FITC-dextran was used to 
determine background. 
 
Immunohistochemistry (IHC) 
 
Immunohistochemistry was performed as previously described in 
Chapter 1 (Whissell et al., 2014). Antibodies are listed in the 
following tables. 
Masson’s Trichromic staining was performed following 
manufacturer’s protocol (DAKO AR17392-2). 
 
Mouse Smoc2 in situ hybridization (ISH) 
 
Paraffin sections of mouse intestine were de-waxed and hydrated 
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following standard procedures. Samples were then treated with 0.2 
N HCl for 15 minutes at RT, washed 3 times in PBS and incubated 
for 15 minutes at 37ºC in Proteinase K (30 µg/ml in PBS). 0,2% 
glycine in PBS was added for 3 minutes to neutralize Proteinase K 
activity and samples were then washed 2 times in PBS. Sections 
were postfixed in 4% PFA for 10 minutes and washed 3 times in 
PBS. Histone acetylation was performed by incubating the samples 
2 times for 5 minutes in a H2O solution containing 1.5% 
triethanolamine, 0.15% HCl and 0.6% Acetic anhydride. Samples 
were then washed and prehybridized for 1h at 70ºC in 
prehybridization solution (50% Formamide, 5X SSC, 2% Blocking 
Reagent (Roche), 0.05% CHAPS, 5 mM EDTA, 50 µg/ml Heparin 
and 50 µg/ml yeast RNA). Full length Smoc2 mRNA probe was 
diluted at 500 ng/ml in prehybridization solution and incubated for 
24h at 68ºC. Post-hybridization washes were performed 3 times for 
20 minutes in 50% Formamide/2X SSC at 65ºC. Sections were 
then rinsed in TBS-T buffer (0.1M Tris-HCl pH 7.5, 0.15M NaCl, 
0.1% Tween20) and blocked for 30 minutes at RT in Blocking 
buffer (0.5% Blocking Reagent, 10% sheep serum in TBS-T). 
Sheep anti-DIG antibody (Roche) was diluted 1/5000 in blocking 
buffer and incubated overnight at 4ºC. Finally, samples were 
washed in TBS-T and then in NTM buffer (0.1M Tris pH 9.5, 0.1M 
NaCl, 0.05M MgCl2) and developed in NBT/BCIP solution (Roche) 
for 24-72h. 
Figure 50 shows Smoc2 ISH performed with RNAScope probe 
following manufacturer’s protocol (Advanced Cell Diagnostics). 
Each dot represents a single target RNA molecule. 
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Mouse intestine measurements 
 
Length of villi: intestinal pictures were taken at magnification 10X 
from at least 3 mice of the same genotype. 20 villi with intact 
transversal section were selected for each genotype. Length was 
measured using ImageJ. 
Number of cells/crypt: Intestinal sections were stained with anti E-
cadherin to highlight cell-cell boundary. Pictures were taken at 20X 
magnification. 20 crypts with intact transversal section were 
selected for each genotype. The number of cells per crypt was 
counted by using the ImageJ plugin “cell counter”. 
Number of proliferative cells/crypt: Intestinal sections were stained 
with anti MKI67 to highlight proliferative cells. Pictures were taken 
at 20X magnification. 20 crypts with intact transversal section were 
selected for each genotype. The number of MKI67+ cells per crypt 
was counted by using the ImageJ plugin “cell counter”. 
Cell migration speed: Mice were injected with BrdU and sacrificed 
after 72 hours. Pictures of intestinal sections were taken at 10X 
magnification. The distance covered by the BrdU positive cell front 
from the crypt-villus boundary was measured with ImageJ. 20 
measurements for each genotype were performed. 
 
Ex vivo intestinal crypt extraction and organoid culture 
 
In order to culture normal mouse crypts, mouse small intestine was 
extracted and washed in HBSS. The tube was longitudinally 
opened and cut in 2 cm pieces. It was incubated in 8 mM EDTA in 
HBSS (Lonza) pH 8, during 5 minutes, at room temperature. After 
replacing EDTA with HBSS, the intestine was vigorously shaken 
and the supernatant discarded. EDTA incubation was repeated on 
ice for 20 minutes. After EDTA replacing with HBSS and shaking, 
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the supernatant containing the intestinal crypts was collected and 
filtered through a 100 µm strainer (BD Falcon). This step can be 
repeated until getting very clean crypt fractions. Intestinal crypts 
were seeded in 50 µl drops of matrigel (Corning) and cultured with 
Advanced DMEM/F12, Hepes, Glutamax, B27 and N2 supplements 
(Life Technologies), Rock inhibitor Y-27632 (Sigma; 10 µM), 
Normocin (Invivogen), rNOGGIN (Peprotech; 100 ng/ml), R-
SPONDIN 1 (1 µg/ml) and EGF (Peprotech; 50 ng/ml). 
In order to culture mouse colon adenoma, Apcflox/flox mice were 
injected with full Tamoxifen (Sigma) over a period of 2 days in 
order to achieve Apc gene ablation. Extracted colon was washed 
and cut in 2 cm pieces. Incubation with EDTA 8 mM (in HBSS) was 
performed at 37ºC for 15 minutes. After incubation, EDTA was 
replaced with HBSS. Following vigorous shaking, the supernatant 
containing colonic crypts was filtered through a 100 um strainer. 
The crypts were seeded in 50 µl drops of BME2 matrix (Amsbio) 
and cultured with basic adenoma medium: Advanced DMEM/F12, 
Hepes, Glutamax, B27 supplement, Rock inhibitor Y-27632, 
Normocin, rNOGGIN, EGF and TGFβ inhibitor LY (1 µM). For IGF1 
treatment, it was used insulin-free B27 supplement (Life 
Technologies) and human rIGF1 (Peprotech; 100 ng/ml).  
 
Organoid growth and clonogenic assay 
 
Organoids formed from normal intestinal crypts were mechanically 
disaggregated with syringe and crypts were seeded in triplicates at 
the same concentration for each condition. After 5 days the number 
of formed organoids was manually counted. 
Adenoma spheres were enzymatically disaggregated with trypsin-
EDTA (Sigma) and the same number of single cells (12000-15000) 
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was seeded in triplicates. After one week, the number of formed 
spheres was counted. Clonogenic capability was assessed by 
repeating the previous steps over passaging. 
 
Polyp disaggregation and staining 
 
Polyps were minced with sterile blade and incubated for 30 minutes 
at 37ºC in HBSS with Collagenase IV 200 U/ml. Pieces were 
shaken every 5 minutes. Enzymatic reaction was stopped by 
adding 10% FBS and single cells were collected by sequential 
filtering through cell strainers of 100 µm, 70 µm and 40 µm. Cells 
were centrifuged, resuspended in 5 ml Ammonium Chloride 
(0.15M; Sigma) and incubated 5 minutes at room temperature to 
lyse the erythrocytes. After two washes in HBSS, cells were 
stained in HBSS 5% FBS with the proper conjugated antibodies for 
30 minutes on ice in the dark. Antibodies are listed in the following 
tables. Dead cells were labeled with DAPI (Sigma Aldrich). Cells 
were selected in the FSC-A/ SSC-A dotplot to remove debris. The 
cells were then gated to exclude cellular aggregates in the FSC-A/ 
FSC-W dot plot. Single cells were selected for viability by excluding 
positive staining with DAPI. Specific polyp cell populations (2000 
cells) were sorted using a FACS Aria 2.0 cell sorter (BD). 
 
RNA extraction and gene expression analysis  
 
For gene expression analysis of mouse intestinal 
organoids/spheres, 1-2 matrigel drops/condition were dissolved in 
TRIzol (Invitrogen). For gene expression analysis of purified mouse 
crypts, the crypt pellet was dissolved in TRIzol. After chloroform 
addition and centrifugation, the RNA from the aqueous phase was 
then purified with the RNA PureLink Kit (Ambion) and quantified by 
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Nanodrop. cDNA was produced with the High-Capacity cDNA 
Reverse Transcription kit (Applied Biosystems) following the 
manufacturer´s instructions. 
RNA from polyp-sorted fractions (2000 cells) was isolated, 
amplified and converted into cDNA by using picoprofiling technique 
(Gonzalez-Roca et al., 2010) in the Genomics facility at IRB. 
To assess changes in expression of selected genes, RT-qPCR was 
performed with their respective TaqMan probes or primers for 
SYBR Green. For TaqMan assays the TaqMan Universal PCR 
Master Mix (Applied Biosystems) was used. In the case of SYBR 
Green reactions the Power SYBR Master Mix (Applied Biosystems) 
was used. To calculate gene expression to a normalization gene 
the comparative threshold cycle method was used. 
For global transcriptomic analysis, samples were hybridized in 
duplicate on Affymetrix® microarrays by the IRB Genomics facility. 
Gene differential expression analysis and gene set enrichment 
analysis (GSEA) of differentially expressed genes was performed 
by the IRB Biostatistics core unit. For further details please refer to 
Methods of Chapter 1. 
 
Protein extraction and Western Blot analysis 
 
For protein expression analysis of mouse intestinal 
organoids/spheres, 2-3 matrigel drops were resuspended and 
incubated in cell recovery solution (BD Biosciences) for 30 minutes 
on ice to get rid of matrigel. After this, the cell pellet was 
resuspended in RIPA lysis buffer (50mM Tris-HCl, pH 7.5; 150nM 
NaCl; 1% NP-40; 0.1% SDS) supplemented with protease and 
phosphatase inhibitors (Sigma Aldrich) and sonicated with a 
Bioruptor for 5 minutes with cycles of 15s ON / 15s OFF. Cell lines 
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were lysed in RIPA buffer supplemented with protease and 
phosphatase inhibitors for 30 minutes on ice. 
After centrifugation (13200 rpm, 15 minutes), the supernatant was 
kept as the protein extract. The samples were quantified with the 
Protein Assay (BioRad), based in the Bradford method, and 
normalized. Equal amounts of protein per sample were separated 
by standard SDS-PAGE and transferred to PVDF membranes. The 
membranes were incubated in TBS-T 0.1% supplemented with 5% 
milk or 5% BSA for 1 hour at RT to block unspecific antibody 
binding. Primary antibodies were incubated overnight at 4ºC. 
Primary antibodies are listed in the following tables. HRP-
conjugated secondary antibodies were diluted 1/10000 in TBS-T 
0.1% supplemented with 5% milk and incubated for 1 hour at RT 
with the membranes. After antibody incubation, membranes were 
washed at least 4 times with TBS-T 0.1% for 10 minutes. Immuno-
complexes were visualized with ECL (Amersham). 
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Primary antibody Table 
Primary 
Antibody 
Manufacturer and 
reference Dilution Technique 
pSMAD1/5/8 Cell Signaling 9511S 1:1000 WB 
FLAG Cell Signaling 2368 
 
1:1000 WB 
SMAD1 Abcam 33902 1:1000 WB 
ACTIN-HRP Abcam 20272 1:15000 WB 
pAKT 
Cell Signaling 
4060P 
 
1:1000 WB 
β-CATENIN Sigma 7207 1:100 IHC 
pSMAD1/5 Cell Signaling 9516S 1:50 IHC 
BRDU Beckton 347580 1:500 IHC 
CHGA Abcam 45138 1:2000 IHC 
MKI67 Novocastra Clone MM1 1:500 IHC 
E-CADHERIN BD 610182 1:400 IHC 
COLLAGEN IV Abcam 6586 1:200 IHC 
GFP ABCAM 6556-25 1:1000 IHC 
KRT20 DAKO M7019 1:200 IHC 
EPHB2 RD System AF467 1:200 IHC 
EPCAM-FITC Santa Cruz 53532 1:100 FACS 
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CD45-APC eBioscience 17-0451-82 1:100 FACS 
CD105-PE eBioscience 12-1051-82 1:100 FACS 
 
RT-qPCR Taqman probe Table 
Gene Taqman probe 
SMOC2 Mm00491553_m1 
LGR5 Mm00438890_m1 
ID1 Mm00775963_g1 
ID2 Mm00711781_m1 
ID3 Mm00492575_m1 
CD45 Mm01293568_m1 
CD31 Mm00476702_m1 
EPCAM Mm00493214_m1 
IGF1 Mm00439560_m1 
IGFBP7 Mm03807886_m1 
CD105 Mm00468256_m1 
SPARC Mm00486330_m1 
SMOC1 Mm00491564_m1 
SMAD6 Mm00484738_m1 
APCDD1 Mm01257557_m1 
OLFM4 Mm01320261_m1 
CRYPTIDIN Mm02524428_g1 
AQP3 Mm01208559_m1 
KRT20 Mm00508106_m1 
DEFCR Mm00655850_m1 
B2M Mm00437762_m1 
ACTb Mm00607939_s1 
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RT-qPCR Primer table  
Gene Primers 5’-3’ 
GREM1 FWD: CATACACTGTGGGAGCGTTG REV: GCTCCTTGGGAACCTTTCTT 
GREM2 FWD: GTGGCTGTGCTGGTAAAGGT REV: TGTTGCTGCTACCATCCTTG 
CHORDIN FWD: TGCATCTGCTCTGAGAATGG REV: GAATATGCACGGGTGAAAGG 
CD3e FWD: CCTCAGCCTCCTAGCTGTTG REV: AGAGGGCACGTCAACTCTACA 
GR1 Ly6C FWD: CATAGAATTGATTGAGGACTC REV: GGGAACTGCTGCATTGCAGAGG 
GR1 Ly6G FWD: TACCTGCCCCTTCTCTGATG REV: AGATGGGAAGGCAGAGATTG 
CX3CR1 FWD: CCTGTTATTTGGGCGACATT REV: CGAGGACCACCAACAGATTT 
CD206 FWD: ATTGTGGAGCAGATGGAAGG REV: ATTTGCATTGCCCAGTAAGG 
CD11c FWD: TAGTTCCTGGGTGGTGGTTG REV: CAGTTGCCTGTGTGATAGCC 
CD68 FWD: CCCTGTGTGTCTGATCTTGC REV: AGGATGGCAGGAGAGTAACG 
GAPDH FWD: CTTCACCACCATGGAGGAGGC 
REV: GGCATGGACTGTGGTCATGAG 
 
 
Genotyping Primer Table 
Gene Primers 5’-3’ 
Smoc2 flox FWD: ACATCAGTGACTTCCAGAGG 
REV: CGATAATAGCTGGCCATAAG 
Smoc2 ∆ FWD: ACATCAGTGACTTCCAGAGG 
REV: GCCTAGCACGAAAGGGGTCCTGGG 
Smoc2 TG FWD: GCCAGTTTCCCTTCTTCCTC 
REV: GGCACAGAGTGGCTTCTGA 
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